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Atherosclerosis is a chronic lipid-driven inflammatory disease affecting arterial
blood vessels. The onset of atherosclerosis already starts in the second decade
of life and persists. Traditionally, atherosclerosis was seen as a lipid disorder in
which the vascular wall became filled up with lipids, but nowadays it is widely
accepted that inflammation plays an important role during atherosclerotic lesion
formation. It is considered to be an enemy of human mankind and per year many
people in the Western world die from cardiovascular events. In 2006, 33% (45.445)
of all people that died that year in the Netherlands, died from a cardiovascular
event. High fat intake, smoking, sedentary life-style and stress are only a few
examples of factors that increase the risk for atherosclerosis. Besides these risk
factors, other disorders of the body such as diabetes, dyslipidemia and obesity
correlate with the incidence of atherosclerosis. The current therapies for athero-
sclerosis are mainly directed to these risk factors. The most prescribed medicines
aimed at lowering plasma cholesterol levels are statins. Together with better
life style advices, this has resulted in a strong decline in the incidence of
atherosclerosis, but cardiovascular disease (CVD) is still the leading cause of
death in Western societies. Therefore, additional therapies to treat atherosclerosis
are highly relevant and will be beneficial in the further lowering of CVD.
Lesion development
Initial lesion formation
Atherosclerosis normally starts during adolescence in most major medium
and large sized arteries and is in the beginning asymptomatic. Atherosclerosis
starts with a dysfunctional endothelium at predisposed sites. A normal healthy
endothelium plays an important role in maintaining vessel wall homeostasis and
protects against the adhesion of platelets and inflammatory cells, thrombus
formation and the proliferation of vascular cells.1 Dysfunction of the
endothelium can be induced by turbulent or oscillatory shear stress, smoking,
hypertension, obesity, atherogenic lipoproteins such as very low-density
lipoprotein (VLDL) and low-density lipoprotein (LDL) and possibly by infectious
microorganisms such as Chlamydia pneumoniae. These factors induce an increased
permeability of the endothelial cell layer for lipoproteins and elevated expression
of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1),
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intercellular adhesion molecule-1 (ICAM-1), E-selectin and P-selectin.2,3
Endothelial cells also start producing chemokines (monocyte chemotactic
protein-1 (MCP-1)), growth factors and vasoactive molecules which affect the
blood pressure.4 Both the deposition of lipids and the expression of the adhesion
molecules correspond with the location where a fatty streak, the first phase of
the atherosclerotic plaque, is formed.5 The adhesion molecules are responsible
for rolling of leukocytes on, and subsequent adhesion to, the endothelium. The
leukocytes, monocytes or T cells, subsequently migrate through the endothelial
layer into the intima (Figure 1.1). Under influence of different cytokines such
as tumor necrosis factor-α (TNFα), macrophage colony stimulating factor
(M-CSF), interferon-γ (IFN-γ), interleukin (IL)-1β, IL-2 and transforming
growth factor-β (TGF-β), monocytes differentiate into macrophages.6,7 T cells
can undergo antigen-dependent activation within the intima. Experiments
using genetically altered mice show the importance of the adhesion molecules.
E-selectin and P-selectin deficiency in apolipoprotein E deficient (apoE-/-) mice
results in a reduced severity of atherosclerosis.8 LDL receptor deficient (LDLr-/-)
mice depleted for functional VCAM-1 also show reduced plaque formation.9
Besides adhesion molecules, also chemokines contribute to the recruitment
of the leukocytes into the vessel wall. Depletion of chemokine (CC) ligand
2 (CCL2) and its receptor CCR2 reduce atherosclerosis10,11, while also CCL5
(RANTES), chemokine (CXC) ligand 10 (CXCL10) and CXCL11 are produced
within the atherosclerotic plaque.12 Blocking CXCR3 reduces the migration of
effector T cells into the vessel wall and consequently results in an attenuation of
atherosclerotic lesion formation (van Wanrooij et al., submitted for publication).
All these data confirm the importance of the immune system in the early stages
of atherosclerosis.
Figure 1.1: Effects of oxidized LDL on leukocyte recruitment into the vessel wall. LDL taken up in
the vessel wall may get oxidized. The oxidized LDL stimulates the adhesion and infiltration of both T cells
and monocytes into the vessel wall. The monocytes differentiate into macrophages and take up oxLDL which
results in foam cell formation. T cells may be activated after presentation of the antigen by macrophages or DCs.
This activation may result in inflammation and subsequently in plaque growth or it can result in a dampened
inflammatory status (adapted from Robertson and Hansson) 13
The other important contributor to the development of atherosclerosis is the
disturbed lipid metabolism. Due to the increased permeability of the vessel
wall, lipids and especially LDL-cholesterol accumulate in the vessel wall. The
cholesterol is incorporated in the monolayer surrounding the lipoproteins which
10
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further consist of phospholipids and apolipoproteins. The core of the lipoprotein
is filled with cholesteryl esters and triglycerides. The lipoprotein family can be
divided in chylomicrons, VLDL, intermediate-density lipoprotein (IDL), LDL and
high-density lipoprotein (HDL).14 The two most important lipoproteins are LDL,
often seen as ”bad cholesterol” and HDL also known as ”good cholesterol”. Both
lipoproteins carry cholesterol in the blood stream. HDL transports cholesterol
from the periphery to the liver where it is excreted from the body via the bile,
while LDL transports the cholesterol from the liver and intestines to several
tissues.
LDL is also entrapped within the vascular wall. Within the intima, the accu-
mulated LDL may undergo modification by oxidation, glycation, aggregation,
association with proteoglycans or incorporation into immune complexes.15–17
Oxidized LDL (oxLDL) can be internalized by the tissue macrophages via
scavenger receptors.15,17–19 This internalization of oxLDL leads to the formation
of lipid peroxides and facilitates the accumulation of cholesterol esters, because
cholesterol derived from oxLDL cannot be mobilized from the cell sufficiently.
This results in the formation of lipid-rich foam cells. The modified LDL is also
chemotactic for other monocytes, attracting more and more of them into the
intima. This may expand the inflammatory response and now also more T cells
are attracted into the intima (Figure 1.1). In this stage, the lesion is called a ”fatty
streak” and remains asymptomatic.
Progression of lesions
Once smooth muscle cells start to migrate from the media into the lesion
a progressive lesion is formed. The smooth muscle cells start to cover the
fatty streak and extracellular matrix components are produced,20 resulting in
a fibrous cap that covers a necrotic core which is composed of cell-free lipids
and cholesterol crystals. The lesion is now called an advanced atherosclerotic
lesion and grows into the lumen of the vessel.21,22 Consequently, the lesion is
exposed to mechanical forces of the blood stream (shear stress) and the lesion is
getting increasingly instable. Instability is also caused by other factors such as
IFN-γ produced by T helper 1 (Th1) cells. IFN-γ inhibits both the proliferation of
vascular smooth muscle cells and the production of collagen by these cells.23,24
In addition, macrophages are very important in reducing plaque stability via
the production of matrix-degrading proteases such as matrix metalloproteinase
(MMP)-1, MMP-8, MMP-9 and MMP-13.25 Also the presence of a number
of immune cells and especially dendritic cells (DCs) in the shoulder regions
of the plaque increase the vulnerability.26 The advanced lesions may become
symptomatic when the fibrous cap ruptures and the necrotic core is exposed to
the bloodstream.27 This induces thrombus formation which may occlude arteries
in various organs and lead to lethal myocardial infarction or strokes and also in
acute limb ischemia. Enhanced instability of the plaque increases the chance of
a rupture (Figure 1.2). From all these data it can be concluded that the immune
system is also accelerating the disease in advanced stages.
11
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Figure 1.2: The development of atherosclerosis: from a normal artery to a myocardial infarction. During
the second decade of life normal arteries start to transform and early atheromas are formed. After this initial
stage they can develop into stabilized or vulnerable plaques. The vulnerable plaque can rupture and cause
thrombus formation. This can result in an acute myocardial infarction and subsequently in death (adapted from
Libby) 28
Immune cells involved in atherosclerosis
As mentioned above, a significant number of cells and molecules are involved in
the immune response during the initiation and the progression of atherosclerosis.
To discuss all cell types and molecules lies outside the scope of this thesis and
therefore we focused on a few but very important cell types which will be
described in separate sections below.
Monocytes/Macrophages
As described above, monocytes and macrophages play an important role in
the initiation of atherosclerosis. Next to the vascular smooth muscle cells,
macrophages are the most abundant cell types within the lesion. They are part of
the innate immune response, normally responsible for the first line defense. The
uptake of oxLDL by macrophages via scavenger receptors (CD36, CD68, CXCL16,
lectin type oxLDL receptor 1, SR-A and SR-B1) not only leads to activation
resulting in inflammatory macrophages but also in the formation of foam cells.15
Macrophages process the ingested oxLDL and oxLDL derived epitopes may be
presented on MHC class II molecules present on the surface of macrophages. This
may lead to the activation of antigen specific CD4+ T cells (Figure 1.1). Blocking
MHC class II molecules with antibodies resulted in an inhibited oxLDL-induced
IFN-γ secretion and T cell proliferation.29 Therefore, macrophages are considered
to be one of the important antigen presenting cells (APCs) in atherosclerosis.
12
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The role of T cells will be discussed in a separate section. Macrophages can
also become activated via toll-like receptors (TLRs).30 These receptors recognize
bacterial toxins such as LPS, stress proteins such as heat shock protein 60 (HSP60)
and also oxLDL.31,32 The activated macrophages produce inflammatory cytokines
such as TNF-α that is pro-atherogenic. In human atherosclerotic lesions many
cells expressing a spectrum of TLRs are found.33 Intervention in the signaling
pathway of TLRs and a lack of TLR4 reduces atherosclerosis in apoE-/- mice.34,35.
Dendritic cells
The most potent APCs are not macrophages but dendritic cells (DCs). DCs
perform multiple important roles in both the innate and the adaptive immune
responses.36 Immature DCs can capture antigens at the site of inflammation
and subsequently migrate, triggered by pro-inflammatory signals, to lymphoid
organs. During migration they maturate and they subsequently present the
captured antigen to naive T cells.37 Several chemokines such as CCR1,
CCR2, CCR5, CCR6, CCR7, CXCR1 and CXCR2 are important regulators
of DC-trafficking.38,39 An important step in the maturation of the DCs is the
upregulation of CD40 and subsequently the interaction between CD40, expressed
on the DCs and CD40L, mainly expressed on CD4+ T cells. This ligation results
in proliferation of T cells and plays a crucial role in immune responses.40 Upon
maturation, DCs also upregulate the expression of several other maturation
markers such as CD80 and CD86 and antigen presenting molecules such as
MHC class I and II molecules and CD1 molecules. Depending on the local
microenvironment of the DCs, they can induce Th1 or Th2 differentiation. In
presence of Th1 cytokines such as IL-12, DCs induce a Th1 response.41 On the
other hand, IL-6, IL-13 and OX40-ligand (OX40L) may induce Th2 responses.42
Chemokines are not only important in trafficking of DCs but also in regulating
the maturation of DCs. Maturation of DCs is impaired when CCL3, CCL19 and
CCL21 are not expressed.43,44 Importantly, IL-10 and TGF-β are able to convert
Th1-inducing DCs to DCs inducing Th2 or regulatory T cells. The DCs that can
induce regulatory T cells are called tolerogenic DCs and produce high levels of
IL-10 and TGF-β and low levels of IL-12. These DCs, which are CD11c+ and
CD11b+ are present in the Peyer’s patches in the intestines and are important in
tolerance induction45 (see below).
In healthy arteries, low numbers of DCs are present within the intima,
immediately beneath the endothelium and in the adventitia along the external
elastic lamina.46,47 These subendothelial DCs may be part of the so-called
vascular associated lymphoid tissue.48 The immature DCs scavenge the vessel
wall for antigens and within the intima they may ingest atherosclerosis-related
antigens.26,49 During atherosclerosis, the subendothelial DCs increase in number,
especially in the shoulder regions of the plaque.26 Circulating monocytes
attracted into the lesion due to chemokines can also differentiate into DCs and
additionally, DCs can migrate from the adventitia into the intima. The presence
of the DCs in the shoulder regions of the plaque may add to the induction
of vulnerable lesions. Within the shoulder region of the lesions, DCs form
clusters with activated T cells and NKT cells.26,50,51 During the maturation
13
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process, the DCs normally migrate due to upregulation of CCR7 and return to
secondary lymphoid organs (lymph nodes, spleen).52 In the lymphoid organs,
the maturated DCs present their ingested antigens to T cells. However, due
to inhibitory signals generated by PAF and oxLDL, hypercholesterolemia may
lead to the activation within the atherosclerotic lesion and to reduced migration
of monocyte-derived DC-like cells from the lesion to the secondary lymphoid
organs.53 These DCs stay within the intima and interact with T cells which
aggravate the inflammation within the lesion and promote thereby progression
of atherosclerotic plaque formation.54
Autoantigens in atherosclerosis
As described, both macrophages and DCs are important APCs in atherosclerosis.
Both cell types can internalize various substances among which proteins and
peptides, (glyco)lipids, etc. which can be processed by the APCs. Epitopes
of these antigens can be presented on antigen presenting molecules. In
atherosclerosis several antigens of both exogenous and endogenous sources
have been identified. Studies indicate that possible antigens derived from
exogenous sources play a contributory role in the inflammatory response in
atherosclerosis. The most extensively studied pathogens in atherosclerosis are
Helicobacter pylori,55 Cytomegalovirus (CMV)56 and Chlamydia pneumoniae57–59.
Patients with cardiovascular diseases have high antibody titers against these
pathogens60–62 and Chlamydia pneumoniae, herpes simplex virus and CMV have
been detected within the atherosclerotic plaque.63 The role of these bacteria and
viruses remains however controversial because many contrasting studies exist.
A T cell response to endogenous antigens can be elicited due to molecular
mimicry, a cross reaction between the immune response to a pathogenic
organism and homologous self-proteins.64 Heat shock proteins (HSPs) are
expressed and secreted by pathogens such as Chlamydia pneumoniae and
Helicobacter pylori. An immune response against microbial HSP65 can cross react
with self-HSP60 and thereby induce an autoimmune response. This is due to
the fact that HSPs form a family of evolutionary highly conserved proteins.65
In mammals, HSPs are expressed on endothelial cells and macrophages66,67 and
can be induced by several stress factors such as fluid shear stress,68 oxidized
lipoproteins69 and cytokines.67 Under these circumstances, HSPs repair or
prevent degradation of denaturated proteins and increase the survival of a
cell in response to stress stimuli.70,71 However, HSP, such as HSP60, are also
involved in inflammatory diseases, probably resulting from their increased
expression in cells exposed to pro-inflammatory mediators.72,73 Expression
of HSP60 on endothelial, vascular smooth muscle and mononuclear cells is
enhanced in human atherosclerotic lesions74 and patients with cardiovascular
diseases have increased titers of HSP60-specific antibodies.67 These antibodies
may contribute to endothelial damage and the inflammatory response in the
vessel wall accelerating atherosclerosis.75 Additionally, HSP60 is expressed by
macrophages exposed to oxLDL.69 Most importantly however, T cell clones with
anti-self-HSP60 reactivity have been detected within atherosclerotic lesions.76
Further on, the induction of tolerance to HSP65 showed to be protective for
14
General introduction
atherosclerosis in LDLr-/- mice77,78 while immunizing mice and rabbits with
HSP60/65 accelerated fatty streak formation.79,80
Another possibility to develop an autoimmune response is by alteration of
self-proteins. The modification of LDL in the vessel wall and in the circulation
is thought to contribute to the immune response in atherosclerosis via this
mechanism.81 For example, reactive aldehydes such as malondialdehyde
(MDA) and 4-hydroxynonenal (HNE) produced by lipid peroxidation may
bind to apolipoprotein B (apoB) resulting in immunogenic oxidative-specific
neo-epitopes.82 The aldehydes can also cross-link amino acids creating many
structural variations that may be identified as neo-epitopes. Oxidation of
LDL can also result in oxidized phospholipids. The best-known altered self-
proteins contributing to the immune response in atherosclerosis are therefore
oxLDL and malondialdehyde modified LDL (MDA-LDL). In addition to
activation of macrophages and endothelial cells, oxLDL is known to induce
T cell activation.83 OxLDL-specific T cells are detected in the vessel wall and
plaques of atherosclerosis patients.84,85 The presence of antibodies to oxLDL in
plasma of animal models for atherosclerosis (LDLr-/- and apoE-/- mice)86 and in
serum of patients with cardiovascular diseases87 again prove that oxLDL is one
of the autoantigens in atherosclerosis. In animal models, the oxLDL-specific
antibodies are mainly IgG2a antibodies, indicating Th1 assistance.86 Anti-oxLDL
and anti-MDA-LDL IgG antibodies induced after immunization with oxLDL
or MDA-LDL are shown to protect against atherosclerosis due to an enhanced
Fc-dependent removal of the antigens by macrophages. This may prevent
oxLDL and MDA-LDL from exerting pro-inflammatory and toxic effects in the
vascular wall.17,88–90 In addition, IgM antibodies against oxidized phospholipids
in oxLDL also protect against atherosclerosis.91 In most of these studies and
in this thesis, oxLDL is made by copper oxidization or by modification with
MDA. The important difference between these forms of oxidization is that
copper oxidization results in many different specific epitopes, including MDA
and HNE-epitopes and oxidized phospholipids, while MDA-modified LDL
contains mainly MDA-epitopes. Immunization of atherosclerosis-prone mice
with LDL and modified forms of LDL such as oxLDL or MDA-LDL and with
peptide sequences of oxLDL resulted in a reduction of atherosclerosis.17,88–90,92
The third protein recognized as a possible autoantigen in atherosclerosis, is
β2-glycoprotein I (β2GPI). Normally, this phospholipid-binding protein, which
is present on platelets and endothelial cells, acts as an anti-coagulant molecule.
However, β2GPI is abundantly expressed within subendothelial regions of
human atherosclerotic plaques. Furthermore, CD4+ T cells colocalize with
β2GPI and this supports the hypothesis that β2GPI initiates a chemoattractant
process that results in the attraction of antigen-specific lymphocytes into the
atherosclerotic plaque.93 Additionally, β2GPI colocalizes with oxLDL within the
atherosclerotic plaque and these oxLDL/β2GPI complexes may be associated
with systemic and chronic inflammation of the vasculature.94 Antibodies to
β2GPI are correlated with the incidence of atherosclerosis in patients and
autoantibodies to oxLDL/β2GPI complexes have been associated with arterial
thrombosis.95 A role for β2GPI in atherosclerosis was further indicated by the
fact that oral tolerance induction to β2GPI reduced atherosclerosis in LDLr-/-
15
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mice96, while immunization of LDLr-/- mice with human β2GPI accelerated
lesion formation.97
Most of the above mentioned antigens are based on a peptide structure. These
epitopes are presented via MHC class I or II molecules and result in the activation
of specific CD8+ or CD4+ T cells, respectively. The activation of these peptide-
antigen-specific T cells most likely occurs in the secondary lymphoid organs
such as lymph nodes and the spleen. The consequence of T cell activation on
atherosclerosis is discussed in detail in the next section.
In addition to the expression of MHC class molecules, the APCs also express
another antigen presenting class of molecules, the CD1 molecules. The family
of CD1 molecules is related to MHC class I molecules but in stead of presenting
protein/peptide antigens they present lipid antigens to T cells.98 The CD1 family
can be subdivided in two main groups. Group 1 molecules, CD1a, CD1b and
CD1c, present foreign lipid-antigens to CD1 specific T cells. These molecules
are absent in mice. Mice only express molecules from group 2, CD1d, which
activates a specific subset of T cells; the natural killer T (NKT) cells, and also
CD1d-restricted T cells. Because atherosclerosis is a lipidic disorder, one may
imagine that lipid antigens exist in atherosclerosis. It was shown that within
the atherosclerotic plaque, CD1d is expressed on DCs that colocalize with T
and NKT cells in the shoulder regions of the plaque.50 In human atherosclerotic
plaques, CD1d has been detected incidentally.99 The role of NKT cell activation
by the presentation of (glyco)lipids and the role of CD1d in atherosclerosis will
be discussed later.
CD4+ and CD8+ T cells
It was already described in 1985 that T cells are present within human
atherosclerotic plaques and that they play a role in the disease process of
atherosclerosis.100 Within human atherosclerotic plaques most of the T cells are
CD45RO-expressing effector and/or memory T cells.101 Almost no naive T cells
are found within lesions and the amount of activated T cells increases with the
severity of coronary syndrome.102,103 Most of the T cells are CD4+ T cells104 and
the majority of those are TCRα/β positive, although TCRγ/δ T cells are also
present.80,101 In atherosclerotic lesions of apoE-/- and LDLr-/- mice, the CD4+
T cell is also the predominant T cell subset. A deficiency in CD4+ T cells105–107
or TCRα/β+ T cells108 and thus a deficiency in adaptive immunity leads to
reduced atherosclerosis in the atherosclerosis-prone mice. A transfer of CD4+ T
cells to immune-deficient scid/scid mice accelerates atherosclerosis, indicating
the important role of CD4+ T cells in the disease.105 Depletion of CD4+ T cells
via antibody administration reduced fatty streak formation in C57Bl/6 mice,
just like CD4-/- C57Bl/6 mice were protected against fatty streak formation.109
The activation of the T cells is mainly important in the early progression of
atherosclerosis, not in the initiation.110 CD8+ T cells have also been detected
within the human atherosclerotic lesions,104 but contrasting data on their role
in atherosclerosis exist. The absence of CD8+ T cells (apoE-/-CD8-/- mice)
has no effect on lesion formation,108 while in another study an acceleration of
atherogenesis due to CD8+ T cell activation is observed.111 Altogether, their
16
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precise role in atherosclerosis remains poorly understood.
The TCRα/β positive CD4+ T cells can be subdivided in several subclasses
depending on the cytokine secretion (Figure 1.3). Cytokines are small proteins
and peptides that are used as signaling compounds between cells. Many
cytokines, both pro-inflammatory and anti-inflammatory, are important
regulators of the autoimmune process in atherosclerosis. T helper 1 (Th1) cells,
partly responsible for cell-mediated immunity, secrete Th1-cytokines such as
IL-1, IL-2, IFN-γ, TNF-α, IL-12 and IL-18, while Th2 cells produce IL-4, IL-5
and IL-13 and may be responsible for antibody production by B cells. Due to
high IL-12 and IFN-γ levels during atherosclerosis, most of the CD4+ T cells
within the plaque are shown to be of a Th1 cell type and produce TNF-α,
IL-2 and IFN-γ. These Th1-cytokines stimulate macrophages and other cells
within the lesion to secrete more pro-inflammatory cytokines.104 IFN-γ enhances
also the recruitment of T cells and macrophages to the plaque, increases lipid
uptake by the macrophages and activates APCs. Deficiency in IFN-γ or the
IFN-γ receptor resulted in attenuated atherosclerosis,112,113 while injections
with IFN-γ accelerates the disease.114 Within the atherosclerotic plaque, IFN-γ
is not only produced by Th1 cells, but also by the later on described NKT
cells. Also deficiency in IL-12 and IL-18 in apoE-/- mice leads to an attenuation
of atherosclerosis11,115, whereas treatment with IL-12 and IL-18 accelerated
atherosclerosis.116,117 Additionally, vaccination against IL-12 was successfully
used to abrogate the Th1 mediated immune response in atherosclerosis. This
effect was due to lowering of especially IFN-γ levels.118 TNF-α, also produced
by macrophages and other cell types, show pro-inflammatory properties and
promotes many autoimmune diseases. TNF-α deficiency also results in a
reduction of atherosclerosis.119
On the opposite side, Th2 cytokines are known for their atheroprotective
characteristics, although there are some conflicting data. IL-5 is a promoter of
B-1 cell development, the producer of natural antibodies. For example, some of
the natural occurring (innate) IgM antibodies cross-react with oxLDL and inhibit
cholesterol uptake and foam cell formation.121 Deficiency in IL-5 leads to an
enhanced plaque formation in LDLr-/- mice.91 IL-4, a so-called Th2 cytokine, is
able to inhibit Th1 induced immune responses and therefore protective against
a number of Th1-mediated autoimmune diseases. In atherosclerosis, the role of
IL-4 is however more complex. IL-4 has athero-promoting characteristics. Recent
studies showed a reduced plaque formation in IL-4-/-LDLr-/- and IL-4-/-apoE-/-
mice.122,123 Van Wanrooij et al. showed that blocking of the OX40 pathway
results in a reduced plaque size in LDLr-/- mice due to lower levels of IL-4
and an increased formation of IgM antibodies.124 IL-4 can cause increased lipid
oxidation, enhanced leukocyte adhesion and recruitment and increased lipid
uptake and foam cell formation. IL-4 can also cause plaque destabilization by
inducing apoptosis of SMCs and MMP-12 production.125 On the other hand,
IL-4 also has some anti-atherogenic properties. Injecting C57Bl/6 mice with IL-4
decreased fatty streak formation.109 It seems that the effects of IL-4 are stage-




Figure 1.3: An overview of the different CD4+ T cells in atherosclerosis. Upon recognition of a specific
antigen presented on MHC molecules by APCs and in presence of co-stimulatory signals, Th1 and Th2 cells
secrete specific cytokines. Upon activation Tregs secrete both IL-10 and TGF-β. Both cytokines can inhibit the
activation of both Th1 cells producing IFN-γ, IL-2 and TNF-α and Th2 cells producing IL-4, IL-5 and IL-13.
(adapted from Tedgui and Mallat) 120
From the discovery of the role of T cells in atherosclerosis it is thought that
the main problem in the immune response is the disbalance between Th1
and Th2 cells. In atherosclerosis, this balance is directed towards Th1. This
is supported by the fact that C57Bl/6 mice which are prone to a Th1 type of
immune responses develop fatty streaks when they are fed a high cholesterol
diet. In contrast, BALB/c mice which are prone to Th2 immune responses are
protected against atherosclerosis.109,126 Many studies described in this section are
performed to recover this balance and are done in either normal atherosclerosis-
prone C57Bl/6 mice or in transgenic more atherosclerosis-susceptible apoE-/-
and LDLr-/- mice.
Regulatory T cells
Recently there was however a change of view on the disturbed Th1/Th2
cytokine balance. IL-10 and TGF-β were found to be very effective in reducing
atherosclerosis. Both are anti-inflammatory cytokines that are produced by
a distinct subset of T cells; the regulatory T cells (Figure 1.3). IL-10, also
produced by macrophages and DCs is produced within the plaque and inhibits
oxLDL-induced production of IL-12 by human monocytes127 and it promotes
plaque stability. In addition, endogenous IL-10128, systemically and locally
administered IL-10129 and T cells overexpressing IL-10130 are protective against
atherosclerosis. Deficiency in IL-10 in C57Bl/6 mice that are fed a atherogenic
diet develop increased quantities of fatty streaks128,131, while IL-10 transgenic
C57Bl/6 mice do not develop fatty streaks. Deficiency in IL-10 in apoE-/- mice
also results in bigger lesions.132 TGF-β is the rising star in anti-atherosclerotic
18
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research. TGF-β neutralizing antibodies133, soluble TGF-β receptors134 and
adenovirus-mediated delivery of TGF-β 135 demonstrates that TGF-β is a potent
inhibitor of atherosclerosis. Crossbreeding of apoE-/- mice with mice deficient
in TGF-β receptors (TβRII-/-) shows a five-fold increase in plaque size.136 The
main functions of TGF-β are lesion stabilization through the induction of the
synthesis of collagen and tissue inhibitors of MMPs, dampening atherogenic T
cell responses and inhibition of leukocyte recruitment and foam cell formation.
Many cells present in the atherosclerotic lesion are capable of producing TGF-β,
but the most likely cell type producing this anti-atherogenic molecule is the
regulatory T cell.137,138
Mallat et al. now hypothesized that in atherosclerosis an imbalance exists
between Th1/Th2 effector T cells and the regulatory T cells (Tregs)(Figure 1.4).
In the past few years, these so-called Treg cells were identified to be responsible
for a unique self-tolerance mechanism and control of autoimmunity. These cells
can actively suppress immune activation and maintain immune homeostasis.
They are specialized in suppression of both Th1 and Th2 pathogenic immune
responses against self or foreign antigens.139 The majority of Tregs are CD4+
cells and constitutively express CD25 (IL-2Rα). This CD25 is necessary for the
development in the thymus, for survival and the function of Tregs. Activation
of Tregs via IL-2, produced by non-Treg cells, results in the suppression of
pathogenic T cells. The suppression of these T cells leads to the inhibition of IL-2
production and a reduction in the number of Tregs. Thus IL-2 is responsible for
the feedback mechanism between pathogenic T cells and Tregs.
Figure 1.4: The proposed anti-atherogenic properties of Tregs. Tregs may be activated in lymphoid organs
by tolerogenic APCs and subsequently migrate to the atherosclerotic lesion just like Th1 and Th2 cells. Upon
restimulation in the lesion the Tregs secrete IL-10 and TGF-β. These cytokines inhibit both Th1 and Th2 cells
and also macrophages are affected. Altogether this results in a dampened inflammation in the lesion (adapted
from Tedgui and Mallat) 120
Tregs can be subdivided in several types. The common ancestor is located in the
19
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thymus and there they can develop into Foxp3+ or Foxp3− Tregs. Subsequently,
Foxp3+ Tregs, called natural Tregs, migrate out of the thymus into the periphery.
The forkhead transcription factor Foxp3 is crucial in the development and
function of these natural Tregs.140 Foxp3 controls several important genes such as
CD25, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and glucocorticoid-inducible
tumor necrosis factor (GITR).141 The immunosuppressive function of these Tregs
is partly mediated by TGF-β and IL-10 which can have direct effects on other cell
types (bystander activation). TGF-β is also expressed on the surface of the natural
Tregs instead of being secreted. The most important way of immuno-suppression
by natural Tregs is through cell-cell contact via CTLA-4 on the Tregs and B7 on
activated APCs and surface bound TGF-β on the Tregs and TβRII on other T cells,
or it can be a combination of cell-cell contact and cytokine secretion.139,142 In vivo,
activation of Tregs can result in the induction of IL-10 in CD4+CD25− T cells and
TGF-β produced by the Tregs may inhibit pathogenic CD8+ T cells.
The Foxp3− Tregs also migrate out of the thymus. These cells may be induced
in the periphery and are called adaptive Tregs. These can be subdivided again,
based on the cytokine they produce most excessively and on the surface markers
they express. Tr1 cells (CD4+CD25−), which develop under influence of IL-10,
produce mainly IL-10.143 Th3 cells (CD4+CD25+) are TGF-β producers. The Tr1
cells are CD4+CD25−Foxp3−. Th3 cells express both CD4 and CD25 and may
express Foxp3 upon activation. There are contrasting studies about this!
Foxp3-expressing T cells are found in human atherosclerotic plaques144 and
Foxp3 mRNA is expressed in the aorta of apoE-/- mice.145 The protective action of
CD4+CD25+ Tregs is proven by injections with anti-CD25 antibodies in apoE-/-
mice.146 Anti-CD3 Fab antibodies stimulate the activation and proliferation of
Tregs and treatment of LDLr-/- mice with these antibodies resulted in a reduction
of the development and progression of atherosclerosis.147 Depletion of several
co-stimulatory molecules such as CD28, CD80 and CD86 resulted in a reduction
in numbers and function of Tregs and subsequently in higher atherosclerosis
susceptibility.146 Furthermore, a transfer of Tr1 cells specific for ovalbumin
elevated IL-10 levels in apoE-/- mice and reduced lesion formation.148 Recently
it was shown that HSP60-specific regulatory T cells can be generated in vitro
and injection of these cells in apoE-/- mice prevented atherosclerotic lesion
development.149
Th17 cells
As described, it was assumed for a long time that T cell-mediated tissue
damage was caused by a disbalance in Th1 and Th2 cells (Th1/Th2 hypothesis).
Later on, Mallat et al. introduced the new view on this balance in athero-
sclerosis. They postulated that a disbalance between pathogenic T cells and
Tregs exist in atherosclerosis (Treg hypothesis). This view on the immunological
process in atherosclerosis changed again very recently. Cua et al. revisited
the immunopathological basis for diseases such as experimental autoimmune
encephalomyelitis (EAE) and collagen induced arthritis (CIA). Traditional block-
ing of IL-12 did not result in protection against these diseases, but blocking of
a specific subunit of IL-23, which shares the subunit p35 with IL-12, resulted in
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an attenuation of both diseases.150 Harrington et al. and Park et al. showed that
development of Th17 cells from naive cells is potently inhibited by IFN-γ and
IL-4, typical Th1 and Th2 cytokines, respectively, whereas already committed
Th17 cells are resistant to suppression by Th1 or Th2 cytokines.151,152 Further
studies defined more functional and phenotypic differences between the so-
called Th17 cells and Th1 cells. This new lineage of T cells, Th17 cells, are now
credited for causing tissue damage.153 Th17 cells are driven by IL-23 and TGF-
β in presence of IL-6 and they mainly produce the pro-inflammatory cytokine
IL-17. IL-17 deficient mice show attenuated disease progression of EAE154
and suppressed collagen-induced arthritis.155–157 Van Es et al. showed that
vaccination against IL-17 protects against atherosclerosis.158 The new view on the
balance of T cells is now called the Th17 hypothesis with Th17 cells on one side
and Tregs on the other. IL-6 and TGF-β seems to be key-players in this balance
since TGF-β plus IL-6 initiates Th17 cells, while TGF-β without IL-6 initiates Tregs
(Figure 1.5).
Figure 1.5: The new view on the balance between T cells in atherosclerosis. Th17 cells and Tregs may
develop from a common Foxp3−CD4+ ancestor. In presence of TGF-β and IL-6 the ancestor differentiates into
th17 cells, while without IL-6 they differentiate into Tregs. Th17 cells produce pro-atherogenic IL-17 and IL-6,
while Tregs may produce NT-atherogenic TGF-β and IL-10.(adapted and modified from Weaver et al. 159)
NKT cells
Besides recognition of peptide antigens by T cells and Tregs, lipid antigens can
be recognized by another specialized subset of T cells, the NKT cells. NKT cells
are characterized by the expression of NK cell receptors such as CD161 (NK1.1
in mice) and an invariant TCR composed of Vα14 and Jα18 (previously known
as Jα281) subunits paired with a restricted set of Vβ chains. Most of the NKT
cells are CD4+ or CD4−CD8−.160–162 These classical NKT cells can recognize
(glyco)lipid antigens presented by CD1d expressed on APCs. NKT cells are
present in both humans and mice and in mice they are found most frequently
within the liver (30-50% of the lymphocyte population) and bone-marrow (20-
30%). They represent a smaller proportion of lymphocytes in the spleen (3%),
lymph nodes (0.3%), blood (0.4%) and lung (7%). Within the liver they reside in
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the sinusoids where they screen for possible ligands. Several subsets of NKT cells
are known at the moment. The CD1d dependent NKT cells can be subdivided in
NK1.1+ and NK1.1− cells and there are also CD1d dependent NKT cells without
expression of Vα14-Jα18 and CD1d independent but NK1.1+ NKT cells. The
most common NKT cell is the invariant NKT cell, which is CD1d dependent
and expresses NK1.1. Upon recognition of a glycolipid antigen, invariant NKT
cells rapidly produce large amounts of both Th1 (IFN-γ, IL-12 and TNF-α) and
Th2 (IL-4, IL-5, IL-10 and IL-13) cytokines and this makes them unique among
lymphocytes163 (Figure 1.6). The question remains how this mix of cytokines
can lead to a regulated immune response. One possible explanation could be
the difference in the affinity of the ligand for CD1d, which can result in different
signaling inside the NKT cell (see below). An important feature of the released
cytokines from NKT cells is the bystander activation of adjacent NK cells, B
cells and dendritic cells164 as well as activation of normal CD4+ and CD8+ T
lymphocytes.160 Recent studies have shown that NKT cells can be activated by in
vivo administration of marine sponge-derived α-galactosylceramide (α-GalCer)
also known as KRN7000. Upon recognition of α-GalCer, mature NKT cells induce
an early burst of IL-4 followed by a more prolonged burst of IFN-γ.165 However,
repeated injections of α-GalCer have been shown to induce an adaptive immune
response which is polarized towards production of Th2 cytokines (IL-4, IL-10).
This results in the protection against autoimmune diabetes,166 experimental
autoimmune encephalomyelitis167 and colitis168 in mice (Table 1.1). Interestingly
some variants of α-GalCer exist that have decreased Th1 compared to Th2
cytokine induction. OCH, which has a truncated sphingosine chain, is one of
these α-GalCer analogs. In vitro administration of OCH results in a higher
ratio of IL-4 to IFN-γ secretion by NKT cells165,169 and in vivo it results in the
prevention of experimental autoimmune encephalomyelitis,165 diabetes170 and
collagen-induced arthritis.171 Also the production of IL-10 by OCH-stimulated
NKT cells is beneficial in Th1-mediated autoimmune diseases170 (Table 1.1). It
has been suggested that the differences in cytokine profiles may be due to the
length of the sphingosine chain. Due to the shorter lipid chain of OCH, it has a
lower affinity for CD1d. This results in a shorter TCR ligation which results in a
poor transcription of the NF-κB family member transcription factor c-Rel. c-Rel
is identified as essential for IFN-γ production by NKT cells. It was observed
that c-Rel is transcribed in α-GalCer-stimulated, but not in OCH-stimulated NKT
cells so this may be responsible for the reduced IFN-γ gene transcription.172
An alternative hypothesis is that the different ligands reach different cell types
upon injection. Th1 responses may result from the uptake of the ligand by for
example IL-12 secreting cells such as certain DC-subsets, whereas Th2 responses
may result from the uptake by non-IL-12 producing cells such as B cells or other
DC-subsets.173,174
The aforementioned antigens are all synthetically made. Recently some microbial
ligands were found. Glycosphingolipids in the cell wall of Sphingomonas strongly
activate NKT cells and NKT cells clear the infection of these bacteria.176–178 In
addition, more recently also a self-ligand for NKT cells was found. The lysosomal
glycosphingolipid iGb3 may activate mouse Vα14 and human Vα24 NKT cells.
This iGb3 seems to be important during the natural development of NKT cells.
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Figure 1.6: Production of both Th1 and Th2 cytokines by activated NKT cells. Upon recognition of
ligands such as α-GalCer and OCH by CD1d on APCs, NKT cells may produce a large diversity on both Th1
(IFN-γ) and Th2 (IL-4, IL-10 and IL-13) cytokines. These cytokines may induce bystander activation of Th1
and Th2 cells and this results in the initiation or prevention of different inflammatory diseases.
It is present within the thymus and is necessary during selection and is CD1d
dependent.179,180 In addition to the microbial and lysosomal ligands, recently
some plant- and bacteria-derived glycolipids were found to be possible ligands.
Especially the phosphatidyl choline (PC) and phosphatidyl ethanolamin (PE)
parts of these glycolipids are shown to activate NKT cells.181,182 Whether all these
”natural” ligands affect the Th1/Th2 cytokine secretion of NKT cells and whether
they can be used as treatment for diseases needs further investigation.183
Because of the activation of NKT cells by (glyco)lipids and the fact that
(glyco)lipids are a major part of the problems in atherosclerosis, NKT cells
may play a role in atherosclerosis. Several groups are active in this field and
both α-GalCer and OCH were used to study the effects of NKT cell activation
on atherosclerosis. The first publication on a possible role for NKT cells in
atherosclerosis showed that apoE-/- mice crossed with CD1d-/- mice exhibit a
25% reduction in lesion size. α-GalCer treatment resulted in a burst of cytokines
and induced a 50% increase in lesion size.184 These data are confirmed by the
study of Major et al.185 In both studies IL-4 and IFN-γ production was increased
after treatment. LDLr-/- mice crossed with CD1d-/- mice also have smaller lesions
compared with LDLr-/- mice.186,187 It is however mentioned that this effect was
only present during the initial stages of atherosclerosis. There was an effect after
4 weeks of diet, while the effect of CD1d deficiency was lost after 8 and 12 weeks
of diet.187 Nakai et al. repeatedly injected apoE-/- mice with both α-GalCer
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Disease Mouse strain Model Treatment protocol Treatment Outcome Proposed mechanism
T1D NOD spontaneous α-GalCer,multiple i.p. protection Th2 deviation,
MDC recruitment
NOD spontaneous α-GalCer + IL-7, multiple i.p. superior protection Th2 deviation
NOD islet transplant α-GalCer, multiple i.p. protection Th2 deviation
NOD CY α-GalCer, multiple i.p. protection Th2 deviation
EAE B6 MOG(35-55) α-GalCer, multiple s.c/i.p. protection Th2 deviation
B6 MOG(35-55) α-GalCer, multiple s.c protection NKT cell IFN-γ
B6 MOG(35-55) α-GalCer, multiple s.c/i.p. slight exacerbation competition for CD1D
B6 MOG(35-55) α-GalCer, single i.p. no effect or protection Th2 deviation
B6 MOG(35-55) APC + α-GalCer + B7.2 protection Th2 deviation
blockade, single i.p.
B6 MOG(35-55) APC + α-GalCer + CD40 exacerbation Th1 deviation
activation, single i.p.
B6 MOG(35-55) OCH, single i.p. or p.o. protection Th2 deviation
PL/J MBP α-GalCer, multiple s.c/i.p. protection Th2 deviation
B10.PL MBP(AC1-9) α-GalCer, co-immun., exacerbation Th1 deviation
single i.p.
B10.P MBP(AC1-9) α-GalCer, pre-immun., i.p. protection Th2 deviation
SJL/J MBP α-GalCer, multiple s.c/i.p. slightly delay, increased Th1 bias of NKT cells
mortality
RA B6, SJL/J collagen α-GalCer, multiple i.p. weak or no protection Th2 deviation
B6, SJL/J collagen OCH, multiple i.p. protection Th2 deviation
SLE NZB/W F1 spontaneous α-GalCer, multiple i.p. exacerbation Th1 deviation
at adult age
MRL-lpr/lpr spontaneous α-GalCer, multiple i.p. decreased dermatitis, regulatory cytokines
no effect on lupus
nephritis
IBD B6 DSS α-GalCer, multiple i.p. weak protection regulatory cytokines
ATH B6.ApoE-/- spontaneous α-GalCer, multiple i.p. exacerbation NKT cell recruitment
and activation in lesion
Table 1.1: The effect of α-GalCer treatment on different inflammatory diseases. In most inflammatory
diseases, multiple injections of α-GalCer or OCH resulted in a protection against the disease. In studies that
observed an exacerbation of the disease the ligand was injected only once or was injected at adult age. The
only exception in this table is atherosclerosis in which multiple injections of α-GalCer accelerated the disease
(adapted from van Kaer) 175
and OCH during the early phase of atherosclerosis. Both ligands caused an
increase in plaque size which was dedicated to an increase in the production
of pro-atherogenic cytokines (IL-4 and IFN-γ).186 The effect of α-GalCer on the
development of atherosclerosis and the produced pro-atherogenic cytokines by
NKT cells suggests that CD1d-dependent NKT cells may play a specific role
in atherogenesis. Furthermore, the results with CD1d-/- mice suggest that the
absence of CD1d-reactive NKT cells attenuates atherosclerotic lesion formation
in mice during early fatty streak formation.
In addition, NKT cells are found in the aortic arch of LDLr-/- and apoE-/- mice
fed a Western-type diet.184–186,188 In advanced human lesions NKT cells have
been identified in the regions bordering the shoulder of the lipid core and the
fibrous cap,189 especially there where DCs are present.50 In these regions, NKT
cells represent 2% of the total lymphocyte population.50,189
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Immunotherapies as treatment for atherosclerosis
Currently, many research groups around the whole world are struggling to
find the best treatment for atherosclerosis. From multiple sides the disease
process is ”attacked”. Lipid lowering therapies, promotion of physical ac-
tivity, blood-pressure lowering methods and many other techniques are still
not sufficient enough to win this battle. With statins and anticoagulants the
development of atherosclerosis and its consequences can be inhibited, but still the
disease is manifest.190 Since the knowledge that atherosclerosis has an important
inflammatory component, major research effort has been done to interrupt the
inflammatory response and thereby reduce the severity of the inflammation and
consequently the severity of atherosclerosis.191 Many approaches are focused on
the role of certain cytokines or cell types. Depletion or overexpression of athero-
promoting cytokines and athero-protective cytokines, respectively, is shown to be
successful in atherosclerosis-prone LDLr-/- and apoE-/- mice (described above).
Another upcoming technique to block key players of atherosclerosis is via active
vaccination. Using a novel vaccination technique192, antibodies to IL-12 can
be induced which specifically block the function of IL-12 and protect against
atherosclerosis in LDLr-/- mice.118 This vaccination strategy was based on a
protein vaccine. Another protein vaccination against cholesteryl ester transfer
protein (CETP) altered the lipoprotein profile in cholesterol-fed rabbits and
reduced the lesion formation.193 Hauer et al. also showed that DNA vaccination
against the vascular endothelial growth factor receptor 2 (VEGFR2) blocked the
initiation and progression of atherosclerosis,194 whereas van Es et al. showed that
DNA-vaccination against IL-17 blocked the initiation of atherosclerosis.158
Another important way to interrupt the disease process is by reducing the
antigen-specific immune responses in atherosclerosis. This can be done by
removing the antigens which is hard to achieve in humans since many antigens
are self-proteins. Two other ways are immunization and tolerance induction
to specific atherosclerotic antigens. Immunization with oxLDL protects against
atherosclerosis in hypercholesterolemic rabbits,195 while immunization with
MDA-LDL and apoB100 peptide sequences reduces atherosclerosis in LDLr-/-
and apoE-/- mice, respectively.88,92
The different approaches used in this thesis are described below. First tolerance
induction to auto-antigens of atherosclerosis is mentioned. This was already
successful in several other publications in which oral and nasal tolerance to
HSP65 and β2GPI protected against lesion formation in LDLr-/- mice77,78,96, while
induction of neonatal tolerance to oxLDL reduced atherosclerosis in apoE-/-
mice.196 Secondly, a new vaccination approach is introduced to reduce athero-
sclerosis. This vaccination technique uses DCs as transfer units of specific
antigens and ligands. The principles of DC vaccination will be clarified in the
second part. At last different strategies to activate NKT cells are mentioned.
Tolerance induction
It is known that Tregs can be induced via mucosal tolerance induction. The
classical definition of mucosal tolerance is a specific suppression of cellular
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and/or humoral immune responses to an antigen by administration of the
antigen via a mucosal surface. It is a form of peripheral tolerance that evolved to
treat external agents that gain access to the body via a natural route. It is of unique
immunologic importance, because it is a continuous natural immunologic event
driven by exogenous antigens. Many processes, both Th1 and Th2-driven, can be
suppressed or induced by mucosal tolerance induction.
To induce mucosal tolerance, the antigen has to be administered to a mucosal
surface. This can be achieved in two ways; nasal or oral administration. The
main pathways in both tolerance mechanisms are the same. It is shown that
oral tolerance induction mainly induced Th3 cells197,198, while nasal tolerance
induction mainly resulted in the activation of Tr1 cells. In recent studies it is
shown that oral tolerance induction also results in an increase in CD4+CD25+
cells expressing either CTLA-4 and/or FoxP3.199,200 In this thesis the method of
oral tolerance induction is used in two chapters and therefore this section of the
introduction is focused on this method of tolerance induction.
The effects of oral tolerance induction are mainly determined by the dose of
the antigen. Low dose feeding results in Treg activation in the gut, while high
doses result in deletion/anergy of the antigen specific T cells.201,202 The antigen-
specific Tregs are activated in the gut due to presentation of the fed antigens
by tolerogenic DCs.203 As mentioned earlier, the Tregs mainly producing IL-10
and TGF-β, may migrate to lymphoid organs and target organs to suppress
the disease both in an antigen-specific and an antigen-non-specific way.204 The
induced Tregs are specific for the fed antigen and can recognize the antigen in the
lymphoid organs or target organs and secrete their cytokines locally. Additionally
they can suppress the disease by releasing antigen-non-specific cytokines, which
is called bystander suppression.
The method of tolerance induction to treat atherosclerosis is used in several
studies. Harats et al. used HSP65 and feeding of certain doses of this antigen
induced a specific immune suppression and a reduction in lesion size in LDLr-/-
mice which were immunized with Mycobacterium tuberculosis or fed an athero-
genic diet to induce atherosclerosis. The mechanism underlying this effect was
however not clearly defined. Low doses of HSP65 reduced plaque size but
without inducing a specific immune suppression.77 Maron et al. showed a
reduction in atherosclerosis after nasal and oral administration of HSP65, but
only nasal administration led to a change in T cell phenotype.78 In a study by
George et al, β2GPI was used as atherosclerosis-specific antigen. Oral feeding of
this antigen also resulted in a reduction of plaque size. They also show a lowered
lymph node cell reactivity to β2GPI and an upregulation in anti-atherogenic
cytokines but again the underlying method remains to be clarified.96
DC vaccination
DCs are more and more used in vaccination strategies to treat not only cancer but
also autoimmune responses in animal models. DCs can be isolated and cultured
from different sources such as bone marrow, blood and lymphoid organs. The
immature DCs can be loaded with different compounds ex vivo. Proteins,
peptides and lipids can be taken up and presented via antigen presenting
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molecules. DCs can also be loaded with DNA or mRNA, viral vectors, tumor
cells and tumor cell lysates. Transferring peptide- or lipid- loaded DCs can
result in the induction of a number of responses. In one study, DCs were pulsed
with bovine collagen type II and injection of the DCs in mice protected against
collagen-induced arthritis.205 The observed effect was dedicated to a decrease
in the collagen-specific Th1-associated IgG2a response. Loading immature DCs
with a peptide of glutamic acid decarboxylase and injection of these DCs in
non-obese diabetic mice protected against type I diabetes.206 Furthermore and
of importance for this thesis, lipids can be loaded on DCs. This may result in
an activation of lipid-specific NKT cells and a prolonged production of IFN-γ by
these cells. These DCs were protective against several forms of cancer.207,208
α-GalCer and OCH administration
As described above, α-GalCer and OCH are injected to activate NKT cells.
In most studies on autoimmune diseases, both ligands are administered in-
travenously (i.v.), intraperitoneally (i.p.) or a combination of both (Table 1.1).
One single injection of α-Galcer mostly results in the activation of NKT cells
producing more Th1 than Th2 cytokines. This results in a exacerbation of
different diseases in mouse models. Multiple injections however switch the NKT
cell activation towards a Th2 phenotype resulting in protection against many
autoimmune diseases except atherosclerosis (Table 1.1).
The ligands for NKT cells can also be administered via the above described
vaccination technique. Two studies showed that NKT cells can be activated by
injecting α-GalCer loaded on mature dendritic cells. This resulted in a sustained
expansion of NKT cells and a prolonged production of IFN-γ.207,208 Both ways of
administering NKT cell ligands may be useful to modify the immune response in
atherosclerosis.
Outline of this thesis
In this thesis several therapeutic strategies are used to treat atherosclerosis. All
these strategies are focused on interruption of the harmful Th1 immune response
in atherosclerosis. In all strategies there is a central role for the DCs. First of
all DCs were used as a vaccination unit to induce an atheroprotective antibody
response and to induce a protective NKT cell activation. Additionally, α-GalCer
was used to treat atherosclerosis and since DCs express CD1d they will be very
important in this process. Two studies are focused on the induction of oral
tolerance to atherosclerosis-specific antigens. Tolerogenic DCs present in the
Peyer’s patches in the gut are important regulators of the activation of Tregs after
oral feeding of the antigens. In the last study, the faith of NKT cells after Western
type diet feeding is described. DCs which engulf lipids can be responsible for the
activation of NKT cells in atherosclerosis. Overall, the focus of this thesis was to
develop novel experimental therapeutic strategies to treat atherosclerosis and to
increase insight in the role of Tregs and NKT cells in atherosclerosis.
Chapter 2 describes a study in which oral tolerance induction to oxLDL leads to
an increase in oxLDL-specific Tregs in several organs and leads to an amelioration
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of early atherosclerotic (30-71%) and advanced atherosclerotic lesions (45%).
Furthermore, an increase in Tregs within the atherosclerotic lesion and an
increased oxLDL-specific TGF-β production was observed.
Chapter 3 also describes a study in which oral tolerance induction was used to
inhibit atherosclerosis. In this study it is shown that tolerance induction to HSP60
or an HSP60 peptide (253-268) reduces atherosclerosis with 81%. After treatment
with HSP60, an increase in Foxp3+ Tregs was observed in several organs and the
atherosclerotic lesion. In addition, treatment with HSP60 increased TGF-β and
IL-10 production by HSP60 specific cells, while splenocytes from HSP60-treated
mice show lower proliferation in response to HSP60.
Chapter 4 describes a study in which mice were treated with oxLDL-pulsed DCs.
Atherosclerosis was dramatically reduced which may be due to an increased
plaque stability, lowered plasma cholesterol levels and increased titers of anti-
oxLDL IgG levels in serum of mice treated with oxLDL-pulsed DCs. This anti-
oxLDL IgG participates in immune-complex formation and reduces foam cell
development.
Chapter 5 describes a study in which the athero-protective effects of α-GalCer
were investigated. In contrast with other studies, a reduction in atherosclerosis
was found after multiple injections with α-GalCer in high fat diet fed LDLr-/-
mice. This effect was not observed in apoE-/- mice. Splenocytes of LDLr-/- mice
were more responsive to α-GalCer and Western-type diet feeding induced a more
abundant increase in NKT cells in LDLr-/- mice when compared to apoE-/- mice.
Chapter 6 describes another DC-vaccination study in which mice were treated
with OCH-pulsed DCs. OCH-pulsed DCs induce an activation of NKT cells,
which are increased in the liver and blood. Additionally we observed a Th2
profile of cytokines in the spleen and a lowering of total plasma cholesterol after
treatment with OCH-pulsed DCs.
Chapter 7 describes the search for natural ligands of NKT cells. Western-type diet
feeding in LDLr-/- mice resulted in an increased number of NKT cells in the liver
and spleen. Proliferation studies with LDLr-/- and LDLr-/-Jα281-/- mice showed
that oxLDL or at least a part of it can activate NKT cells. However, a similar lesion
size in LDLr-/-Jα281-/- and LDLr-/- mice fed a Western-type diet for 12 weeks was
observed.
Chapter 8 discusses the findings of this thesis and future perspectives of these
studies. Also the therapeutic implications will be evaluated.
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Oxidation of low-density lipoprotein (LDL) and the subsequent processing of oxidized
LDL (oxLDL) by macrophages results in activation of specific T cells, which contributes to
the development of atherosclerosis. Oral tolerance induction and the subsequent activa-
tion of regulatory T cells may be an adequate therapy for the treatment of atherosclerosis.
Tolerance to oxLDL and malondialdehyde-treated LDL (MDA-LDL) was induced in
LDLr-/- mice fed a Western-type diet by oral administration of oxLDL or MDA-LDL
before the induction of atherogenesis. Oral tolerance to oxLDL resulted in a significant
attenuation of the initiation (30-71%; P<0.05) and progression (45%; P<0.05) of athero-
genesis. Tolerance to oxLDL induced a significant increase in CD4+CD25+Foxp3+
cells in spleen and mesenteric lymph nodes, and these cells specifically responded to
oxLDL with increased transforming growth factor-β production. Tolerance to oxLDL also
increased the mRNA expression of Foxp3, CTLA-4 and CD25 in the plaque. In contrast,
tolerance to MDA-LDL did not affect atherogenesis. In conclusion, oxLDL-specific T cells,
present in LDLr-/- mice and important contributors in the immune response leading to
the atherosclerotic plaque, can be counteracted by oxLDL-specific CD4+CD25+Foxp3+
regulatory T cells activated via oral tolerance induction to oxLDL. We conclude that the
induction of oral tolerance to oxLDL may be a promising strategy to modulate the immune




The uptake of oxidized low-density lipoprotein (oxLDL) in the vessel wall by
antigen presenting cells (APCs), such as macrophages and dendritic cells, is
one of the hallmarks of the T helper 1 (Th1)-mediated immune response in
atherosclerosis. OxLDL ingested by macrophages is processed, and oxLDL-
derived epitopes will be presented on the cell surface via major histocompatibility
complex (MHC) class I and II molecules. Via the T cell receptor, oxLDL-
specific CD8+ and CD4+ T cells bind to MHC class I or II antigen complex,
respectively, and this results in the activation and proliferation of oxLDL-specific
T cells. The putative role of this oxLDL-specific response in atherosclerosis
is established by the presence of oxLDL-specific T cells in the vessel wall
and atherosclerotic plaques.1,2 These T cells are especially Th1 cells producing
Th1 cytokines such as interferon- IFN-γ, interleukin (IL)-12, IL-2 and tumor
necrosis factor (TNF)-α.3–5 In addition, immunoglobulin G2a (IgG2a) antibodies
against oxLDL, indicating Th1 assistance, predominate in plasma of low-density
lipoprotein receptor (LDLr)-/- and apolipoprotein E (apoE)-/- mice during early
stages of atherosclerosis.6 The presence of antibodies to oxLDL in serum of
patients with cardiovascular diseases also proves that oxLDL is one of the
(auto)antigens in atherosclerosis.7
Oral tolerance induction to autoantigens is one of the possible treatments for
Th1-mediated autoimmune diseases such as multiple sclerosis,8,9 rheumatoid
arthritis10,11 and type I diabetes.12,13 Antigens administered orally enter the gut
associated lymphoid tissue (GALT),14,15 which, as primary function, protects the
host from ingested pathogens and proteins.16,17 Currently, 2 primary effector
mechanisms of oral tolerance induction are known. Feeding high doses of
an antigen result in anergy or deletion of antigen-specific T cells,18,19 whereas
low doses of an antigen result in the induction of antigen-specific regulatory T
cells.20 These regulatory T cells can be divided into three groups: Th3 cells and
Tr1 cells, mediating suppression via secretion of TGF-β and IL-10, respectively,
and CD4+CD25+ regulatory T cells characterized by the expression of the
transcription factor forkhead box P3 (Foxp3). The regulatory function of the
CD4+CD25+Foxp3+ cell is mediated by cell contact and surface-bound TGF-
β and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4).21 After activa-
tion in the GALT, the regulatory T cells migrate to the site of inflammation
and on reencountering the fed antigen they display their specific suppressive
effect, resulting in an attenuated Th1 mediated immune response specific for
the fed antigen. Initial studies show that oral tolerance induction to β2-
glycoprotein I22 and HSP6523,24 results in the suppression of early atherosclerosis
and demonstrate that oral tolerance induction could be a successful treatment for
atherosclerosis.
In the present study we demonstrate that induction of oral tolerance to oxLDL
attenuates both the initiation and the progression of atherosclerosis, whereas
malondialdehyde-treated LDL (MDA-LDL) was unable to mediate this effect.
The effect of oxLDL tolerance may be explained by a significant increase in
CD4+CD25+Foxp3+ regulatory T cells in the mesenteric lymph nodes and
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spleen, an increased production of TGF-β by these cells and a significant
upregulated expression of Foxp3 and CD25 in the atherosclerotic lesions.
Methods
Animals
All animal work was approved by Leiden University and was in compliance with
the Dutch government guidelines. LDLr-/- mice were from the Jackson Labora-
tory, Bar Harbor, Me. They were kept under standard laboratory conditions and
administered food and water ad libitum.
Antigens and adjuvant
Dimethyl dioctadecyl ammonium bromide (DDA) was from Sigma Diagnostics,
St. Louis, MO. LDL was isolated from serum of a healthy volunteer.25 Isolated
LDL was oxidized by 10 µM CuSO4 at 37◦C for 20 hrs26 and MDA-LDL was
made by addition of 0.5 M MDA to 10 mg of LDL for 3 hours at 37◦C.
Immunizations
LDLr-/- mice were immunized with 100 µg of oxLDL or MDA-LDL together
with 100 µg of DDA via one i.p. injection. After 14 days spleens were used in
proliferation assays.
Spleen cell proliferation assay
Spleen cells were collected by squeezing the spleen through a 70 µm cell strainer,
erythrocytes were removed by an erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM
NaHCO3, 0.1 mM EDTA, pH 7.3). Splenocytes were cultured at 2·105 cells/well
in 96-wells plates in RPMI 1640 (2 mM L-Glutamine, 10% FCS) for 24-48 hours.
Concanavalin A (Con A; Sigma-Diagnostics, MO) was used as a positive control.
Cultures were pulsed for the final 16 hours with [6-3H]-thymidine (1 µCi/well,
Amersham Biosciences, The Netherlands). Subsequently, cells were washed,
lysed and [3H]-thymidine incorporation was measured. Responses are expressed
as stimulation index (SI): ratio of mean counts per minute of triplicate cultures
with antigen to triplicate cultures without antigen.
Flow cytometric analysis
Splenocytes were incubated with oxLDL (1-10 µg/ml) in the presence of anti-
CD3 (5 µg/ml) and anti-CD28 (5 µg/ml). 48 hours later cells were harvested,
incubated with 1% normal mouse serum and stained with PerCP-conjugated
anti-CD3 and FITC-conjugated anti-F4/80 (0.5 µg Ab/200,000 cells). After
washing, cells were analyzed by flow cytometry on a FACSCalibur. To de-
tect CD4+CD25+Foxp3+ T cells, a three color flow cytometry was performed.
Mononuclear cells were isolated from spleen, mesenteric lymph nodes, Peyer’s
patches, and blood using Lympholyte (Cedarlane, Canada). Cells were stained
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with FITC-conjugated anti-CD4 (0.125 µg/sample) and APC-conjugated anti-
CD25 (0.06 µg/sample) mAb, cells were washed, fixed and permeabilized.
Subsequently cells were stained with PE-conjugated anti-Foxp3 (0.2 µg/sample).
Cells were washed and analyzed by FACS. Data were analyzed with CELLQuest
software (BD Biosciences, The Netherlands) and antibodies were from eBio-
science, Belgium.
Induction of atherosclerosis
Atherosclerosis was induced in LDLr-/- mice by feeding a Western-type diet
(0.25% cholesterol and 15% cocoa butter (Special Diet Services, Witham, Essex,
UK)) two weeks prior to placement of perivascular collars.27 Total cholesterol
levels were quantified using an enzymatic procedure (Roche Diagnostics, Ger-
many) using Precipath as an internal standard.
Oral tolerance induction during atherosclerosis
To induce tolerance LDLr-/- mice were fasted for 16 hrs. 2 mg of soybean
trypsin inhibitor (STI, Sigma, MO) was administered orally to prevent antigen
degradation and 10 minutes thereafter mice orally received PBS, 30 µg of Super
Oxide Dismutase, (SOD, Sigma-Diagnostics, MO), 30 µg of oxLDL or MDA-
LDL. Injections were repeated 3 times to a total of 4 injections in 8 days. After
administering the antigens mice were kept on Western-type diet. This was
performed either in the first week of diet or after 10 weeks of diet.
Plaque analysis
Six weeks after collar placement the mice were anaesthetized with ketamine-
hypnorm and perfused with FormalFixx. Common carotid arteries and both
carotid bifurcations were removed for analysis.27 Arteries were embedded in
OCT compound (TissueTek; Sakura Finetek, The Netherlands) and 5 µm sections
were made on a Leica Cryostat proximal to the collar. Cryosections were stained
with hematoxylin (Sigma Diagnostics, MO) and eosin (Merck Diagnostica, Ger-
many). For analysis of the aortic root 10 µm thick sections were made of the
aortic root containing the aortic valves. Sections were stained with Oil-Red-O
and hematoxylin. Plaque sizes were measured using a Leica DM-RE microscope
and LeicaQwin software. Sections were also stained immunohistochemically
using antibodies against a macrophage-specific antigen (MOMA-2, Research
Diagnostics Inc) and α-smooth muscle cell actin (monoclonal mouse IgG2a,
Sigma) exactly as described.28
Cytokine assays
Mesenteric lymph node cells were cultured at 2·106 cells/ml with or without
5 µg/ml oxLDL. IL-10, IFN-gamma (eBioscience, Belgium) and TGF-β (Bender
MedSystems, Austria) concentrations were determined by ELISA in the super-
natants.
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Real-time PCR assays
Carotid arteries from control and oxLDL-treated mice were isolated and mRNA
was extracted using the guanidium isothiocyanate (GTC) method and reverse
transcribed (RevertAid M-MuLV reverse transcriptase). Quantitative gene ex-
pression analysis was performed on an ABI PRISM 7700 sequence detector
(Applied Biosystems, CA) using SYBR green technology. The following primer
pairs were used: 5’-GGAGCCGCAAGCTAAAAGC-3’ and 5’-TGCCTTCGTG-
CCCACTGT-3’ for Foxp3; 5’-CTTATATTGCAAATGTGGCACAATC-3’ and 5’-
ATCAATCATCAGTGGGACAATCTG-3’ for CD25; 5’-CGAGGTCCTGCACCA-
ACTG-3’ and 5’-TCCATCACCATCGGTTTATGC-3’ for CTLA4. Acidic ribo-
somal phosphoprotein PO (36B4) was used as the endogenous reference gene
and detected using the primers 5’-GGACCCGAGAAGACCTCCTT-3’ and 5’-
GCACATCACTCAGAATTTCAATGG-3’.
Detection of anti-oxLDL antibodies
OxLDL (5 µg/ml) dissolved in a NaHCO3/Na2CO3 buffer (pH 9.0) was coated.
Measurement of IgG1 and IgG2a levels in serum was performed using an ELISA
Ig detection kit (Zymed Laboratories, CA) conform the manufacturer’s protocol
and appropriate controls were performed.
Statistical analysis
All data are expressed as mean±SEM. The two-tailed student’s t-test was used to
compare proliferative responses to antigens, FACS data, differences in cytokine
production, and atherosclerotic parameters between the different groups.
Results
T cells specific for oxLDL and MDA-LDL in LDLr-/- mice
The presence of T cells specific for oxLDL and MDA-LDL epitopes in LDLr-/-
mice was investigated via a spleen cell proliferation assay. Splenocytes isolated
from naive LDLr-/- mice were incubated with several concentrations of oxLDL or
MDA-LDL. Low concentrations of oxLDL, 1 and 5 µg/ml, resulted in a 1.53±0.17
(P<0.05) and 2.52±0.23 (P<0.001) fold increase in proliferation, respectively
(Figure 2.1A). In case of MDA-LDL, incubation of splenocytes with 1, 5 and
10 µg/ml of MDA-LDL, resulted in a 1.62±0.15 (ns), 2.90±1.15 (P<0.05) and
4.41±0.89 (P<0.01) fold increase in proliferation, respectively (Figure 2.1B).
OxLDL was toxic at concentrations >10 µg/ml, whereas MDA-LDL was only
toxic at concentrations >100 µg/ml (data not shown). In all experiments conA,
a general pan T cell activator, induced a >50-fold increase in proliferation (data
not shown).
In addition we determined whether the T cell response to modified LDL can be
modulated in vivo. LDLr-/- mice were immunized by intraperitoneal injection
of 100 µg of oxLDL or MDA-LDL in combination with the adjuvant DDA.
Two weeks thereafter, the mice were euthanized and isolated splenocytes were
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incubated with oxLDL or MDA-LDL. OxLDL induced a higher proliferation at 1
and 5 µg/ml of 2.89±0.29 and a 7.25±0.81 fold, respectively, compared with the
controls (P<0.01) (Figure 2.1C). Incubation of splenocytes isolated from MDA-
LDL immunized mice with 1, 5 and 10 µg/ml MDA-LDL resulted in a 2.07±0.82
(ns), 3.94±0.41 (P<0.01) and 6.17±1.50 (P<0.05) fold increase in proliferation
(Figure 2.1D).
A flow cytometric analysis was performed on the proliferating cells to determine
the cell type responsible for the cell proliferation. The amount of CD3+ T
cells increased significantly from 34.5±1.5% to 46.9±2.4% when splenocytes
were incubated with 5 µg/ml of oxLDL (Figure 2.1E; P<0.05). The amount of



















































































Figure 2.1: Spleen cell proliferation in response to oxLDL and MDA-LDL. LDLr-/- mice were immunized
via one i.p. injection with 100 µg of oxLDL or MDA-LDL. Two weeks thereafter, splenocytes were isolated
from naive and immunized LDLr-/- mice and cultured with oxLDL (A and C, respectively) or MDA-LDL (B and
D, respectively) for 24 hrs. In the control situation, splenocytes from naive or immunized mice were cultured in
absence of oxLDL or MDA-LDL. The amount of proliferation was measured by incorporation of 3H-thymidine,
which was added for the final 16 hours of the assay. Data are shown as the stimulation index (S.I.) ± SEM. The
S.I. is defined as the ratio of the mean counts per minute of triplicate cultures with antigen to the mean counts
per minute in culture medium without antigen. Graph E shows the percentage of CD3+ cells (mean±SEM)
after proliferation of the splenocytes with 1, 5 and 10 µg/ml of oxLDL. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001
Effect of oral tolerance induction to oxLDL and MDA-LDL on the initiation of
atherosclerosis
To determine the effect of oral tolerance induction to oxLDL and MDA-LDL
on atherosclerotic plaque initiation, atherosclerosis was induced after oral ad-
ministration of oxLDL and MDA-LDL to LDLr-/- mice. Mice were put on a
Western-type diet for one week and subsequently, oral tolerance was induced
by oral administration of 30 µg of oxLDL or MDA-LDL. Treatment was repeated
every other day to four times in total. After tolerance induction, the Western-type
diet feeding was continued and one-week later mice were equipped with collars
around both carotid arteries to induce atherosclerosis.29 During the experiment
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total plasma cholesterol levels were not significantly different between the groups
and increased from 679±64 mg/dl (before diet) to 1554±140 mg/dl in control
mice, to 1755±146 mg/dl in oxLDL treated mice and to 1718±77 mg/dl in
MDA-LDL treated mice. Six weeks after collar placement atherosclerotic plaque
formation was analyzed after a hematoxylin-eosin staining of cryosections of the
carotid arteries (Figure 2.2A, 2.2B). Oral feeding of LDLr-/- mice with SOD had
no effect on plaque size as compared to PBS (data not shown). Oral tolerance
induction to oxLDL resulted in a significant 71.2% reduction in plaque area
(Figure 2.2C; 20768±5964 versus 6046±1941 µm2; P<0.05) when compared to
control mice. Furthermore, a beneficial 55.3% reduction in intima/lumen ratio
(Figure 2.2D; 0.25±0.06 versus 0.11±0.03; P<0.05) and a 72.1% reduction in
intima/media ratio (data not shown; 0.75±0.23 versus 0.21±0.04; P<0.05) was
observed. In case of MDA-LDL, oral tolerance induction did not result in a
significant effect on plaque size (Figure 2.2E; 23314±8016 versus 37327±13137
µm2; P=0.41) and also no significant effect on intima/lumen ratio (Figure
2.2F; 0.29±0.12 versus 0.50±0.16; P=0.34) and intima/media ratio (data not
shown; 0.42±0.15 versus 1.12±0.34 in the MDA-LDL-treated group; P=0.12) was
observed. In a second independent experiment the effect on plaque formation in
the aortic root was determined at 8 weeks of diet. Oral treatment with oxLDL
(Figure 2.3B) resulted in a significant 29.9% reduction in plaque size (Figure
2.3C; 669243±56643 versus 469288±27950 µm2; P<0.01) when compared with
control-treated mice (Figure 2.3A). Immunohistochemical analysis of the plaques
of both experiments showed that oral tolerance induction to oxLDL and MDA-
LDL had no effect on the relative macrophage and smooth muscle cell content
when compared to plaques of control mice (data not shown).
Effect of oral tolerance induction to oxLDL on progression of atherosclerosis
Next we determined the effect of tolerance induction to oxLDL on the progression
of atherosclerosis. To this end, LDLr-/- mice were put on a Western-type diet for
10 weeks, which resulted in the initial formation of plaques in the aortic root. At
that time point oral tolerance to oxLDL was induced (30 µg of oxLDL, 4 times)
and subsequently the LDLr-/- mice were kept on a Western-type diet for another
7 weeks. During the experiment total plasma cholesterol levels increased from
503±67 to 2727±243 mg/dl and 2422±366 mg/dl in the control and oxLDL-
treated mice, respectively (no significant difference). After 7 weeks, the mice
were sacrificed, cryosections of the aortic root of control-treated (Figure 2.4A) and
oxLDL-treated (Figure 2.4B) mice were stained with Oil-red-O and atherosclerotic
plaque formation in the aortic root was analyzed. OxLDL-treated mice showed
a modest, but significant 24.3% reduction in plaque size at the aortic root (Figure
2.4C; 715523±56365 µm2 versus 541353±55239 µm2; P<0.05) as compared to
control-treated mice. The effect of oral tolerance induction to oxLDL is more
impressive when it is taken into account that the size of the plaques at the time
of tolerance induction was 300000 µm2 in a third group of mice. Subtraction of
the lesion size at the start of the oral feeding establishes that oxLDL treatment led
to a 42.4% reduction in plaque progression (Figure 2.4D). Interestingly, no effect












































































Figure 2.2: Effect of oral tolerance induction to oxLDL on atherosclerotic plaque formation in collar
induced atherosclerosis in the carotid artery LDLr-/- mice were fed oxLDL or MDA-LDL four times
before atherosclerosis was induced by collar placement around both carotid arteries. Six weeks after collar
placement the mice were killed and the carotid arteries of control-treated (A), oxLDL-treated (B) and MDA-
LDL-treated (not shown) mice were sectioned and stained with hematoxylin-eosin. The lesions were quantified
by computer-assisted morphometric analysis and the plaque size and intima/lumen ratio of oxLDL-treated (C



























Figure 2.3: Effect of oral tolerance induction to oxLDL on atherosclerotic plaque formation in the aortic
root LDLr-/- mice were fed oxLDL four times before atherosclerosis was induced by feeding a Western-type
diet. After eight weeks of diet mice were killed and the aortic roots of control-treated (A) and oxLDL-treated (B)
mice were sectioned and stained with Oil-red-O and hematoxylin. The lesions were quantified and the plaque
size was determined (C). ∗∗P<0.01
smooth muscle cell content in the plaque (data not shown).
Effect of oral tolerance induction to oxLDL on CD4+CD25+Foxp3+ regulatory T
cells
To determine whether oral tolerance induction to oxLDL was associated with
a change in regulatory T cell levels, a flow cytometric analysis was performed.
CD4+CD25+Foxp3+ cells are normally present in low numbers in spleen
(0.8±0.2%), mesenteric lymph nodes (3.0±0.4%), Peyer’s patches (1.7±0.4%)
and blood (1.7±0.1%) of control LDLr-/- mice. Two and four days after the
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Figure 2.4: Oral tolerance induction to oxLDL attenuates atherosclerotic plaque progression in LDLr-/-
mice. LDLr-/- mice were fed a Western-type diet for 10 weeks before oxLDL was administered orally 4 times.
After oral tolerance induction the mice were kept on a Western-type diet for 7 more weeks. The aortic roots of
control-treated (A) and oxLDL-treated (B) mice were sectioned and stained with Oil-red-O and hematoxylin.
Lesions at the aortic root were quantified by computer-assisted morphometric analysis and the plaque size (C)
was determined. Graph D shows a dot plot of lesion size in all mice. The bar at 0.30·106 µm2 represents the
lesion size of mice after 10 weeks of diet without oral treatment. ∗P<0.05
fourth and last oral feeding of oxLDL, the number of CD4+CD25+Foxp3+ cells
increased significantly to 1.3±0.1% and 1.6±0.2% in the spleen, respectively
(Figure 2.5A; P<0.05) and to 5.2±0.2% and 5.8±0.6% in mesenteric lymph nodes,
respectively (Figure 2.5B; P<0.01). No significant changes were seen in the
Peyer’s patches and blood. To determine if the effect was long lasting, mice
were sacrificed 14 days after the last oral feeding. CD4+CD25+Foxp3+ cells
were still increased in spleen and mesenteric lymph nodes (1.4±0.1% (P<0.05)
and 5.4±0.3% (P<0.01), respectively) after oral feeding of oxLDL (Figure 2.5A,
2.5B), whereas MDA-LDL did not affect the number of CD4+CD25+Foxp3+
cells (not shown). To determine the effect of induction of CD4+CD25+Foxp3+
cells on cytokine production, mesenteric lymph nodes of control, oxLDL, and
MDA-LDL-treated mice were re-stimulated with 5 µg/ml oxLDL or MDA-LDL
in vitro. We observed that oxLDL only induced a significant 6-fold increase
in TGF-β in lymph node cells from oxLDL tolerant mice, but not in control
pretreated mice, whereas MDA-LDL was unable to induce TGF-β in MDA-LDL
pretreated or control mice (not shown). The IL-10 and IFN-γ levels were in any
of the experiments below the detection limits.
Expression of regulatory T cell markers in atherosclerotic plaques
We analyzed the expression of CD25 and Foxp3 in atherosclerotic plaques in the
carotid arteries. After treatment with oxLDL (n=14) and 8 weeks of Western-
type diet feeding, the relative mRNA expression of Foxp3, CTLA-4 and CD25





































































































Figure 2.5: Effect of oral tolerance induction to oxLDL on CD4+CD25+Foxp3+ cells in spleen and
MLNs. LDLr-/- mice were fed PBS or oxLDL 4 times and were killed at day 2, 4 and 14. The dot plots
show representative examples of lymphoid cells isolated from the spleen (A) and mesenteric lymph nodes (B)
stained for CD4 and CD25 (left panels). The right panel of dot plots shows the percentage of Foxp3+ cells
within the CD4+CD25+ population. Graph C represents the percentage of CD4+CD25+Foxp3+ cells in the
spleen, graph D the percentage of CD4+CD25+Foxp3+ cells in the mesenteric lymph nodes (mean±SEM). (E)
TGF-β production by mesenteric lymph node cells isolated 14 days after treatment from control and oxLDL-
treated mice and restimulated with PBS (open bars) or oxLDL (closed bars) in vitro. ∗P<0.05, ∗∗P<0.01,
∗∗∗P<0.001 (compared to all other bars)
control mice (n=8). Foxp3 showed a 1.5-fold increase, CTLA-4 a 1.7-fold increase
and CD25 a 2.2-fold increase (Figure 2.6; P<0.05).
Influence of oral tolerance induction to oxLDL on IgG patterns
OxLDL-specific IgG1 and IgG2a levels in serum were determined at the end of
the experiment on the initiation of atherosclerosis. No detectable differences
in IgG1 and IgG2a levels were observed (Figure 2.7A, 2.7B, respectively) and
no difference in the IgG1/IgG2a ratio in control and oxLDL-treated mice was
observed (Figure 2.7C).
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Figure 2.6: Expression of regulatory T cell markers in oxLDL-treated and control mice. mRNA was
isolated from carotid arteries of control (n=8) and oxLDL-treated (n=14) mice and the mRNA levels of Foxp3,













































Figure 2.7: Effect of tolerance to oxLDL on oxLDL-specific IgG1 and IgG2a levels. LDLr-/- mice were
treated orally with PBS or oxLDL and serum levels of oxLDL-specific IgG1 (A) and IgG2a (B) were measured
using a capture enzyme-linked immunosorbent assay. Values are mean OD(405) values ± SEM. Graph C
represents the effect of oral tolerance induction to oxLDL on the IgG1/IgG2a ratio.
Discussion
One of the first events in atherosclerosis is the oxidative modification of LDL and
the subsequent uptake of oxLDL by macrophages. Epitopes from oxLDL, such
as apolipoprotein B-100 peptides,30 and oxidized phosphorylcholine-containing
phospholipids,31 can be presented by antigen presenting cells and result in T cell
activation.32 Autoreactive T cells specific for oxLDL epitopes have been found in
human atherosclerotic plaques,1 and in atherosclerotic lesions in apoE-/- mice.2
We now demonstrate that naive LDLr-/- mice already contain T cells specific for
oxLDL and MDA-LDL as shown in spleen cell proliferation assays. In addition,
we show that the in vivo response to oxLDL and MDA-LDL can be modified by
immunization with oxLDL or MDA-LDL. The spleen cell proliferation showed
an enhanced proliferation (3-7-fold) in the immunized mice when compared to
the naive mice.
It is well known that the T cells in atherosclerotic lesions, reactive to several
antigens such as oxLDL and heat shock proteins, mainly produce Th1 cytokines
resulting in a disturbed balance between Th1 and Th2 cytokines. Several
studies show that via Th1 cytokine inhibition the extent of atherosclerosis
can be reduced.28,33–35 The other way around, stimulation of the Th2 cytokine
production can attenuate atherosclerosis.29,36 Although restoration of the
imbalance between Th1 cells and Th2 cells may be effective in atherosclerosis,
some debate on the beneficial role of Th2 cells in atherosclerosis exists:
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experiments with IL-4, a Th2 cytokine, show that IL-4 may be pro-atherogenic.33
Mallat et al. hypothesized that in atherosclerosis an imbalance exists between
pathogenic T cells (Th1 and/or Th2) and regulatory T cells (Tregs) specific
for ’altered’ self and non-self antigens.37 Recently, Ait-Oufella et al. showed
that regulatory T cells play an important role in controlling the development
of atherosclerosis.38 A possible mechanism to achieve a beneficial shift in the
balance between pathogenic T cells and regulatory T cells is mucosal tolerance
induction. The regulatory T cells induced via nasal tolerance, Tr1 cells, mainly
produce IL-10 and regulatory T cells induced via oral tolerance, Th3 cells, mainly
produce TGF-β.39 Besides Tr1 and Th3 cells, mucosal tolerance induction can also
lead to activation of CD4+CD25+Foxp3+ cells. Foxp3 is known as an exclusive
marker for natural regulatory T cells.40 The regulatory function of these cells is
mediated by cell contact and surface-bound TGF-β and CTLA-4.21
In our current study we show that oral tolerance induction to oxLDL can
both attenuate atherosclerosis in an early stage and in an advanced stage. A
relative low dose of oxLDL (30 µg, four times) significantly attenuated early
atherosclerotic lesion formation in the carotid arteries by 71.2% and at the aortic
root by 29.9%. The effect on lesion initiation is reflected in the intima/lumen
ratio (55.3% reduction) and the intima/media ratio (72.1% reduction) of carotid
arteries. Our results are in line with studies that showed that oral or nasal
tolerance induction to HSP65 and β2-glycoprotein I may be a useful treatment
for atherosclerosis.22–24 In our current study also a significant 24.3% reduction in
advanced atherosclerotic lesion size was observed. Taken the initial lesion size
into account a 42.4% reduction in plaque progression is obtained. In line with
the studies on HSP65 and β2-glycoprotein I, no effect on the relative macrophage
and collagen content of the plaque was seen in both experiments.22,24 We
have previously shown that overexpression of IL-10, another way to modulate
the inflammatory process in atherosclerosis, largely reduced (62.2%) the
atherosclerotic lesion formation without any effect on macrophage, collagen and
SMC content of the plaque.29
Besides oxLDL, MDA-LDL was also used in this study as antigen for oral
tolerance induction. Surprisingly, no significant effect on atherosclerotic plaque
area was seen after oral tolerance induction with 30 µg of MDA-LDL in LDLr-/-
mice. The LDLr-/- mice treated orally with MDA-LDL showed a 60.8% (P=0.41)
increase in plaque area and a 71.1% (P=0.34) increase in intima/lumen ratio.
We also explored the possible effect of oral tolerance induction on the antibody
isotype distribution. No significant alterations in oxLDL-specific IgG1 and IgG2a
levels were detected and consequently also no effect on the IgG1/IgG2a ratio
was observed, suggesting that the Th1/Th2 ratio in the mice was not altered by
tolerance induction.
The lack of an effect on oxLDL-specific antibodies demonstrate that the
suppressing effects shown after oral tolerance induction are not caused by an
effect on the humoral immune response. In the majority of the studies and in
all studies on atherosclerosis the exact mechanism behind oral tolerance is still
unclear. Increasing levels of IL-10 and TGF-β after oral tolerance induction are
dedicated to a stimulated development of adaptive immune cells.24 Zhang et
al. found an increased amount of CD4+CD25+ cells after feeding mice with
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OVA. These ”regulatory” T cells were declared to be responsible for the high
levels of IL-10 and TGF-β.41 Recently, CD4+CD25+ cells with Foxp3 expression
were found to be immuno-suppressive. We demonstrate that oxLDL tolerance
induction significantly increases the number of CD4+CD25+Foxp3+ cells for
up to two weeks in the spleen and the mesenteric lymph nodes. Since these
regulatory T cells exert their suppressive effect via cell-cell contact and surface-
bound TGF-β, we determined the TGF-β production in the mesenteric lymph
nodes. Lymph node cells from oxLDL tolerant mice produced 6-fold higher
levels of TGF-β upon re-stimulation with oxLDL than cells from control mice,
indicating the induction of TGF-β producing regulatory T cells.
In addition, analysis of mRNA expression levels showed that oxLDL tolerance
induction increased the expression of Foxp3, CTLA-4 and CD25 within the
plaque, clearly indicating the presence of regulatory T cells within the lesions
upon tolerance induction. The profile of gene expression upon oxLDL tolerance
induction, together with the induction of Foxp3 in spleen and lymph nodes
and concurrent oxLDL specific TGF-β production in the absence of IL-10 and
IFN-γ production highly suggest that CD4+CD25+Foxp3+ Tregs rather than Tr1
or Th3 are responsible for the observed effects of oxLDL tolerance induction
on atherosclerosis. The absence of induction of Tregs by MDA-LDL and the
absence of TGF-β induction in lymph node cells of MDA-LDL pretreated cells
by MDA-LDL may explain the absence of an regulatory effect of oral treatment
with MDA-LDL.
It may be speculated that oxLDL specific Tregs induced by oral tolerance regulate
the action of oxLDL specific CD4+ T cells within the plaque in the following
way: oxLDL specific CD4+ T cells are within the plaque activated by oxLDL
presenting APCs, which may lead to the expression of TGF-β receptor II (TβRII)
by these cells. OxLDL specific Tregs also recognize oxLDL presented by the APCs
and via the enhanced production of TGF-β, Tregs can modulate the action of
oxLDL specific CD4+ T cells.42,43 TGF-β-TβRII interaction leads to the activation
of a Smad-dependent pathway, resulting in a blockade of IL-2 production43,44
and a reduced proliferation of oxLDL-specific T cells.
In conclusion we describe that LDLr-/- mice can be tolerized to oxLDL which
results in an attenuation of both early an advanced atherosclerotic lesions.
The mechanism underlying this effect can be dedicated to the induction of
CD4+CD25+Foxp3+ regulatory T cells which counteract within the plaque
the oxLDL-specific CD4+ T cells. These results are promising and prove that
the mechanism of oral tolerance induction could be an effective treatment for
atherosclerosis.
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HSP60-specific T cells contribute to the development of the immune responses in
atherosclerosis by producing proinflammatory cytokines. This can be dampened by
regulatory T cells (Tregs) which are activated via oral tolerance induction. In this study
we explored the effect of oral tolerance induction to HSP60 and the peptide HSP60(253-
268) on experimental atherosclerosis. HSP60 and HSP60(253-268) were administered
orally to LDLr-/- mice prior to induction of atherosclerosis and oral tolerance induction
resulted in a significant 80.7% and 81.3% reduction (P<0.05) in plaque size in the
carotid arteries, respectively, and in a 27.4% reduction in plaque size at the aortic root in
HSP60-treated mice. Reduction in plaque size correlated with an increase in the number
of CD4+CD25+Foxp3+ Tregs in several organs and also an increased expression of Foxp3,
CD25 and CTLA-4 in the atherosclerotic lesion was observed in HSP60-treated mice. In
addition, an increased production of IL-10 and TGF-β by mesenteric lymph node cells in
response to HSP60 was observed, while splenocytes from HSP60-treated mice proliferated
much lower in response to HSP60 when compared with PBS-treated mice. In conclusion,
oral tolerance induction to HSP60 and a small HSP60-peptide leads to an increase in
the number of specific CD4+CD25+Foxp3+ Tregs, resulting in a decrease in plaque size
as a consequence of increased production of IL-10 and TGF-β. We conclude that these
beneficial results of oral tolerance induction to HSP60 and HSP60(253-268) may provide




Heat shock proteins (HSPs) are a family of highly conserved proteins with
various functions in normal and stressful situations. Expression of HSPs on
endothelial cells and macrophages1,2 can be induced by several stress factors,
such as fluid shear stress,3 oxidized lipoproteins4 and cytokines.2 Under these
circumstances, HSPs repair or prevent degradation of denaturated proteins
and increase the cell’s ability to survive stressful stimuli.5,6 HSPs such as
HSP60 are also involved in inflammatory diseases, probably resulting from
their raised expression in cells exposed to proinflammatory mediators.7,8 In
human atherosclerotic lesions,9 enhanced HSP60 expression has been detected.
In addition, patients with atherosclerosis show an elevated concentration of
HSP60-specific antibodies in serum,2 and T cell clones with self-HSP60 reactivity
have been detected within the atherosclerotic plaques.10 This may be related to
initial immune responses against bacterial heat shock proteins which are highly
homologous to HSPs in various other species including men, rats and mice.11 It
is possible that the HSP60-specific antibodies contribute to endothelial damage
and the inflammatory response in the vessel wall accelerating atherosclerosis.12
The autoimmune process in atherosclerosis is characterized by a T cell response
to different autoantigens, e.g. oxidized LDL13, glycoproteins14 and HSPs15.
HSP60-specific T cells are mainly of a Th1 phenotype, producing pro-atherogenic
cytokines, such as IFN-γ, IL-12 and TNF-α and causing a disturbed balance
between Th1 and Th2 cytokines in atherosclerosis.16 For a long time, this
disturbed balance was regarded as the cause of the ongoing inflammation in
atherosclerosis. Recent publications however suggest that Tregs play an impor-
tant role in prevention of Th1 mediated autoimmune diseases such as multiple
sclerosis,17 diabetes mellitus18 and atherosclerosis.19 Mallat et al. hypothesized
that in atherosclerosis an imbalance exists between pathogenic T cells (Th1
and Th2) and Tregs (Tregs) specific for ’altered’ self and non-self antigens (e.g.
oxidized phospholipids, heat shock proteins).20
One way to increase the number of antigen specific Tregs is ”low dose” oral
tolerance induction. This method is already used as a treatment in animal
models for Th1 mediated autoimmune diseases such as multiple sclerosis,21,22
rheumatoid arthritis23,24 and type I diabetes.25,26 Initial studies also show that
oral tolerance induction to β2-glycoprotein I27 and HSP6528,29 results in the
suppression of early atherosclerosis. However, these studies do not show the
involvement of Tregs. We describe in a recent study an increase in the number
of CD4+CD25+Foxp3+ cells after oral tolerance induction to oxidized LDL
(oxLDL)30 and a subsequent reduction in plaque size. These CD4+CD25+Foxp3+
cells form a class of Tregs that may either be natural Tregs which act via cell-
cell contact via surface-bound TGF-β 31 or cytotoxic T lymphocyte-associated
antigen-4 (CTLA-4)32 or they may be adaptive Tregs operating via the secretion
of TGF-β.
In the present study we demonstrate that induction of ”low dose” oral tol-
erance to HSP60 and a peptide based on the highly conserved 253-268 se-
quence of mycobacterial HSP60 (HSP60(253-268)) attenuates atherosclerosis. The
regulatory effect on atherosclerosis is explained by an increased number of
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CD4+CD25+Foxp3+ Tregs in both lymphoid organs and the atherosclerotic
lesion. This is accompanied by an increase in HSP60-specific TGF-β and IL-10
production in mesenteric lymph node cells. In addition, tolerance induction to
HSP60 reduces the proliferation of splenocytes in response to HSP60.
Methods
Animals
All animal work was approved by the regulatory authority of Leiden University
and carried out in compliance with the Dutch government guidelines. Male
LDLr-/- mice were obtained from the Jacksons Laboratory. Mice were kept
under standard laboratory conditions and were fed a normal chow diet or a
’Western-type’ diet containing 0.25% cholesterol and 15% cocoa butter (Special
Diet Services, Witham, Essex, UK). All mice used were 10-12 weeks of age. Diet
and water were administered ad libitum.
Antigens and adjuvant
Dimethyl dioctadecyl ammonium bromide (DDA; Sigma Diagnostics, MO), used
as adjuvant, was dissolved in phosphate buffered saline (PBS) and 100 µg
was mixed with 100 µg of the antigen (HSP60, HSP60(253-268) or HSP70(111-
125)) before immunization. Purified recombinant HSP60 of Mycobacterium bovis
bacillus Calmette-Gurin was kindly provided by J.D.A. van Embden (National
Institute of Public Health and Environmental Hygiene, Bilthoven, The Nether-
lands). HSP60(253-268) based on the sequence of mycobacterial HSP60 aa 253-268
(NH2-EGEALSTLVVNKIRGT-amide), was made by regular peptide synthesis
(FMOC protection). Another peptide HSP70(111-125) was based on a partially
conserved (human, rat, mouse) sequence of the HSP70 peptide aa 111-125 (NH2-
ITDAVITTPAYFNDA-amide).33
Immunizations
LDLr-/- mice were immunized via one i.p. injection with PBS or 100 µg of HSP60,
HSP60(253-268) or HSP70(111-125). The antigens were dissolved in 200 µl of PBS
containing 100 µg DDA. After 14 days the spleens were dissected and used in the
proliferation assay described below.
Spleen Cell Proliferation Assay
Spleens from either naive (n=3 or 12), immunized (n=3) or oral treated mice
(n=12) were dissected and squeezed through a 70 µm cell strainer (Falcon, The
Netherlands). The erythrocytes were eliminated by incubating the cells with
erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH
7.3). The splenocytes were cultured for 48 hours in triplicate at 2·105 cells per
well of a 96-wells round-bottom plate in the presence or absence of different
concentrations of HSP60, HSP60(253-268) or HSP70(111-125). RPMI 1640 (with
L-Glutamine, 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 µg/ml
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streptomycin (all from BioWhittaker Europe)) was used as culture medium.
Concanavalin A (Con A; Sigma-Diagnostics, MO) (2 µg/ml) was used as a
positive control. Cultures were pulsed for an additional 16 hours with [6-3H]-
thymidine (1 µCi/well, sp. act. 24 Ci/mmol; Amersham Biosciences, The
Netherlands). The amount of [6-3H]-thymidine incorporation was measured
using a liquid scintillation analyzer (Tri-Carb 2900R). The magnitude of the
proliferative response is expressed as stimulation index (SI) defined as the ratio of
the mean counts per minute of triplicate cultures with antigen to the mean counts
per minute in culture medium without antigen.
Induction of atherosclerosis
To determine the effect of oral tolerance induction on the initiation of atheroscle-
rosis, atherosclerosis was induced in LDLr-/- mice. The mice were put on a
Western-type diet three weeks prior to surgery. Atherosclerosis was induced
by placement of perivascular collars, prepared from elastic tubing (0.3 mm
inside diameter; Dow Corning, Midland, Michigan), around both carotid arteries
(method described by von der Thüsen et al.34). During the experiment, the
diet response was followed by measuring the cholesterol and triglyceride levels
in serum of these mice. Total cholesterol levels were quantified spectrophoto-
metrically using an enzymatic procedure (Roche Diagnostics, Germany). Pre-
cipath standardized serum (Boehringer, Germany) was used as an internal
standard.
Oral tolerance induction
After one week of Western-type diet and two weeks prior to collar placement, the
LDLr-/- mice were treated 4 times over a period of 8 days with intragastrically
administered antigens. Before each intragastrical administration, the animals
were deprived of food but not water for 16 hours. To prevent degradation of the
administered antigen, 2 mg of soybean trypsin inhibitor (STI, Sigma-Diagnostics,
MO) was administered intragastrically. Ten minutes after the STI administration,
the control group received 100 µl of PBS (n=7). The other mice received 30 µg
of HSP70(111-125) (n=6), HSP60 (n=6) or HSP60(253-268) (n=7). All antigens
and STI were diluted and dissolved in physiological saline (0.9% NaCl) prior to
injection. After administering the antigens intragastrically, the mice were kept on
Western-type diet for another week before collars were placed.
Plaque analysis
Six weeks after collar placement the mice were euthanized and exsanguinated by
femoral artery transsection. The mice were perfused and fixated through the left
cardiac ventricle with PBS and FormalFixx (Thermo Shandon, Pittsburgh, PA)
for 30 min. Common carotid arteries and the heart with the aortic root were
removed for analysis as described by von der Thüsen et al.34 The arteries were
embedded in OCT compound (TissueTek; Sakura Finetek, The Netherlands) and
proximally of the place of collar occlusion 5 µm sections were made on a Leica CM
3050S Cryostat (Leica Instruments, UK). These cryosections were stained with
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hematoxylin (Sigma Diagnostics, MO) and eosin (Merck Diagnostica, Germany).
10 µm section were made of the aortic root and these sections were stained
with Oil-red-O and hematoxylin. Plaque areas and intima/lumen ratios were
measured using a Leica DM-RE microscope and LeicaQwin software (Leica
Imaging Systems, UK).
Flow cytometric analysis
For the detection of CD4+CD25+Foxp3+ T cells, a three color flow cytome-
try was performed. 4 and 14 days after oral treatment with HSP60, spleen,
mesenteric lymph nodes, Peyer’s patches, and blood were isolated from HSP60-
treated and untreated mice (n=5). Mononuclear cells were isolated using
Lympholyte (Cedarlane, Ontario, Canada) conform the manufacturers proto-
col. Cells were subsequently stained with FITC-conjugated anti-CD4 (0.125
µg/sample) and APC-conjugated anti-CD25 (0.06 µg/sample) mAb (eBioscience,
Belgium) for 30 min. Cells were then fixed and permeabilized for 16 hrs
with Fixation/Permeabilization solution according to the suggested protocol
(eBioscience, Belgium). Subsequently, the cells were stained with PE-conjugated
anti-Foxp3 (0.2 µg/sample) (eBioscience, Belgium) for 30 min. Cells were
analyzed immediately by flow cytometry on a FACSCalibur. All data were
analyzed with CELLQuest software (BD Biosciences, The Netherlands).
Cytokine assays
Mesenteric lymph nodes were isolated from untreated (n=5) and HSP60-treated
mice (n=5) 14 days after oral treatment with HSP60. The lymph nodes were
squeezed through a cell strainer and the cells were cultured at 1·106 cells per
well of a 24-wells plate in the presence or absence of 20 µg/ml HSP60. Culture
supernatants were harvested after 48 hours of incubation. IL-10, IFN-γ (both from
eBioscience, Belgium) and TGF-β (Bender MedSystems, Austria) concentrations
were determined by enzyme-linked immunosorbent assays (ELISA) according to
the manufacturers suggestions.
Real-time PCR assays
Carotid arteries from control and HSP60-treated mice were isolated and mRNA
was extracted using the guanidium isothiocyanate (GTC) method and reverse
transcribed (RevertAid M-MuLV reverse transcriptase). Quantitative gene ex-
pression analysis was performed on an ABI PRISM 7700 sequence detector
(Applied Biosystems, CA) using SYBR green technology. The following primer
pairs were used: 5’-GGAGCCGCAAGCTAAAAGC-3’ and 5’-TGCCTTCGTG-
CCCACTGT-3’ for Foxp3; 5’-CTTATATTGCAAATGTGGCACAATC-3’ and 5’-
ATCAATCATCAGTGGGACAATCTG-3’ for CD25; 5’-CGAGGTCCTGCACCA-
ACTG-3’ and 5’-TCCATCACCATCGGTTTATGC-3’ for CTLA4. Acidic ribo-
somal phosphoprotein PO (36B4) was used as the endogenous reference gene




Detection of anti-HSP60 antibodies
HSP60 (10 µg/ml) dissolved in a NaHCO3/Na2CO3 buffer (pH 9.0) was coated.
Measurement of IgG1, IgG2a and IgM levels in serum was performed using an
ELISA Ig detection kit (Zymed Laboratories, CA) conform the manufacturer’s
protocol and appropriate controls were performed.
Statistical analysis
All data are expressed as mean± SEM. The two-tailed student’s t-test was used to
compare proliferative responses to antigens, FACS data, cytokine levels, mRNA
expression and atherosclerotic parameters between the different groups. P -
values less than 0.05 are considered to be statistically significant.
Results
T cells specific for HSP60 and HSP60(253-268) epitopes are present in LDLr-/- mice
Because of the important role of HSP60-specific T cells in atherosclerosis, we
first investigated the presence of T cells specific for HSP60, HSP60(253-268) or
HSP70(111-125) epitopes in the LDLr-/- mice. Splenocytes were isolated out of
naive LDLr-/- mice and were incubated with several concentrations of the HSP
epitopes. Incubation with 5 µg/ml HSP60 or HSP60(253-268) had no effect on
naive splenocytes, while incubation with 20 µg/ml HSP60 or HSP60(253-268)
resulted in a 2.70±0.42 and 2.04±0.35 fold increase in proliferation, respectively
(Figure 3.1A and B; P<0.05). HSP70(111-125) did not stimulate proliferation of
the splenocytes (data not shown). In all experiments ConA, a general pan T cell
mitogen, was used as a positive control, and incubation of splenocytes with 2
µg/ml of ConA resulted in a more than 50-fold increase in proliferation (data not
shown).
To determine whether the T cell response to HSP-epitopes can be induced in
vivo we immunized LDLr-/- mice by an intraperitoneal injection of 100 µg
of HSP60, HSP60(253-268) or HSP70(111-125) using DDA as adjuvant. After
two weeks mice were killed, and isolated splenocytes from HSP60-immunized
mice incubated with 5 and 20 µg/ml of HSP60 showed a 7.40±1.29 (P<0.01)
and a 12.71±2.30 (P<0.01) fold increase in proliferation, respectively (Figure
3.1C). Incubation of splenocytes from HSP60(253-268)-immunized mice with 5
and 20 µg/ml HSP60(253-268) resulted in a 7.29±2.32 (P<0.05) and 9.26±2.58
(P<0.01) fold increase, respectively (Figure 3.1D). Incubation of splenocytes from
HSP70(111-125)-immunized mice with 5 and 20 µg/ml HSP70(111-125) did not
result in a significant effect on proliferation (Figure 3.1E).
Effect of oral tolerance induction to HSP60, HSP60(253-268) and HSP70(111-125)
on atherosclerosis
Next we investigated the immunomodulatory effect of oral tolerance induction
to these compounds on atherosclerosis. LDLr-/- mice were put on a Western-
type diet for one week prior to oral administration of PBS or 30 µg of HSP60,
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Figure 3.1: Spleen cell proliferation in response to HSP60 and HSP60(253-268). Splenocytes were isolated
from naive LDLr-/- mice (A and B) and mice immunized via i.p. injection with 100 µg of HSP60, HSP60(253-
268) or HSP70(111-125) (C,D and E). The naive and primed splenocytes were re-stimulated in vitro with HSP60
(A and C), HSP60(253-268) (B and D) or HSP70(111-125) (E) for 48 hours. Proliferation was measured by
incorporation of 3H-thymidine. Data are shown as the stimulation index (S.I.) ± SEM. The S.I. is the ratio of
the mean cpm of cultures with antigen to the mean cpm of cultures without antigen. ∗P<0.05, ∗∗P<0.01.
HSP60(253-268) or HSP70(111-125). The oral treatment was given 4 times in
total, every other day. Subsequently, mice were equipped with collars around
both common carotid arteries and fed a Western-type diet. Six weeks thereafter,
atherosclerotic plaque formation was analyzed. Representative hematoxylin-
eosin stained cryosections of the carotid arteries of PBS, HSP70(111-125), HSP60,
and HSP60(253-268)-treated mice are shown in figure 3.2A-D. No significant
difference in plaque size was observed in LDLr-/- mice fed HSP70(111-125)
(21181±5273 µm2) compared to PBS-treated mice (20471±5273 µm2). Oral
administration of HSP60 (3959±582 µm2) resulted in a significant 80.7%
(P<0.01) reduction in plaque size when compared to PBS-treated mice. Oral
tolerance induction to HSP60(253-268) (3419±460 µm2) resulted in an 83.3%
(P<0.05) reduction in plaque size (Figure 3.2E). Furthermore, the intima/lumen
ratio was reduced significantly with 68.8% in the HSP60 treated mice (P<0.05;
0.082±0.007) and with 74.3% in the HSP60(253-268)-treated mice (P<0.05;
0.067±0.010) when compared to the PBS-treated mice (0.261±0.074) (Figure
3.2F). During the experiment total plasma cholesterol levels increased due to
the Western-type diet, but no significant differences were detected between the
different groups (Figure 3.2G). In addition, lesion development at the aortic root
of PBS-treated mice (Figure 3.3A) and HSP60-treated mice (Figure 3.3B) was
investigated. A 27.4% reduction in plaque size at the aortic root was observed in
HSP60-treated mice (377000±37200 µm2) when compared with PBS-treated mice
(Figure 3.3C; 519000±44600 µm2; P<0.05). Immunohistochemical analysis of all
plaques showed that oral tolerance induction to HSP60 and HSP60(253-268) had
no effect on the relative macrophage and smooth muscle cell content (data not
shown). To determine the effect of tolerance induction to HSP60 on the HSP60-




































































































Figure 3.2: Oral tolerance induction to HSP60 and HSP60(253-268) attenuates plaque formation in
collar induced atherosclerosis in LDLr-/- mice. LDLr-/- mice were fed PBS, HSP70(111-125), HSP60 or
HSP60(253-268) four times before induction of atherosclerosis and six weeks thereafter mice were sacrificed
and the carotid arteries of PBS-treated (A), HSP70(111-125)-treated (B), HSP60-treated (C) and HSP60(253-
268)-treated (D) mice were sectioned and stained with hematoxylin-eosin. Lesions were quantified by computer-
assisted morphometric analysis and plaque size (E) and intima/lumen ratio (F) were determined. During
the experiment plasma cholesterol levels of PBS-treated (closed squares), HSP70(111-125)-treated (closed




























Figure 3.3: Oral tolerance induction to HSP60 reduces plaque formation at the aortic root in LDLr-/-
mice. LDLr-/- mice were fed a Western-type diet and were treated intragastrically four times with PBS or
HSP60 as in figure 2. After 8 weeks, sections of the aortic root of PBS-treated (A) and HSP60-treated (B) mice
were stained with Oil-red-O and hematoxylin and subsequently lesions were quantified and plaque size was
determined (C). Values are mean lesion size ± SEM. ∗P<0.05
and HSP60-treated mice. The splenocytes were cultured with or without 5 and
20 µg/ml of HSP60. Splenocytes from PBS-treated mice respond to HSP60 with
an increased proliferation; a stimulation index of 4.4±0.7 and 10.4±2.5 when
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incubated with 5 and 20 µg/ml of HSP60, respectively. Mice orally treated with
HSP60 showed a 56.8% and 68.2% reduction in the proliferative response to 5






















Figure 3.4: Oral tolerance in-
duction to HSP60 reduces the
proliferative response of spleno-
cytes to HSP60. LDLr-/- mice in
which atherosclerosis was induced
by a combination of Western-type
diet feeding and collar placement
around both carotid arteries were
treated 4 times intragastrically with
PBS or HSP60 after one week.
Seven weeks later, splenocytes of
PBS-treated mice (white bars) and
HSP60-treated mice (black bars)
were cultured with or without 5
and 20 µg/ml of HSP60. The
extent of proliferation is shown
as stimulation index. Values are
mean±SEM. ∗P<0.05 ∗∗P<0.01
Effect of oral tolerance induction to HSP60
on CD4+CD25+Foxp3+ Tregs
To evaluate whether oral tolerance induction to
HSP60 was associated with a change in Tregs,
flow cytometry analysis was performed. HSP60-
treated LDLr-/- mice were sacrificed 4 and 14 days
after the oral treatment. In untreated control mice,
CD4+CD25+Foxp3+ T cells are present in low
numbers in Peyer’s patches (0.79±0.16%), blood
(2.21±0.12%), spleen (0.80±0.07%) and mesenteric
lymph nodes (3.82±0.25%). The dot-plots in figure
3.5A are one representative example of FACS
analysis on CD4+CD25+ cells (left panels) and
Foxp3+ cells within the CD4+CD25+ population
(right panels) in mesenteric lymph nodes. 4 days
after oral treatment with HSP60, the number
of CD4+CD25+Foxp3+ T cells in the Peyer’s
patches and blood was increased significantly to
1.73±0.30% (P<0.05) and 2.86±0.21% (P<0.01),
respectively, when compared to untreated mice
(Figure 3.5B, upper part). No significant
change was seen in the mesenteric lymph nodes
(4.67±0.41%) and spleen (0.85±0.06%) (Figure
3.5B, lower part). 14 days after oral treatment,
the number of CD4+CD25+Foxp3+ T cells in the
Peyer’s patches decreased again to 1.07±0.08% and was not significantly different
from untreated mice whereas the number of CD4+CD25+Foxp3+ T cells in blood
was still enhanced (2.81±0.20%, P<0.01) (Figure 3.5A, upper part), while in the
mesenteric lymph nodes and spleen a significant increase to 5.36±0.10% (P<0.01)
and 1.24±0.11% (P<0.01) was observed when compared with the situation
without treatment (Figure 3.5B, lower part).
Effect of tolerance induction on cytokine production
Furthermore, we investigated whether the increased number of
CD4+CD25+Foxp3+ T cells also demonstrated a change in the production
of cytokines in response to stimulation with HSP60. This may contribute to
the decreased plaque size in the mice orally treated with HSP60. Mesenteric
lymph node cells, isolated 14 days after the oral treatment with HSP60, were
stimulated in vitro in presence or absence of 20 µg/ml of HSP60. Incubation of
these lymph node cells with HSP60 resulted in a significant larger production




















































































Figure 3.5: Oral tolerance induction to HSP60 leads to an increased amount of CD4+CD25+Foxp3+
cells. LDLr-/- mice were fed HSP60 four times and killed 4 and 14 days after oral treatment. As a control,
untreated animals were used. The dot plots show representative examples of lymphoid cells isolated from
mesenteric lymph nodes stained for CD4 and CD25 (left panel). The right panels show the percentage of
Foxp3+ cells within the CD4+CD25+ population. The graphs represent the amount of CD4+CD25+Foxp3+
cells in the Peyer’s patches, blood, spleen and mesenteric lymph nodes (mean±SEM). ∗P<0.05, ∗∗P<0.01.
versus 6.41±1.72 pg/ml; P<0.05) when compared with mesenteric lymph node
cells cultured without HSP60 (Figure 3.6A and 3.6B). Furthermore, HSP60-
stimulated mesenteric lymph node cells isolated from HSP60-treated mice (14
days after treatment) produced significantly more TGF-β than HSP60-stimulated
mesenteric lymph node cells isolated from untreated mice (1.86±0.22 ng/ml
versus 0.96±0.22 ng/ml; P<0.05; data not shown). In all cases IFN-γ levels were
































Figure 3.6: Oral tolerance induction to HSP60 induces anti-atherogenic cytokine production by
mesenteric lymph node cells. LDLr-/- mice were treated orally with HSP60 four times. 14 days after the
treatment, mesenteric lymph nodes were isolated from HSP60-treated mice and the lymphocytes were cultured
in vitro with or without HSP60 for 48 hours. The production of TGF-β (A) and IL-10 (B) was monitored using
ELISA. Data are mean±SEM. ∗P<0.05.
Regulatory T cell markers in atherosclerotic plaques
After tolerance induction to HSP60 and the induction of atherosclerosis, carotid
arteries were dissected and mRNA was isolated. Subsequently, the expression of
64
Oral tolerance to HSP60 reduces atherosclerosis
different Treg markers (CD25, CTLA-4 and Foxp3) in the atherosclerotic plaques
in the carotid arteries was determined. After oral treatment with HSP60 (n=5)
and 8 weeks of Western-type diet feeding, the mRNA expression of CD25, CTLA-
4 and Foxp3 was significantly upregulated in the atherosclerotic plaque when
compared with control mice (n=9). CD25 showed a 4.9-fold increase (P<0.05),





























Figure 3.7: Increased expression of Treg markers is observed within lesions of HSP60-treated LDLr-/-
mice. To investigate the presence of Tregs within atherosclerotic lesions, mRNA was isolated from carotid
arteries of PBS (n=9) and HSP60-treated (n=5) mice and the mRNA expression of CD25, CTLA-4 and Foxp3
was quantitatively determined and expressed relative to 36B4. ∗P<0.05
Effect of oral tolerance to HSP60 on HSP60-specific antibodies
After oral treatment with HSP60 and the induction of atherosclerosis, HSP60-
specific IgG1, IgG2a and IgM levels in serum were determined. No detectable





























Figure 3.8: Effect of tolerance induction to HSP60 on HSP60-specific antibody-levels. LDLr-/- mice in
which atherosclerosis was induced by a combination of Western-type diet feeding and collar placement around
both carotid arteries were treated 4 times intragastrically with PBS or HSP60 and serum levels of HSP60-specific
IgG1, IgG2a and IgM were measured using a capture enzyme-linked immunosorbent assay. Values are mean
OD(405) values±SEM.
Discussion
Previous studies have demonstrated the importance of HSPs in the pathology
of atherosclerosis. HSP47 is expressed in fibrous regions of human atheroma
and is regulated by growth factors and oxidized lipoproteins.35 HSP47 is also
associated with collagen production.36 Furthermore, it is known that there is
increased HSP70 expression at different sites of atherosclerosis and that oxLDL
induces HSP70 expression on human smooth muscle cells37 and endothelial
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cells.38 However, the HSP with the biggest impact on atherosclerosis is HSP60.
Autoantibodies to HSP60 cause endothelial damage12 and macrophage lysis39
and are associated with an increase in susceptibility in atherosclerosis. T cells
reactive to HSP60 are found to correlate with early atherosclerotic events40 and
are found in atherosclerotic plaques in rabbits41 and humans.42 Furthermore,
Chlamydia pneumoniae, Gram-negative bacteria often linked with atherosclerosis,
can induce an immune reaction because of its HSP60 expression, which is highly
homologous to human and mouse HSP60. In the current study we show
that LDLr-/- mice contain T cells specific for HSP60 and for the small peptide
HSP60(253-268), but no T cells with any reactivity against the HSP70(111-125)
peptide. HSP60 was derived from Mycobacterium bovis bacillus, but due to the
high degree of amino acid sequence homology between different species, T cells
specific for this HSP60 were found to be cross reactive against self-HSP608.
A spleen cell proliferation assay demonstrated a 2-3-fold increase in T cell
proliferation in response to 20 µg/ml HSP60 or HSP60(253-268). Immunization of
LDLr-/- mice with HSP60 or HSP60(253-268) and a subsequent proliferation assay
with 20 µg/ml HSP60 or HSP60(253-268) resulted in a 13- and 9-fold increase in
proliferation, respectively, when compared with the non-stimulated splenocytes.
Even a lower concentration (5 µg/ml) was sufficient to trigger the splenic T cell
population and resulted in a 7-fold increase in proliferation. These data confirm
that HSP60 but also the small HSP60-peptide can induce a T cell response in
LDLr-/- mice, while the small HSP70-peptide was not effective in these mice
Intervention in the anti-HSP60 autoimmune response could be beneficial for
atherosclerosis. Many strategies are used to interrupt autoimmune responses
directed towards autoantigens and one of these strategies used in animal models
for Th1-mediated autoimmune diseases is mucosal tolerance induction. Mucosal
tolerance induction, subdivided in oral and nasal tolerance induction, can lead
to a deletion of Th1 and Th2 cells or to an activation of Tregs depending on
the administered dose of the antigen. Tregs, induced by low doses of the
antigen, are known for the production of TGF-β and IL-10, which both have anti-
atherogenic properties. Recently Mallat et al. hypothesized that in atherosclerosis
an imbalance exists between pathogenic T cells (Th1 and/or Th2) and Tregs
(Tregs) specific for ’altered’ self and non-self antigens (e.g. oxidized phos-
pholipids, heat shock proteins).20 Ait-Oufella et al. showed that Tregs play
an important role in controlling the development of atherosclerosis in mice.19
Recently is was shown that a transfer of in vitro generated HSP60-specific Tregs
to RAG1-/-LDLr-/- mice reduced the development of atherosclerotic lesions.43
Consequently, mucosal tolerance induction and the subsequent activation of
Tregs may be a useful strategy to ameliorate atherosclerosis. Several studies
already showed the potency of oral tolerance induction on atherosclerosis. Oral
tolerance induction to β2-glycoprotein I,27 HSP6528,29 and oxLDL30 results in the
suppression of early atherosclerosis. However, these studies do not give a clear
explanation for the observed reduction in atherosclerosis and they do not show
whether Tregs are involved in this process.
In our current study we show that oral tolerance induction to HSP60 and
HSP60(253-268) attenuates atherosclerosis. A relatively low dose of HSP60 (30
µg, four times) significantly reduced early atherosclerotic lesion formation by
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80.7%, reflected in the intima/lumen ratio (68.8% reduction). We now clearly
show that an immunogenic peptide present in HSP60 based on the highly
conserved sequence 253-268, and capable of inducing a T cell response cross
reactive with self-HSP, can also induce tolerance and reduces plaque size by
83.3% and the intima/lumen ratio by 74.3%. The specificity of the response
and the involvement of T cells is reflected by the finding that HSP70(111-
125), a peptide based on a conserved sequence found in the HSP70 protein
of men, rats, and mice, was not effective in reducing atherosclerosis, which
may be explained by its inability to induce T cell responses. The experimental
setup of our current study is comparable with two previous studies on oral
tolerance induction to HSP65/HSP60.28,29 Both Harats et al.28 and Maron et
al.29 show a decreased proliferation of splenocytes after oral treatment but no
effects on Tregs were described. Maron et al.29 observed a decreased IFN-γ
and an increased IL-10 production by lymphocytes after oral treatment with
HSP65. This could indicate an activation of Tr1 cells, a subset of adaptive Tregs,
particularly producing IL-10. In our previous study on oral tolerance induction
to oxLDL we already showed CD4+CD25+Foxp3+ cells to be responsible for
the reduction in atherosclerosis. In our current study, we show that T cells
specific for HSP60 epitopes are involved in the regulation of atherosclerosis. Low
doses (30 µg) of HSP60 and HSP60(253-268) were administered and therefore we
investigated the possible activation of Tregs. Four days after the oral HSP60-
treatment, the number of CD4+CD25+Foxp3+ Tregs was significantly increased
in Peyer’s patches and blood, as compared to untreated mice. After two
weeks, the number of CD4+CD25+Foxp3+ T cells was significantly increased
in blood, mesenteric lymph nodes and spleen. In the Peyer’s patches, the
first site of activation, the number of Tregs decreased after two weeks, which
may be attributed to the migration of the activated CD4+CD25+Foxp3+ T cells
to peripheral lymphoid organs and the site of inflammation (atherosclerotic
lesions). The Tregs may recognize self-HSP60 known to be upregulated in
atherosclerotic lesions. Therefore we also investigated the mRNA-expression of
markers for Tregs within the lesions and we observed an increased expression of
CD25, CTLA-4 and Foxp3. In addition, oral treatment with HSP60 reduced the
proliferative response of splenocytes to HSP60. This dampened response is in
line with the studies by Maron et al. and Harats et al.28,29 Mesenteric lymph node
cells of HSP60-treated mice produced an increased level of TGF-β (2.0-fold) and
IL-10 (3.1-fold) after in vitro re-stimulation with HSP60.
Natural Tregs, which are CD4+CD25+Foxp3+ T cells can display their specific
immunosuppressive effects via TGF-β on their surface, which binds to TβRII
expressed on T cells specific for the same antigen. TGF-β-TβRII interaction leads
to the activation of a Smad-dependent pathway, resulting in a blockade of IL-2
production and a reduced proliferation of HSP60-specific T cells. CTLA-4 is also
important in the cell-cell interaction between Tregs and other T cells. It is however
more likely that adaptive Tregs (Th3 and Tr1 cells) are involved in oral tolerance
induction, because the natural Tregs are thymus-derived and can not be activated
in the periphery. Th3 cells, which can be activated in the periphery, are known
for the production of anti-inflammatory TGF-β and upon activation they may
express Foxp3. Tr1 cells, which can also be activated in the periphery, produce
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particularly anti-inflammatory IL-10 but whether these Tregs express Foxp3 is
still not clear. It is also known that Th3 cells are especially activated via oral
tolerance induction and Tr1 cells via nasal tolerance induction. Therefore we
assume that in this study, oral tolerance induction led to an increase in Foxp3-
expressing Th3 cells, producing excessive amounts of TGF-β but also IL-10. This
IL-10 may however also be produced by induced Tr1 cells, but these cells do not
contribute to the increase in Foxp3+ Tregs.
In conclusion we describe that LDLr-/- mice can be tolerized to HSP60 and
a HSP60 peptide (HSP60(253-268)) which results in an attenuation of early
atherosclerotic lesions. The mechanism underlying this effect can be attributed to
the induction of CD4+CD25+Foxp3+ Tregs by oral HSP60 administration. These
Tregs could produce TGF-β and IL-10 upon recognition of self-HSP60 known to
be upregulated in atherosclerotic lesions. In this way they can down-regulate
the inflammatory response locally.8 Altogether, these beneficial results of oral
tolerance induction to HSP60 and HSP60(253-268) on atherosclerosis may provide
new therapeutic approaches for the treatment of atherosclerosis.
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Abstract
Modification of lipoproteins plays an important role in the development of atherosclerosis.
OxLDL has a number of pro-inflammatory effects, whereas immunization with various
forms of oxLDL is able to reduce atherosclerosis. The uptake of modified LDL by dendritic
cells (DCs) and the presentation of epitopes thereof may form an important step in the
immunomodulatory effects of LDL. In this study we transferred oxLDL-pulsed DCs to
LDLr-/- mice and examined the effects on atherosclerosis. Bone marrow derived DCs
were cultured for 10 days in the presence of GM-CSF. Immature DCs were matured by
LPS and pulsed with cupper oxidized LDL (Cu-oxLDL). These cells were transferred to
LDLr-/- mice every other day before induction of atherosclerosis by Western-type diet
feeding. Transfer of oxLDL-pulsed DCs resulted in a 92% and 87% reduction in carotid
artery lesion size compared to the PBS-treated mice or mice treated with mature DCs
(mDCs), respectively (P<0.001). Lesion size in the aortic valves was not affected but we
observed at both sites an increase in plaque stability. The reduction in atherosclerosis was
accompanied by a 3.8-fold increase (P<0.05) in Cu-oxLDL specific IgG levels whereas the
levels of MDA-LDL-specific IgG and IgM were not significantly affected. In addition, we
also showed that the serum of mice treated with oxLDL-pulsed DCs reduced the formation
of foam cells as compared to serum from PBS-treated mice or mice treated with mDCs.
We conclude that oxLDL-pulsed DCs induce an enhanced production of anti-oxLDL IgG
levels which leads to a reduction in atherosclerosis by modulating the immunostimulatory
effects of oxLDL. These data indicate that vaccination with oxLDL-pulsed DCs provides a




Atherosclerosis is a slowly progressing disease that develops at sites of lipid
accumulation in large and medium sized arteries, which can lead to infarction of
the heart or the brain. Over the past several years, accumulating data has identi-
fied a key role for inflammation in atherosclerosis and both innate and adaptive
immune responses are involved.1–5 Several antigens have been implicated in
the initiation of immune responses during atherosclerosis including exogenous
infectious pathogens such as Chlamydia pneumoniae, and cytomegalovirus but also
endogenous proteins such as heat-shock proteins and β2-glycoprotein-Ib.6–8 The
most intensively studied endogenous antigen is oxidized low-density lipoprotein
(oxLDL). Oxidation of lipoproteins in the arterial intima, followed by their uptake
by macrophages and subsequent foam cell formation, plays an important role
in the development of atherosclerosis. Also, peroxidization of polyunsaturated
fatty acids in phospholipids and cholesteryl esters generates highly reactive
breakdown compounds such as malondialdehyde (MDA) and 4-hydroxynonenal
that cause cell damage and local inflammation.9–11 In addition, oxidation of LDL
results in many structural modifications of apoB-100 and thus the formation of
many neo-epitopes, which renders the modified LDL immunogenic and leads
to both a cellular and humoral response. Since the different epitopes of oxLDL
induce atherogenic immune responses, it is attractive to modulate the immune
response towards oxLDL. Also, a number of studies show that immunization
against oxLDL reduces atherosclerosis in several animal models.12–14
OxLDL also plays a role in the maturation of dendritic cells (DCs). DCs are
the most potent antigen-presenting cells of the immune system.15–17 In the
periphery they act as sentinels for the innate immune system whereas in the
lymph nodes they are the key messengers in adaptive immunity. Immature
DCs differentiate from bone marrow progenitors or circulating blood monocytes.
They reside in the blood stream or peripheral tissues where they survey incoming
pathogens. An interaction with pathogens induces maturation during which DCs
generate MHC-peptide complexes and upregulate the expression of costimula-
tory molecules such as CD40, CD80 and CD86. These changes render the DCs
fully competent to activate T cells. Several studies showed that oxLDL induces
several changes, characteristic for DC maturation, including a higher expression
of costimulatory molecules and the increased ability to stimulate T cells.18,19
Due to their potent capacity to stimulate T cells, DCs are being investigated in
vaccine and therapy approaches.20,21 We wanted to assess the use of oxLDL-
pulsed DCs as an immunotherapy for atherosclerosis. DCs obtained from the
bone-marrow can be pulsed ex vivo by inducing maturation in the presence of
oxLDL. Such cultivation of DCs will mimic the in vivo processing of oxLDL by
DCs. In this study we show that repeatedly injection of oxLDL-pulsed DCs
induced an enormous reduction in lesion size and increased the production of
oxLDL-specific antibodies (Ab). The high titers inhibit foam cell formation and
thus prevent the negative effects of oxLDL on the arterial wall. In conclusion,
these data indicate that vaccination with oxLDL-pulsed DCs provides a novel
and powerful strategy in the battle against atherosclerosis.
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Methods
Animals
All animal work was approved by the regulatory authority of Leiden University
and carried out in compliance with the Dutch government guidelines. Male
LDLr-/- mice and UBC-GFP mice were from Jackson Laboratories on a C57Bl6
background and bred in-house. Male C57BL/6J mice were from Charles River
Laboratories. Mice were kept under standard laboratory conditions and were fed
a normal chow diet or a Western-type diet containing 0.25% cholesterol and 15%
cocoa butter (Special Diet Services, Witham, Essex, UK). Mice were 10-12 weeks
old at the start of the experiment. Diet and water were administered ad libitum.
Media and reagents
The cell culture medium used for dendritic cells was IMDM (Cambrex, Belgium)
supplemented with 8 % FBS (PAA, Germany), 100 U/ml streptomycin/penicillin
(PAA, Germany), 2 mM glutamax (Invitrogen, The Netherlands) and 20 µM β-
mercaptoethanol. LDL was isolated from serum of a healthy volunteer after
centrifugation of the serum according to Redgrave et al.22 The isolated LDL was
dialyzed against phosphate buffered saline (PBS) with 10 M EDTA (pH 7.4) for 24
hours at 4◦C and oxidized by exposure to 10 µM CuSO4 at 37◦C for 20 hours as
previously described.23
Generation and injection of BM-DCs
For each injection time-point, bone marrow cells were isolated from the tibia and
femora of 3 C57BL/6 mice. Cells were immediately pooled and cultured during
10 days in complete IMDM in the presence of granulocyte-macrophage colony-
stimulating factor (GM-CSF). After 10 days of culture, immature DCs were
activated with 1 µg/ml of lipopolysaccharide (LPS from Salmonella typhosa,
Sigma Aldrich, Zwijndrecht, The Netherlands) during 24 hours. Simultaneously,
DCs were pulsed with or without 7.5 µg/ml of cupper-oxidized LDL. Purity
and functionality of the DCs were assessed using flow cytometry. CD11c was
used as a specific DC marker (purity > 90%). Functionality was determined by
the expression of several costimulatory molecules (CD40, CD80, CD86) and the
expression of MHC-II and CD1d. Mice were injected intravenously (8, 6 and 3
days prior to atherosclerosis induction by Western-type diet feeding) with 200 µl
of PBS (n = 8) or 1.5·106 DCs (oxLDL-pulsed or unpulsed mDCs) in 200 µl PBS
(n = 11). DCs from the UBC-GFP mice were identically isolated en cultured.
Cytospin
300 µl of cell suspensions were centrifuged for 5 min at 500 rpm using the Thermo
Shandon Cytospin 4. After centrifugation, slides were fixed for 30 minutes using
zinc formal Fixx (Shandon, Pittsburgh, USA). Lipid loading in the DCs was




Male LDLr-/- mice were injected 3 times intravenously (1 injection every other
day) with 1.5·106 DCs or saline prior to Western-type diet feeding. After
3 weeks of diet, atherosclerosis was induced by bilateral perivascular collar
placement (2 mm long, diameter 0.3 mm) around both carotid arteries and
continuous Western-type diet feeding.24 During the experiment, plasma samples
were obtained by tail vein bleeding. 7 weeks after collar placement, mice were
sacrificed and tissues were harvested after in situ perfusion using PBS and
subsequent perfusion using formalin. Fixated tissues were embedded in OCT
compound (Sakura Finetek, The Netherlands), snap frozen in liquid nitrogen and
stored at -20◦C until further use.
Histological analysis and morphometry
Transverse 5 µm cryosections were prepared in a proximal direction from
the carotid bifurcation. Cryosections were stained with hematoxylin (Sigma
Aldrich, Zwijndrecht, The Netherlands) and eosin (Merck Diagnostica, Germany)
or with hematoxylin and Oil-Red-O. Hematoxylin-eosin stained sections of
right carotid artery and Oil-Red-O stained sections of heart valves were used
for morphometric analysis of atherosclerotic lesions as described previously.24
Corresponding sections were stained immunohistochemically with antibodies
against a macrophage specific antigen, (MOMA-2, polyclonal rat IgG2b, Research
Diagnostics Inc, NJ) or were stained for collagen fibers using the Masson’s
Trichrome method (Sigma Aldrich, Zwijndrecht, The Netherlands). The site of
maximal stenosis was used for assessment. The images were analyzed using
the Leica DM-RE microscope and LeicaQwin software (Leica Imaging Systems,
Cambridge, UK).
Flow Cytometry (FACS analysis)
Antibodies used for staining were purchased from eBiosience, Belgium. Staining
was done in PBS in the presence of 1 % mouse serum. FACS analysis was
performed on the FACSCalibur (Becton Dickinson, Mountain View, CA). Data
were analyzed using Cell Quest software.
Cholesterol assay
Blood was collected at several time points during the experiment by tail vein
bleeding. Plasma was obtained after centrifugation and total plasma cholesterol
levels were measured using enzymatic procedures and a spectrophotometer
(Roche Diagnostics, The Netherlands). Precipath was used as an internal
standard (Boehringer, Mannheim, Germany). The cholesterol distribution over
the different lipoproteins was analyzed by fractionation using a Superose 6
column (3.2 x 30 mm, Smart-System, Pharmacia).
ELISA for IgM and IgG antibodies against LDL, MDA-LDL and Cu-oxLDL
Antibodies against LDL, MDA-LDL and Cu-oxLDL were determined according
to Damoiseaux et al.25 MaxiSorp 96 well plates (Nunc, Roskilde, Denmark) were
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coated overnight with 100 µg native LDL or oxLDL in 100 µl PBS at 4◦C. Plates
were washed 5 times with 0.01M Tris, 0.15 M NaCl and 0.05% Tween20 (pH 8.0).
Mouse serum was added in duplicate at a 1:50 dilution in incubation buffer (0.1
M Tris, 0.3 M NaCl and 0.05% Tween20 (pH 8.0) overnight at 4◦C. After washing,
plates were incubated with either alkaline phosphatase-labelled anti-mouse IgM
or IgG (Jackson Immuno-Research, Pennsylvania) both at a 1:4000 dilution in
incubation buffer for 1 hour at 37◦C. After washing, substrate (1 mg/ml disodium
p-nitrophenyl phosphate, Sigma, The Netherlands) was added. After 2 hours at
room temperature, absorbance was read at 405 nm.
ELISA for detecting subclasses specific Ab
IgG1 and IgG2A levels were detected using the Mouse MonoAb ID kit (Zymed
Laboratories Inc., South San Fransisco, USA) according to manufacturers’ instruc-
tions. Briefly, high binding plates were coated overnight with 50 µl Cu-oxLDL (5
µg/ml). Serum samples were 1:1 diluted in PBS. IgG1 and IgG2A levels were
detected using a spectrophotometer at 405 nm.
Foam cell formation
To obtain macrophages, bone-marrow cells from C57BL/6 mice were resus-
pended in complete RPMI supplemented with 20% FCS and 30% of L929-
conditioned medium (source for monocyte-colony-stimulating factor, M-CSF).
After 7 days of culture, macrophages were seeded in Lab-Tek chamber slides
(BD Falcon, The Netherlands) (0.8 ·106 cells/well) in cRPMI + 10% FCS. After 4
hours of incubation, cells were washed and resuspended in cRPMI without FCS.
After 4 hours, a mixture of oxLDL (10 µg/ml) plus an equal volume of mouse
serum (2 fold diluted, serum from 2 mice were pooled) was added. This mixture
of oxLDL and mouse serum was made 30 minutes before addition to the cells.
After overnight culture, cells were fixed using zinc formal Fixx, stained for lipids
using Oil-Red-O and counter stained with hematoxylin. The amount of Oil-Red-
O staining was corrected for the number of cells as indicated by the hematoxylin
staining. 8 random fields per condition were analysed using the Leica DM-RE
microscope and LeicaQwin software.
Statistical analysis
Values are expressed as mean ± SEM. Differences between different treated
groups were assessed with parametric or non-parametric ANOVA followed by
a t-test using the Instat3 software. To measure the effects on cholesterol, the
repeated measures ANOVA was used. Probability values of P< 0.05 were
considered significant.
Results
Effect of oxLDL on dendritic cells
Firstly we investigated whether DCs did engulf oxLDL and whether the uptake
of lipoproteins by DCs did affect the maturation of DCs. During maturation, DCs
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upregulate the expression of costimulatory molecules and the maturation level
of DCs can thus be followed by flow cytometry of several typical markers (CD40,
CD80, CD86, MHCII, and CD1d). Increasing concentrations of oxLDL (up to 20
µg/ml) were added to immature DCs. After 24 hours of incubation we stained
the intracellular lipid accumulation in the DCs and found that increasing oxLDL
concentrations induced an increasing lipid accumulation. However, oxLDL
levels exceeding 7.5 µg/ml induced a concentration dependant increase in cell
death and a lowering of the expression of the DC-specific markers (data not
shown). Therefore we have chosen a concentration of 7.5 µg/ml which induced
optimal lipid loading but no cell death.
We treated immature DCs (Figure 4.1A) with the TLR4 agonist, LPS (1 µg/ml),
in the absence or presence of oxLDL (7.5 µg/ml). After 24 hours of incubation,
DCs were collected and stained with Oil-Red-O and analyzed for surface markers
by flow cytometry. The addition of oxLDL to both imDCs and mDCs resulted
in lipid accumulation in more than 95% of the DCs (Figure 4.1B and 4.1C
respectively). Treatment with LPS resulted in a typical mature DC cell surface
phenotype showing high expression of CD11c (a specific marker for mouse DCs),
MHCII, CD1d and the costimulatory molecules CD40, CD80, CD86. The addition
of oxLDL during maturation had no effect on the expression level of these
































Figure 4.1: The effect of oxLDL on dendritic cells. Immature DCs were treated with LPS (1 µg/ml) in the
absence or presence of oxLDL (7.5 µg/ml). After 24 hours, DCs were collected. Oil-Red-O staining of DCs:
immature DCs in the absence of oxLDL (A), in the presence of oxLDL (B) and mature DCs in the presence
of oxLDL (C). Expression levels of surface markers analysed by FACS on immature DCS (white bars), mature
DCs (grey bars) and mature oxLDL-pulsed DCs (black bars).
Homing of dendritic cells.
To determine the fate of DCs in vivo, we cultured DCs from UBC-GFP mice,
which have a high and constitutive expression of GFP and injected 1.5·106 DCs
into LDLr-/- mice. We injected both mature unpulsed and mature oxLDL-pulsed
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GFP-DCs and 72 hours after injection, mice were sacrificed and GFP expression
was determined in different tissues using flow cytometry. While there were
almost no GFP+ DCs present in the blood, DCs did migrate towards the lung
and liver, and towards organs involved in immune responses such as spleen,
mediastinal and inguinal lymph nodes (Figure 4.2). Mature unpulsed and




































Figure 4.2: Homing of GFP+-
DCs. 1.5·106 mature GFP+-
DCs (grey bars, n=4) and mature
oxLDL-pulsed GFP+-DCs (black
bars, n=4) were injected i.v. into
LDLr-/- mice. Mice were sacrificed
after 72 hours. GFP+ cells as
percentage of the total number of
leukocytes in the different organs
are shown.
Effect of vaccination using oxLDL-pulsed
DCs on atherosclerosis
To evaluate the effect of vaccination using oxLDL-
pulsed DCs on de novo atherosclerosis, LDLr-/-
were injected intravenously 3 times (day -8, -6
and -3) with either PBS (n = 8), mDCs (n
= 11) or oxLDL-pulsed DCs (n = 11). On
day 0, mice were put on a Western-type
diet. Three weeks thereafter, atherosclerosis was
induced by perivascular collar placement around
the carotid arteries and subsequent Western-
type diet feeding. Seven weeks after collar
placement, mice were sacrificed and plaque
formation in the right carotid artery and the aortic
root were analyzed using the hematoxylin/eosin
staining and hematoxylin/Oil-Red-O staining,
respectively. Figure 4.3A-C show representative
examples of hematoxylin/eosin staining in the
carotid arteries. Injection of oxLDL-pulsed DCs
resulted in a significant 92% (48578±9231 µm2 vs
4024±504 µm2; P<0.001) or 87% (31919.8±7914 µm2 vs 4024±504 µm2; P<0.001)
reduction in plaque size in the carotid arteries compared to the PBS-treated or
mDC-treated groups, respectively (Figure 4.3D). Also a concomitant reduction
in intima/lumen ratio of 87% (0.560±0.097 vs 0.071±0.009; P<0.001) or 85%
(0.461±0.089 vs 0.071±0.009; P<0.001) was observed (Figure 4.3E). In contrast,
we did not observe significant effects of treatment with dendritic cells on plaque
size in the aortic roots (PBS: 199411±17408 µm2; mDCs: 293181±36193 µm2;
mDCs plus oxLDL: 224983±48546 µm2) (Figure 4.3F).
Plaque morphology was assessed using the MOMA-2 staining for detecting
macrophages and the Masson’s Trichrome method was used for visualizing
collagen fibers. In the carotid arteries we observed non-significant decreases
in the MOMA-2/intima ratio (Figure 4.4A). The macrophage content was also
reduced in the aortic root, where we saw a significant 2.5-fold reduction
compared to the PBS-treated group (P<0.05) and a non-significant 1.9-fold
reduction in MOMA-2/intima ration compared to the mDC-treated group
(Figure 4.1D). The collagen content of the intima was increased in both the carotid
arteries (Figure 4.4B; P<0.05) and the aortic root (Figure 4.4E). Additionally,
we calculated the MOMA-2/collagen ratio as an indicator for plaque stability.
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There was a significant 4.3-fold (P<0.05) and 4.1-fold (P<0.05) reduction in
MOMA-2/collagen ratio in the group treated with oxLDL-pulsed DCs compared
to the group treated with PBS and a significant 3.9-fold and 2.8-fold reduction
compared to the group treated with mDCs in both the carotid arteries and aortic
root, respectively (Figure 4.4C and 4.4F). This reduced MOMA-2/collagen ratio




































































Figure 4.3: Effect of DC vaccination on atherosclerosis. Representative sections of lesions in the carotid
arteries of PBS-treated (A), mDC-treated (B) and oxLDL-pulsed DC-treated (C) mice. Lesion size (D) and
intima/lumen ratio (E) in the carotid arteries were determined. Plaque size in the aortic root was quantified after
hematoxylin/Oil-Red-O staining (F). (n=7-11 per group; ∗∗P<0.01, ∗∗∗P<0.001)
Effect of vaccination on total cholesterol levels
Both body weight and total cholesterol levels were measured at different time
points during the experiment. There were no significant differences in body
weight between the different groups throughout the entire experiment. As
shown in figure 4.5A, cholesterol levels of the PBS and mDC-treated groups
kept on increasing in time, whereas the cholesterol levels in the group treated
with oxLDL-pulsed DCs levelled off after 7 weeks. The repeated measurements
ANOVA did not result in significant differences over time. It remains however
interesting that at sacrifice, mice treated with oxLDL pulsed DCs showed
significant 30% (P< 0.05) and 27% (P< 0.01) lower cholesterol levels compared
to mice treated with PBS and mDCs, respectively. The reduction did not result
from the lowering of one particular class of lipoproteins (VLDL, LDL or HDL) as
depicted in the lipoprotein profile (Figure 4.5B).
Humoral response after vaccination
Plasma samples from each mouse were obtained after sacrifice and IgG, IgM
and subclass specific antibodies were determined. The T cell-dependent IgG
antibodies against Cu-oxLDL were significantly higher in mice vaccinated with
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Figure 4.4: Plaque morphology. LDLr-/- mice were treated with PBS, mDCs or mature oxLDL-pulsed DCs.
Subsequently mice were put on a Western-type diet and 10 weeks later plaque composition was assessed in the
carotid artery (A-C) and in the aortic root (D-F). The amount of macrophages was determined as the MOMA-2
positive area per intima area (A and D), the amount of collagen was determined by quantifying the blue collagen
staining of the Masson’s Trichrome stain within the plaque (B and E). The plaque stability was quantified as









































Figure 4.5: Effect on total plasma cholesterol. Cholesterol levels were determined in plasma of the different
mouse groups (PBS (open squares), mDCs (open triangles) and oxLDL-pulsed mDCs (closed diamond)) at the
indicated time points (A). Serum was separated on a Sepharose 6 column and fractions were collected to obtain
lipoprotein profiles (B). (n=8-11 per group; ∗∗P<0.01).
oxLDL-pulsed DCs compared to the mice treated with PBS or mDCs (Figure
4.6A) (P< 0.001 and P< 0.01, respectively). Interestingly no significant effect
was found on the IgG levels against MDA-LDL which indicates a highly specific
response against Cu-oxLDL (Figure 4.6B). No differences in titers of IgM against
MDA-LDL or Cu-oxLDL were detected between the various groups (Figure
4.6C and D, respectively). We also analyzed whether IgG1 or IgG2a mainly
contributed to the rise in anti-oxLDL IgG levels and we observed significantly
higher levels of both IgG1 and IgG2A in the mice treated with oxLDL-pulsed
DCs compared to the mDC-treated group indicating that the production of anti-
















































































PBS mDCs mDCs 
+oxLDL
Figure 4.6: Humoral response against oxLDL and MDA-LDL. At the end of the experiment, IgG and
IgM titers were determined in serum of mice treated with PBS, mDCs and mature oxLDL-pulsed DCs using an
ELISA. IgG titers against oxLDL and MDA-LDL are presented in A and B, respectively. Figures C and D show
IgM levels against oxLDL and MDA-LDL, respectively. (n=8-11 per group; ∗P<0.05).
Cellular response to vaccination strategy
To evaluate the effect of DC treatment on a number of different subsets of
leukocytes, blood was collected before injection of DCs, after each injection,
before collar placement and at sacrifice and FACS analysis was performed on
leukocytes. We observed no significant differences in number of blood CD8+ or
CD4+CD25+ cells at any time point during the experiment. We also performed
FACS analysis on spleen, liver and mediastinal lymph nodes after sacrifice. There
were no differences in number of T cells, regulatory T cells, CD11c+ or CD1d+
cells (data not shown).
Inhibition of foam cell formation
Macrophages were obtained by culturing bone marrow derived cells from C57Bl6
mice in L929-conditioned medium (source of M-CSF). The phenotype of the
macrophages was tested using FACS analysis. Cells were >90% positive for
F4/80 and CD11b and <10% positive for CD11c and thus considered to be
macrophages (Figure 4.7A-C). Foam cell induction in these macrophages by
incubation with oxLDL was hampered by serum from animals treated with
oxLDL-pulsed DC (Figure 4.7D). Lipid loading in the foam cells was 3.8 (P<0.01)
and 2.5 (P<0.001) times lower using serum from mice treated with oxLDL-pulsed
DC as compared to serum from PBS or mDC-treated mice, respectively.
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Figure 4.7: Inhibition of foam cell formation. Bone-marrow derived macrophages were analysed by FACS
analysis. The fluorescence intensity of respectively CD11b, F4/80 and CD11c (grey curves) are depicted in
A, B and C, respectively. The white curves represent the isotype control. The amount of Oil-Red-O staining
of macrophages was corrected for the number of cells as indicated by the hematoxylin staining. The addition
of mouse serum from mice treated with oxLDL-pulsed DCs (black bars) inhibits the uptake of oxLDL by
macrophages as compared to the serum from mice treated with PBS (white bars) and mDCs (grey bars) (D).
(n=3, 8 fields per condition) ∗∗P<0.01; ∗∗∗P<0.001.
Discussion
Oxidation of lipoproteins and oxidative processes play an important role in
the initiation and progression of atherosclerosis. In this study we show that
vaccination using oxLDL-pulsed DCs is a successful strategy in reducing arterial
atherosclerotic lesion formation in LDLr-/- mice. In healthy vascular tissue low
numbers of DC reside within the intima, immediately beneath the endothelium
and in the adventitia along the external elastic lamina.26,27 In atherosclerosis-
prone regions of healthy carotid arteries, the DCs accumulate and form clusters
at sites subjected to major haemodynamic stress. This accumulation of DCs at
sites prone to develop atherosclerosis has already been established in children
from 8 weeks to 10 years old.26,27 So, vascular DCs become already activated
in very early stages of atherosclerosis and induce a primary immune response
against the antigens present in the adventitia such as oxLDL. In the advanced
atherosclerotic plaques the number of DCs increases by invasion of DCs from the
adventitia and from blood. After antigen uptake within the lesions, activated
DCs form clusters with T and NKT cells in the shoulder regions of the plaques
and may thus play an important role in plaque destabilization.28,29 It has been
suggested that the migratory routes of vascular DCs are similar to those in
other peripheral tissues. After uptake of antigen, vascular DCs tend to migrate
towards regional lymph nodes where they activate T cells. Importantly, plaque
progression was linked to a reduced emigration of monocyte-derived DC-like
81
Chapter 4
cells from developing lesions.30 In accordance, histopathological studies on
human arterial tissues demonstrated that some DCs migrate towards the lymph
nodes while other DCs stay within the intima and interact with T cells.31
Also, hyperlipidemia suppressed the migration of skin DCs.32 Taken together,
these studies emphasize the important immunoregulatory role of vascular DCs
and that the impaired migration of DCs may play an important role in the
development of atherosclerosis.
We therefore treated atherosclerosis-prone mice with DCs that were loaded ex-
vivo with modified LDL to prime the immune response against modified LDL,
which is one of the main pro-inflammatory antigens in atherosclerosis. At present
we show that the use of oxLDL-pulsed DCs resulted in a 92% or 87% reduction
in lesion seize in the carotid arteries compared to the PBS or the mDC-treated
control groups, respectively. Ex-vivo generated and antigen-loaded DCs have
been used in vaccination protocols in many animal models33,34 and have been
used to improve immunity in cancer35 and HIV-infected patients.36,37 Since the
initial study of Palinski38, a number of studies have shown the effectiveness of
immunization with oxLDL or apoB100 peptides as an immunotherapy for athero-
sclerosis in experimental animal models leading to a reduction in atherosclerosis
ranging from 40 to 70% in mice and rabbits.12–14,39 The use of oxLDL loaded den-
dritic cells provided us with a simple but very sufficient method of manipulating
the immune system and DC-therapy does not require the use of adjuvants. Also,
DCs present a broad spectrum of epitopes after internalizing and processing the
Ag. Therefore DCs are capable of activating a wide range of Ag-specific T cells
and immune escape is minimized. Additionally, we showed that oxLDL is easily
engulfed by immature DCs and that the presence of oxLDL during maturation
also resulted in the uptake of lipids as shown by the Oil-Red-O staining. By
injecting GFP+ DCs we showed that after 3 days both mature unpulsed and
mature oxLDL-pulsed DCs homed in an identical manner to various organs
including lymph nodes and spleen, where they can interact with other immune
cells and thus induce immune responses, as observed by others.40
The observed reduction in lesion size in the carotid arteries was accompanied by
a decrease in macrophage numbers and an increase in collagen fibers, leading to a
significantly more stable phenotype in the oxLDL-pulsed DC group as compared
to both the PBS-treated and mDC-treated group. In contrast, we did not observe
a significant reduction in lesion size in the aortic valve leaflets. This discrepancy
is similar to that observed by Fredrikson et al. who showed that immunization
with apoB-100 induced a 60% reduction in plaque size in the descending aorta
but did not affect the size of the subvalvular plaques.13 On the other hand, we
did observe a significant reduction in the number of macrophages in the aortic
sinus, indicating a reduced inflammatory status of the lesions in the valve area
and we did observe an increase in collagen fibers. Taken together, these data
indicated a more stable phenotype in the aortic root and confirmed the effect of
oxLDL-pulsed DCs on the composition of the plaque in the carotid arteries.
During the experiment, cholesterol levels were evaluated. Interestingly, after
DC vaccination and 10 weeks of diet, a significant reduction in total cholesterol
levels in mice treated with oxLDL-pulsed DCs was observed. The lowering of
total cholesterol observed was not due to a change in the lipoprotein profile as
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shown by SMART analysis. Although this decrease of cholesterol cannot explain
the enormous decrease in atherosclerotic lesion formation, since the overall
cholesterol load during the experiment was comparable between the two groups,
it may form an additional interesting long-term effect of treatment with oxLDL
pulsed DCs. The reduction in cholesterol levels observed is in accordance with
Freigang et al. who showed a significant reduction in total plasma cholesterol in
MDA-LDL immunized LDLr-/- mice after 15 weeks of diet.14
The lowering of cholesterol was accompanied by an increase of oxLDL-specific
IgG antibodies. We did not detect differences in IgM levels when comparing
the three groups. However, we did observe an increase in T cell-dependent
IgG Ab towards Cu-oxLDL and not towards MDA-LDL in the group treated
with oxLDL-pulsed DCs. This indicates that the treatment with oxLDL-pulsed
DCs induced an activation of Cu-oxLDL-specific T cells. In addition, we also
showed that the serum of mice treated with oxLDL-pulsed DCs reduced the
formation of foam cells as compared to serum from PBS or mDC-treated mice.
These mice have higher titers of oxLDL-specific IgG Ab and we argue that
the oxLDL-specific IgG can inhibit foam cell formation via complex formation
with oxLDL. This is in agreement with the findings of the group of Witztum
who showed that monoclonal IgG Fab Ab directed to oxLDL blocked foam cell
formation in macrophages.41 Also, Caligiuri et al. showed that serum from
ApoE-/- mice, immunized with phosphorylcholine reduced the uptake of oxLDL
by macrophages. In addition, both Zhou et al. and Freigang et al. demonstrated
an inverse correlation between lesion size and anti-MDA-LDL IgG levels in mice
immunized with MDA-LDL.14,42 These data suggest that the presence of oxLDL-
immune complexes play an atheroprotective role.
Taken together, this strategy of DC vaccination provides a highly efficient route
to modulate the immune responses to oxLDL during atherosclerosis and is a new
efficient vaccination strategy that is practically feasible.
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Abstract
It has been shown that NKT cell activation via the administration of α-GalCer accelerates
atherosclerosis in apoE-/- mice. ApoE is however an important mediator in the
presentation of exogenous lipids via CD1 molecules to NKT cells which may complicate
conclusions on the role of NKT cell activation in atherosclerosis. Treatment of LDLr-/-
mice with α-GalCer during Western-type diet feeding is therefore of interest to investigate
the role of NKT cells in atherosclerosis. Atherosclerosis was induced by the combination
of Western-type diet feeding and collar placement around the carotid arteries in both
LDLr-/- and apoE-/- mice. Subsequently, the mice were treated twice a week for 7
weeks with α-GalCer. This resulted in a 84% reduction in plaque size in LDLr-/- mice
(P<0.05), while no effect was observed in apoE-/- mice. In vitro incubation of splenocytes
with α-GalCer showed that LDLr-/- splenocytes proliferated strongly, while apoE-/-
splenocytes show only a minor proliferative response. This is reflected in a larger increase
in production of cytokines and especially IL-10 after in vitro stimulation of LDLr-/-
splenocytes with α-GalCer compared with apoE-/- splenocytes. Additionally, feeding a
Western-type diet for 1.5 weeks induced a strong increase in the number of NKT cells
within the liver and spleen of LDLr-/- mice. This increase was slower and less prominent
in apoE-/- mice which only showed an increased level of NKT cells in the liver after 4.5
weeks of diet. To conclude, administration of α-GalCer to LDLr-/- mice in combination
with Western-type diet feeding reduced plaque formation, but this effect was not seen
in apoE-/- mice. This may be explained by the decreased presentation of lipids on CD1
molecules due to the lack of apoE. In this study we proved for the first time that NKT cells




Atherosclerosis is a chronic inflammatory disease of the vasculature in which
both the innate and the adaptive immune system play an important role. T
cells, B cells, monocytes and dendritic cells (DCs) are detected in atherosclerotic
plaques of mice and humans.1,2 The inflammatory response in atherosclerosis is
mainly driven by Th1 cells, producing pro-atherogenic cytokines such as IL-12
and IFN-γ.3–5 The counteracting Th2 cells produce anti-atherogenic cytokines
such as L-5, IL-10 and IL-13. IL-4, which is a Th2 cytokine, has however
pro-atherogenic properties in initial stages of atherosclerosis.6–8 More recently,
natural killer T (NKT) cells have been reported to play a role in the inflammatory
process of atherosclerosis. NKT cells represent a subset of T cells expressing
receptors such as NK1.1 (CD161) found on NK cells. This NK1.1 is only detected
on NKT cells in C57Bl/6 mice, and not in Balb/c mice. The majority of NKT
cells express a semi-invariant T cell receptor (TCR) composed of a Vα14-Jα18
α-chain paired with a Vβ8 or Vβ2 β-chain. This TCR is unique because of it’s
specificity for (glyco)lipid antigens. (Glyco)lipid antigens are presented by the
MHC class I like molecule CD1d, which is expressed on most antigen presenting
cells (APCs). Upon stimulation, NKT cells are able to produce large amounts of
both Th1 cytokines (IFN-γ, IL-12 and TNF-α) and Th2 cytokines (IL-4, IL-5, IL-10
and IL-13). This make NKT cells a unique T cell population with potentially both
pro- and anti-inflammatory properties.9
NKT cells are found in atherosclerotic plaques of both humans10,11 and
atherosclerosis-prone (LDLr-/- and apoE-/-) mice.12–15 In human lesions, NKT
cells colocalize with CD1d-expressing dendritic cells (DCs) in the shoulder
regions and this contributes to plaque destabilization. The NKT cells represent
2% of the total lymphocyte population within the lesion.10,11 Recent studies show
that depletion of NKT cells by crossing apoE-/- and LDLr-/- mice with CD1d-/-
mice results in an attenuation of atherosclerosis.12–14,16 More recently an adoptive
transfer of NKT cells into RAG1-/-LDLr-/- mice accelerated atherosclerosis.17
These studies indicate that a deficiency in CD1d-dependent NKT cells accelerates
atherosclerosis, and this may suggest that endogenous activation of NKT cells is
a pro-atherogenic process. However, many studies on NKT cells use the synthetic
glycolipid α-galactosylceramide (α-GalCer) as a ligand. Studies on a number
of Th1-mediated autoimmune diseases showed that activation of NKT cells via
repeated injections with α-GalCer can polarize the adaptive immune response
towards a Th2 like response18,19 Treatment with α-GalCer resulted in protection
from autoimmune diabetes,20 experimental autoimmune encephalomyelitis21
and colitis22 in mice. Studies on Th1-mediated atherosclerosis showed however
that α-GalCer treatment, significantly increases the disease in apoE-/- mice.12–14
The administration of α-GalCer (single and multiple i.p. and i.v. injections)
to apoE-/- mice caused an increase in pro-atherogenic (IFN-γ, IL-4) cytokines
within the lesion.13,14 However, in one study, in addition to the pro-atherogenic
cytokines, an increase in anti-atherogenic IL-10 was observed within the lesion14.
In serum of apoE-/- mice, injected once with α-GalCer, an increase in IFN-γ,
TNFα, IL-2, IL-4 and IL-5 was observed, whereas no cytokines were detected
after multiple injections.13 A recent publication shows that apoE is an important
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mediator of lipid antigen presentation on CD1 molecules, which may complicate
conclusions on the effect of α-GalCer activation of NKT cells on atherosclerosis
in apoE-/- mice23. Therefore it would be of major interest to determine what the
effect of α-GalCer activation of NKT cells is in atherosclerosis induced in LDLr-/-
mice in combination with endogenous activation.
In this study, we show that multiple injections with α-GalCer reduced
atherosclerosis in LDLr-/- mice but was not protective in apoE-/- mice. ApoE-/-
splenocytes showed a lower proliferative response towards α-GalCer and
showed a dampened cytokine production, both in vitro and in vivo. Both effects
may be caused by the lack of apoE. In addition, Western-type diet feeding of
LDLr-/- mice increased NKT cell numbers in liver and spleen. Our findings
suggest that in combination with endogenous activation of NKT cells, treatment
with α-GalCer can be protective against atherosclerosis.
Methods
Animals
All animal work was approved by the regulatory authority of Leiden University
and carried out in compliance with the Dutch government guidelines. Male
LDLr-/- and apoE-/- mice were obtained from the Jacksons Laboratory as mating
pairs and bred at the Gorlaeus Laboratories, Leiden, The Netherlands. Jα281-/-
mice on a C57BL/6 background were obtained from Dr M. Taniguchi. All mice
were kept under standard laboratory conditions and were fed a normal chow
diet or a ’Western-type’ diet containing 0.25% cholesterol and 15% cocoa butter
(Special Diet Services, Witham, Essex, UK). All mice used were 10-12 weeks of
age at the start of the experiment. Diet and water were administered ad libitum.
Glycolipids
α-Galactosylceramide (α-GalCer; KRN7000) and the control analogue
β-galactosylceramide (β-GalCer) were developed and manufactured by the
Pharmaceutical Research Laboratory of Kirin Brewery Co. (Gunma, Japan).
Both α-GalCer and β-GalCer were dissolved in water. For intraperitoneal and
intravenous injections, both glycolipids were diluted in 0.9% NaCl.
Effect of α-GalCer on lesion formation
To determine the effect of α-GalCer on the initiation of atherosclerosis, athero-
sclerosis was induced in LDLr-/- and apoE-/- mice. The mice were fed a
Western-type diet 2 weeks prior to surgery. After 2 weeks, atherosclerosis was
induced by placement of perivascular collars prepared from elastic tubing (0.3
mm inside diameter; Dow Corning, Midland, Michigan), around both carotid
arteries (method described by von der Thüsen et al.24). For this surgery the mice
were anaesthetized by a subcutaneous injection of ketamine (60 mg/kg; Eurovet
Animal Health), fentanyl citrate (1.26 mg/kg; Janssen Animal Health) and
fluanisone (2 mg/kg; Janssen Animal Health). The diet response was followed
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by measuring the cholesterol levels in serum of these mice. Total cholesterol
levels were quantified spectrophotometrically using an enzymatic procedure
(Roche Diagnostics, Germany). Immediately after collar placement, the mice
were injected twice a week with 2 µg of β-GalCer or α-GalCer. All injections were
performed half i.v./half i.p. and continued for 6 weeks. Subsequently, the mice
were anaesthetized by a s.c. injection with ketamine-hypnorm and exsanguinated
by femoral artery transsection. The mice were perfused and fixated through the
left cardiac ventricle with PBS for 15 min. and subsequently with FormalFixx
for about 30 min. Common carotid arteries and both carotid bifurcations were
removed for analysis as described by von der Thüsen et al.24 The arteries were
embedded in OCT compound (TissueTek; Sakura Finetek, The Netherlands) and
5µm sections were made on a Leica CM 3050S Cryostat (Leica Instruments, UK)
proximally of the place of collar occlusion. These cryosections were stained with
hematoxylin (Sigma Diagnostics, MO) and eosin (Merck Diagnostica, Germany).
Plaque areas were measured using a Leica DM-RE microscope and LeicaQwin
software (Leica Imaging Systems, UK).
Spleen Cell Proliferation Assay
To test the responsiveness of splenocytes to α-GalCer, spleens from LDLr-/-,
apoE-/- and Jα281-/- mice were dissected and single cell suspensions were
obtained by squeezing the spleen through a 70 µm cell strainer (Falcon, The
Netherlands). The erythrocytes were eliminated by incubating the cells with
erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH
7.3). Subsequently, the splenocytes were cultured in triplicate at 2·105 cells per
well of a 96-wells round-bottom plate in the presence or absence of different
concentrations of α-GalCer. RPMI 1640 (with L-Glutamine) supplemented with
10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 µg/ml streptomycin (all
from BioWhittaker Europe) was used as culture medium. The splenocytes were
incubated for 48 hours in a humidified atmosphere (37◦C; 5% CO2). Cultures
were pulsed for the final 16 hours with [6-3H]-thymidine (1 µCi/well, sp. act.
24 Ci/mmol; Amersham Biosciences, The Netherlands). The amount of [6-3H]-
thymidine incorporation was measured using a liquid scintillation analyzer
(Tri-Carb 2900R). The magnitude of the proliferative response is expressed as
stimulation index (SI) defined as the ratio of the mean counts per minute of
triplicate cultures with α-GalCer to the mean counts per minute in culture
medium without α-GalCer.
Cytokine assays
To determine the cytokine production by splenocytes upon stimulation with
α-GalCer, splenocytes were isolated from LDLr-/- and apoE-/- mice and
incubated with 100 ng/ml α-GalCer in RPMI-1640 medium (supplemented
with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin and 50 µM 2-
mercaptoethanol). After 0, 24 and 48 hours culture supernatants were collected
for ELISA assays to measure the IFN-γ, IL-10 and IL-4 production conform
the manufacturers protocols (eBioscience, Belgium). To determine the in vivo
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response to α-GalCer, LDLr-/- and apoE-/- mice were fed a Western-type diet
and α-GalCer was injected i.p. and i.v. (50%/50%) twice a week during 7 weeks.
72 hours after the last injection the mice were sacrificed and the spleen and
the mediastinal lymph nodes were dissected. Mononuclear cells were isolated
using Lympholyte (Cedarlane, Ontario, Canada) conform the manufacturers
protocol. The cells were stimulated o/n with anti-CD3 and anti-CD28, coated
onto a 96-wells plate. Cells were subsequently stained with APC-conjugated
anti-CD4 or anti-CD3 (0.125 µg/sample) for 30 min and subsequently fixated
and permeabilized for 20 min. Then, the cells were stained with PE-conjugated
anti-IL-4 mAb, PE-conjugated anti-IL-10 mAb and PE-conjugated anti-IFN-γ
mAb (eBioscience, Belgium) for 30 min. Cells were washed two times and
analyzed immediately by flow cytometry on a FACSCalibur. All data were
analyzed with CELLQuest software (BD Biosciences, The Netherlands).
Effect of Western-type diet on NKT cells
To investigate the effect of Western-type diet on the amount of NKT cells, LDLr-/-
and apoE-/- mice were fed a Western-type diet for 0, 1.5 and 4.5 weeks. After
diet feeding, the mice were sacrificed and the liver and spleen were dissected.
Mononuclear cells were isolated from these organs using Lympholyte (Cedarlane,
Ontario, Canada) conform the manufacturers protocol. Subsequently, the cells
were stained with PerCP-conjugated CD3 and FITC-conjugated NK1.1 antibodies
(eBioscience, Belgium) for 30 min. Cells were washed two times and analyzed
immediately by flow cytometry on a FACSCalibur. All data were analyzed with
CELLQuest software (BD Biosciences, The Netherlands).
Statistical analysis
All data are expressed as mean±SEM. The two-tailed student’s t test was used
to compare all data. P -values less than 0.05 are considered to be statistically
significant.
Results
α-GalCer protects against atherosclerosis in LDLr-/- mice, but not in apoE-/- mice
Two mouse models for atherosclerosis were used to investigate the effect of
multiple injection of α-GalCer to activate NKT cells on plaque formation. Male
LDLr-/- and apoE-/- mice, fed a Western-type diet for two weeks, were equipped
with perivascular collars around both carotid arteries to induce atherosclerosis.
After surgery, diet was continued and the mice were treated by combined i.p.
and i.v. injections (50%/50%) of 2 µg α-GalCer or β-GalCer per treatment.
Both ligands were administered twice a week for 7 weeks. Representative
examples of plaques of β-GalCer and α-GalCer treated LDLr-/- mice, stained
with hematoxylin and eosin, are shown in figure 5.1A and 5.1B, respectively.
Treatment with α-GalCer led to an 84.1% reduction in plaque size in LDLr-/- mice,
when compared with β-GalCer treated LDLr-/- mice (Figure 5.1C; 16488±6286
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Figure 5.1: Multiple injections with α-GalCer reduces plaque formation in LDLr-/- mice. LDLr-/- mice
were treated twice a week with 2 µg of α-GalCer or β-GalCer after collars were placed around the carotid
arteries. Representative cryosections of plaques from β-GalCer (A) and α-GalCer (B) treated mice were stained
with hematoxylin and eosin. Using computer assisted morphometric analysis plaque size (C) and intima/lumen
ratio (D) were determined. During the experiment total serum cholesterol levels were monitored (E). ∗P<0.05.
µm2 versus 2621±263 µm2, respectively; P<0.05). α-GalCer treatment also
resulted in an 85.7% reduction in intima/lumen ratio (Figure 5.1D; 0.26±0.10
versus 0.04±0.01 ; P<0.05) and a 77.3% reduction in intima/media ratio (data
not shown; 0.63±0.23 versus 0.14±0.02; P<0.05). Figure 5.2A and 5.2B represent
examples of plaques of β-GalCer and α-GalCer treated apoE-/- mice, respectively.
In apoE-/- mice a non-significant reduction on plaque size was observed (Figure
5.2C; 21700±2644 µm2 versus 14922±3060 µm2; P=0.30). In addition, the
intima/lumen ratio (Figure 5.2D; 0.37±0.08 versus 0.25±0.04; P=0.18), and
intima/media ratio (data not shown; 0.83±0.14 versus 0.64±0.07; P=0.23) were
not significantly affected in apoE-/- mice. In both studies no effect of α-GalCer on
total plasma cholesterol levels (Figure 5.1E and 5.2E) and body weight (data not
shown) was observed.
In vitro effects of α-GalCer
To investigate the effect of α-GalCer on proliferation of spleen cells, splenocytes
were isolated from LDLr-/-, apoE-/- and Jα281-/- mice. Splenocytes from LDLr-/-
mice respond to α-GalCer with a significant proliferative response. Incubation
with 100 and 500 ng/ml of α-GalCer induced a 15- to 22-fold increase in
proliferation (Figure 5.3, left graph, P<0.01). On the other hand, the response
of splenocytes of apoE-/- mice was much lower. Incubation with 100 ng/ml of
α-GalCer had no significant effect, while 500 ng/ml of α-GalCer caused a 5.2-
fold increase in proliferation (Figure 5.3, middle graph, P<0.05). As a control,
splenocytes were isolated from Jα281-/- mice, lacking CD1d-restricted NKT cells,
and incubation of these cells with α-GalCer did not induce any proliferation of
splenocytes using both concentrations of α-GalCer (Figure 5.3, right graph).
Additionally, the cytokine production of splenocytes from LDLr-/- and apoE-/-
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Figure 5.2: Multiple injections with α-GalCer have no significant effect on atherosclerosis in apoE-/-
mice. ApoE-/- mice were treated with 2 µg of α-GalCer or β-GalCer just like the LDLr-/- mice in Figure
5.1. Representative cryosections of plaques from β-GalCer (A) and α-GalCer (B) treated apoE-/- mice were
stained with hematoxylin and eosin. Plaque size (C) and intima/lumen ratio (D) were determined. During the













































Figure 5.3: Proliferative response of splenocytes from different mouse strains on α-GalCer. Splenocytes
were isolated from LDLr-/-, apoE-/- and Jα281-/- mice and were incubated for 48 hrs with 100 or 500 ng/ml of
α-GalCer. As a control, non-stimulated cells were used. Cells were pulsed with [6-3H]-thymidine for the final
16 hrs and the amount of proliferation was measured. Data are shown as the stimulation index (S.I.) ± SEM.
The S.I. is defined as the ratio of the mean counts per minute of triplicate cultures with α-GalCer to the mean
counts per minute in culture medium without α-GalCer. ∗∗P<0.01, ∗∗∗P<0.001
mice in response to α-GalCer was determined. Stimulation of LDLr-/- splenocytes
with 100 ng/ml of α-GalCer for 48 hours resulted in an increase in the production
of IL-10 (101±13 pg/ml vs. 1559±133 pg/ml), IL-4 (36±9 pg/ml vs. 585±100
pg/ml) and IFN-γ (39±13 pg/ml vs. 381±80 pg/ml) when compared with cells
cultured without α-GalCer (Figure 5.4, upper panel). Splenocytes of apoE-/- mice
cultured with 100 ng/ml of α-GalCer for 48 hrs produced much lower amounts
of IL-10 (16±1 pg/ml), IL-4 (92±22 pg/ml) and IFN-γ (9±1 pg/ml) (Figure 5.4,
lower panel). When compared with splenocytes of apoE-/- mice cultured without
α-GalCer stimulation, the relative increase in IL-4 and IFN-γ is rather high but
the relative production of IL-10 is much lower when compared with the cytokine













































































Figure 5.4: Cytokine production by splenocytes of LDLr-/- and apoE-/- mice after in vitro stimulation
with α-GalCer. Splenocytes were isolated from LDLr-/- (upper panel) and apoE-/- (lower panel) mice and
incubated with 100 ng/ml of α-GalCer or without α-GalCer (control). After 24 and 48 hrs of incubation the
production of IL-10, IL-4 and IFN-γ was monitored by an ELISA on the supernatant of the cells. Values are
mean cytokine concentration ± SEM.
In vivo effects of α-GalCer on cytokine production
To determine whether injections with α-GalCer affected the cytokine profile in
LDLr-/- and apoE-/- mice, the cytokine production of CD3+ and CD4+ cells in
spleen and mediastinal lymph nodes was determined after multiple injections
with α-GalCer. FACS analysis showed that only a small percentage of the CD4+
cells in both the spleen and the lymph nodes produce Th1 and Th2 cytokines.
In β-GalCer-treated LDLr-/- mice, 1.22±0.22%, 0,76±0.13% and 1.20±0.13%, of
the CD4+ cells in the spleen produce IL-4, IL-10 and IFN-γ, respectively. There
was no effect on CD4+IL-4+ splenocytes (1.81±0.50%; P=0.35) and CD4+IFN-γ+
splenocytes (1.66±0.28%; P=0.20) after multiple treatment of LDLr-/- mice with
α-GalCer but a significant increase in CD4+IL-10+ splenocytes (2.12±0.32%;
P<0.01) was observed (Figure 5.5A, upper panel). In the mediastinal lymph
nodes, the CD4+IL-4+ and CD4+IL-10+ lymphocytes increased after multiple α-
GalCer injections (0.38±0.09% vs. 1.33±0.12% and 0.46±0.12% vs. 1.42±0.11%,
respectively; P<0.05). No effect on CD4+IFN-γ+ lymphocytes (0.52±0.06% vs.
0.56±0.12%; P=0.79) was observed (Figure 5.5A, lower panel). In the spleen
of β-GalCer-treated apoE-/- mice, 0.84±0.21%, 1.90±0.29% and 1.31±0.16% of
the lymphocytes are CD3+IL-4+, CD3+IFN-γ+ and CD3+IL-10+, respectively.
There was no effect on these percentages after multiple injections with α-GalCer
(1.18±0.16%, 2.50±0.18% and 1.64±0.12%, respectively) (Figure 5.5B, upper
panel). In the mediastinal lymph nodes of these mice, no effect on CD3+IL-
4+ (0.41±0.09% vs. 1.09±0.12%), CD3+IL-10+ (0.55±0.03% vs. 1.05±0.23%)
and CD3+IFN-γ+ (2.71±0.41% to 2.28±0.29%) lymphocytes was observed after
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multiple injections with α-GalCer (Figure 5.5B, lower panel).
Effect of Western-type diet feeding on NKT cell numbers
LDLr-/- and apoE-/- mice were fed a Western-type diet and sacrificed at different
time points. After diet feeding, the number of NKT cells in both the liver
and the spleen was analyzed. After 1.5 weeks of diet feeding, the percentage
of CD3+NK1.1+ cells increased significantly from 3.24±0.14% to 6.95±0.42%
(P<0.01) in the spleen and from 19.05±1.21% to 42.37±2.21% (P<0.05) in the
liver of LDLr-/- mice, when compared with LDLr-/- mice sacrificed before feeding
a Western-type diet. This effect was at this time point absent in the apoE-/- mice.
In these mice there was no increase of NKT cell numbers in the spleen and a minor
increase in the liver. After 4.5 weeks of diet, the percentage of NKT cells increased
even more in the spleen of LDLr-/- mice (7.50±0.84%; P<0.05). In the liver of
LDLr-/- mice, the percentage returned to control levels. In apoE-/- mice still no
effect of Western-type diet on NKT cell numbers in the spleen was observed,
whereas in the liver a 2.4-fold increase in NKT cells was observed (11.10±1.42%
versus 27.18±1.50%; P<0.05)(Figure 5.6).
Discussion
In this study we demonstrate for the first time that α-GalCer activation of NKT
cells may, depending on the experimental conditions, act in an atheroprotective
manner. Activation of NKT cells via a combination of intraperitoneal and intra-
venous injections of α-GalCer, resulted in a 84% reduction of lesion formation
in LDLr-/- mice in which shear-stress induced atherosclerosis was induced via
collar placement around both carotid arteries and by feeding a Western-type
diet. No significant effect of α-GalCer treatment was observed in the carotid
arteries of apoE-/- mice that were also fed a Western-type diet (31% reduction,
not significant). In both experiments, the β-variant of α-GalCer (β-GalCer) was
used as a control ligand. This glycolipid is known to bind to CD1d but is not
able to induce any proliferative response and does not affect NKT cells.25 Several
other studies showed that administration of α-GalCer to mice modulates the
disease process in atherosclerosis and accelerates lesion formation. Nakai et al.
showed that repeated i.p. administration of α-GalCer to apoE-/- mice increased
atherosclerotic lesions with 67%.12 Major et al. and Tupin et al. found a similar
increased plaque size when apoE-/- mice, fed a normal chow diet, were treated
with α-GalCer twice a week for 10 weeks.13,14 It was hypothesized that the effect
on atherosclerosis resulted from an increase in IL-4 and IFN-γ production. In
a number of other Th1-mediated diseases, multiple injections of α-GalCer were
shown to be protective because of the induction of Th2 cytokines IL-4, IL-5, IL-10
and IL-13 and this was beneficial in mouse models for autoimmune diseases such
as diabetes20, colitis22 and multiple sclerosis21, for several infectious diseases
such as malaria26 and hepatitis B27, and for tumor treatment. Therefore it was
surprising that in atherosclerosis studies, repeated injections of α-GalCer led
to an increase in plaque development in atherosclerosis in apoE-/- mice. We
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Figure 5.5: Cytokine production after in vivo treatment of LDLr-/- and apoE-/- mice with α-GalCer.
LDLr-/- and apoE-/- mice were fed a high fat diet and were treated by multiple injections of α-GalCer. After
the last injection, the mice were sacrificed and the spleen and mediastinal lymph nodes were isolated. Using
the FACS the percentage of CD3+ and CD4+ cells producing IL-4, IL-10 and IFN-γ within the lymphocyte
population was determined. Figure A represents the LDLr-/- mice with on the upper side the graphs for the
spleen and on the lower side for the lymph nodes. Figure B represents the apoE-/- mice. ∗P<0.05
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Figure 5.6: Effect of Western-type diet feeding on the number of NKT cells in LDLr-/- and apoE-/- mice.
LDLr-/- and apoE-/- mice were fed a Western-type diet. After 0, 1.5 and 4.5 weeks mice were sacrificed and the
number of CD3+NK1.1+ cells in the spleen and liver was measured using FACS analysis. Values are mean ±
SEM. ∗P<0.05, ∗∗P<0.01
diet and no effect in apoE-/- mice on a Western-type diet, whereas previous
studies showed an aggravation of atherosclerosis in apoE-/- mice fed a normal
chow diet. A major difference between the two species is their response to
α-GalCer: NKT cells from apoE-/- mice showed less proliferation in response to
α-GalCer than those from LDLr-/- mice. This is explained by the study of van
den Elzen et al. that shows that apoE is an important mediator in presentation of
lipid antigens via CD1 molecules.23 They proposed that apoE binds exogenous
lipid antigens and efficiently targets them for receptor mediated uptake by DCs.
Furthermore, intracellular apoE may be important in the delivery of the lipid to
compartments containing CD1d, leading to presentation of α-GalCer on CD1d.
In line with the defect in lipid presentation, apoE-/- mice show exacerbated
experimental allergic encephalomyelitis (EAE),28 and it may be speculated that
this results from a reduced activation of sulfatide-specific CD1d-restricted NKT
cells in apoE-/- mice, which normally inhibit EAE.29 The lack of apoE thus
explains the lower response to α-GalCer in apoE-/- mice compared to splenocytes
from LDLr-/- mice which is in line with Major et al. who showed a reduced
NKT cell proliferation upon α-GalCer stimulation in apoE-/- mice, compared
with C57Bl/6 mice.14 However, since CD1d-restricted NKT cells are still present
in apoE-/- mice it can be concluded that apoE is not a prerequisite for NKT
cell activation and other pathways can result in CD1d antigen presentation.
Lipid transporters, apolipoproteins and lipoprotein receptors are also likely
to participate in lipid antigen uptake and subsequent presentation via CD1
molecules.30 This is confirmed by the low, but significant response of apoE-/-
splenocytes to α-GalCer in our experiment and that of Major et al.14 The lower
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degree of activation of NKT cells in apoE-/- mice is confirmed by the fact that
in our study, apoE-/- mice had 50% less NKT cells in the liver when compared
with age-matched LDLr-/- mice. In addition, one publication showed that aged
apoE-/- mice have fewer CD1d-restricted NKT cells in the spleen than young
apoE-/- mice.14
In our current study we observed that splenocytes from apoE-/- mice produce
lower amounts of cytokines in response to α-GalCer when compared with
LDLr-/- mice. These data correlate with the lower splenocyte proliferation
observed in apoE-/- mice and may also explain the effect of α-GalCer on
atherosclerosis. Especially the relative increase in production of IL-10 after
α-GalCer stimulation was much smaller in splenocytes from apoE-/- mice when
compared with LDLr-/- mice, while the relative increase in production of IL-4 and
IFN-γ was almost the same.
In addition, it is surprising that we did not observe an aggravating effect of
α-GalCer in apoE-/- mice in contrast to previous publications.12–14 This result
may be caused by the fact that our mice were fed a high fat diet. As we now
show in this study, Western-type diet feeding of LDLr-/- mice caused a rapid 2.2-
fold increase in NKT cells in the liver, which returned to control levels after 4.5
weeks of diet. In spleen a 2-fold increase was observed for up to 4.5 weeks of diet
which may be explained by migration of NKT cells from the liver to the spleen.
After 9 weeks of diet feeding all NKT cell levels were back at basal levels (data
not shown). This may be in line with the study of Aslanian et al. who showed
an effect of CD1d deficiency in LDLr-/- mice on initial stages of atherosclerosis
only. After 4 weeks of diet feeding, lesions were smaller in the CD1d-/-LDLr-/-
mice16. This is the time point at which we observed the largest increase in NKT
cells. After 8 and 12 weeks of diet no effect of CD1d deficiency on atherosclerosis
was observed. In apoE-/- mice the increase in NKT cells in the liver was delayed
and in the spleen no increase was observed. This may of course result from the
reduced lipid antigen presentation in apoE-/- mice.30,31
Although the natural ligand for NKT cells is still not known, our data strongly
suggest that a high fat diet induces a proliferation and probably an activation
of NKT cells in liver and spleen. Whether this endogenous activation of NKT
cells is harmful in atherosclerosis needs further investigation, but from data on
CD1d-/-LDLr-/- mice we conclude that endogenous activation may accelerate
atherosclerosis. In our current study the LDLr-/- and apoE-/- mice were treated
with a combination of endogenous activation (diet feeding) and a synthetic ligand
(α-GalCer). When α-GalCer was injected for the first time, the mice were already
fed the high fat diet for two weeks. At that time point the NKT cells are
triggered endogenously and present in increased levels in both liver and spleen
of the LDLr-/- mice. We hypothesize that α-GalCer turns these ”triggered” NKT
cells into Th2-cytokine producing cells that ameliorate atherosclerosis. This is
confirmed by our data on the in vivo cytokine profile after high fat diet feeding
and multiple injections of α-GalCer. We observed a significant increase in both
IL-4 and IL-10 producing T cells in the spleen and mediastinal lymph nodes of the
LDLr-/- mice. No effect on the production of IFN-γ was observed. In apoE-/- mice
there was however no significant effect on IL-4, IL-10 and IFN-γ production by T
cells after high diet feeding and multiple injections of α-GalCer. After two weeks
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of diet feeding and at the beginning of α-GalCer administration, the hepatic and
splenic NKT cells of apoE-/- mice are not endogenously triggered by the diet
yet. Administration of α-GalCer at that time point may have activated the NKT
cells but was not protective. We however did not see an increased lesion size
and increased levels of IL-4 and IFN-γ as was observed in former studies.12–14
It is therefore concluded that the endogenous activation of NKT cells which is
delayed in apoE-/- mice still affects the previously described negative effect of
α-GalCer activation of NKT cells in a beneficial way, but not sufficiently enough
to significantly reduce atherosclerosis.
In conclusion we describe in this study that in hyperlipidemic conditions,
NKT cell activation by α-GalCer may have a protective role in atherosclerosis.
However, this protective effect is only found in LDLr-/- mice, and not in apoE-/-
mice since these mice have a retarded lipid antigen presentation. The proposed
negative role of NKT cells in atherosclerosis may need reconsideration and
further investigation into the endogenous ligands will be necessary.
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Abstract
Natural killer T (NKT) cells contribute significantly to the inflammatory response
in atherosclerosis. In atheroprone apolipoprotein E (apoE) deficient mice, NKT
cells have an atherogenic phenotype and their activation with the synthetic ligand
α-galactosylceramide (α-GalCer) causes an increase in atherosclerotic plaque formation.
Stimulation with the α-GalCer analog OCH is shown to provoke a T helper 2 (Th2)
cytokine phenotype in NKT cells. In this study we observed an increased interleukin-10
(IL-10) production in LDLr-/- mice after intraperitoneal treatment with OCH, but no
effect on atherosclerosis. Therefore we used mature dendritic cells (mDCs) to deliver
the OCH to the NKT cells in the liver. Treatment with OCH-pulsed mDCs resulted
in an increased number of IL-10 producing NKT cells in the liver and in a subsequent
reduction in atherosclerotic plaque formation. Additionally, a reduction in cholesterol
levels was observed in mice treated with OCH-pulsed DCs. Altogether, this strategy
of immunomodulation with mDCs loaded with OCH may form a new therapeutical




In the chronic inflammatory response that underlies atherosclerosis, both innate
and adaptive mechanisms are very important.1 Antigen presenting cells (APCs),
such as macrophages and dendritic cells (DCs), are reported to initiate the
autoimmune response by the uptake of autoantigens, such as oxidized low-
density lipoprotein (oxLDL) and heat shock proteins. Peptides of these antigens
are presented to T cells via MHC class I and II molecules.2,3 By this, the peptides
elicit the activation of T cells, especially T helper 1 (Th1) cytokine producing
CD4+ T cells.4–7 T cell triggering naturally occurs within the lymphatic system,
especially within the lymph nodes and spleen. After triggering, T cells migrate
to the site of inflammation i.e. infiltrate the atherosclerotic plaque, where they
may re-encounter their specific antigen, become activated and mediate their
inflammatory damage. This is the onset of a process in which increasing numbers
of immune cells are attracted to the atherosclerotic plaque and can result in
occlusion of the vessels and severe cardiovascular disorders.
APCs such as macrophages and DCs are also attracted into the atherosclerotic
plaque. APCs and especially the DCs express CD1 molecules, MHC class I like
molecules, which specifically present lipidic antigens to T cells.8 In mice, only
CD1d, a CD1 family member, is expressed on DCs9 and Bobryshev et al. observed
that CD1d is expressed within the atherosclerotic plaque.10 The complex of CD1d
with a lipid antigen can be recognized by invariant natural killer T (NKT) cells.
NKT cells are a specialized subset of T cells expressing both an invariant T
cell receptor (TCR) α chain composed of Vα14-Jα18 segments and the NK cell
marker NK1.1. In atherosclerosis a colocalization of NKT cells and DCs within
the shoulder regions of the plaque is observed, suggesting that NKT cells are
activated by antigen presentation on the DCs.11
NKT cells can be activated using synthetic ligands such as α-galactosylceramide9
(α-GalCer) and the α-GalCer analog ((2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-2-
(N-tetracosanoylamino)-1,3,4-nonanetriol) (OCH).12,13 Activation by α-GalCer
induces a rapid aspecific mixed Th1/Th2 response, in which the NKT cells
produce large amounts of IL-4, IL-10, IL-12, IL-13 and IFN-γ. Recent studies
showed that in contrast with other Th1-mediated autoimmune-like diseases such
as autoimmune diabetes,14–16 experimental autoimmune encephalomyelitis17,18
and colitis,19,20 treatment with α-GalCer accelerated the disease process in
atherosclerosis-prone apoE deficient mice.21–23 OCH, which has a truncated
sphingosine chain and therefore a lower affinity for CD1d, induces a more Th2-
like cytokine profile. OCH-activated NKT cells produce predominantly IL-4,
IL-10 and IL-13 and low levels of IFN-γ.12,13 This feature makes OCH an interes-
ting glycolipid, which abrogates Th1-mediated immune responses.12,19,24,25
Because of their capacity to stimulate T and NKT cells, DCs are widely used
in vaccination therapies. DCs may be pulsed with an antigen ex vivo and
subsequently these ”pulsed” DCs are returned into the bloodstream. This
approach is successfully used in cancer26 and in several autoimmune diseases.
DCs pulsed with bovine collagen type II protect mice from collagen-induced
arthritis27 and immature DCs (imDCs) pulsed with a peptide of glutamic acid
decarboxylase protect nonobese diabetic (NOD) mice against type I diabetes.28
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In studies on cancer it was observed that DCs pulsed with α-GalCer induced a
prolonged IFN-γ-producing NKT cell response.29,30
In this study we observed that intraperitoneal injections of OCH had no ef-
fect on atherosclerosis despite an increased IL-10 production by splenic CD4+
lymphocytes. In contrast, injection of OCH-pulsed mDCs in low density lipo-
protein receptor (LDLr) deficient mice reduced atherosclerotic plaque formation
which may be explained by a significant increase in IL-10+ producing NKT cells
in the liver. Additionally a significant reduction in serum cholesterol levels was
observed after treatment with OCH-pulsed mDCs.
Methods
Animals
All animal work was approved by the regulatory authority of Leiden University
and carried out in compliance with the Dutch government guidelines. Male
LDLr-/- and GFP+ mice were obtained from Jackson’s Laboratory and male
C57BL/6j mice from Charles River Laboratories (Maastricht). All mice were kept
under standard laboratory conditions and bred in-house. The mice were fed a
normal chow diet or a Western-type diet containing 0.25% cholesterol and 15%
cocoa butter (Special Diet Services, Witham, Essex, UK). Water and food were
administered ad libitum.
Media and reagents
R1 cells, producing Granulocyte-Macrophage Colony-Stimulating Factor
(GM-CSF), and dendritic cells were cultured in IMDM (Cambrex, Belgium)
supplemented with 8% FBS, 100 U/ml penicillin/streptomycin (both from
PAA, Germany), 2 mM glutamax (Invitrogen, The Netherlands) and 20 µm
β-mercaptoethanol (Sigma Aldrich,The Netherlands). β-GalCer was obtained
from the Kirin Brewery Co Ltd, (Gunma, Japan). OCH ((2S,3S,4R)-1-O-(α-D-
Galactopyranosyl)-2-(N -tetracosanoylamino)-1,3,4-nonanetriol) was synthesized
as previously described by Fan et al. and dissolved in dimethyl sulphoxide
(DMSO).31 The synthesis of OCH was analyzed via nuclear magnetic resonance
(NMR).
Intraperitoneal treatment with OCH
To test the direct effect of OCH on atherosclerosis, LDLr-/- mice were injected
intraperitoneally with either 100 µg/kg β-GalCer (n=11) or OCH (n=13), twice
a week for 7 weeks. Both β-GalCer and OCH were dissolved in PBS with 1%
DMSO. After 3 weeks of Western-type diet feeding and prior to the treatment
with β-GalCer and OCH, atherosclerosis was induced in both carotid arteries
by bilateral perivascular collar placement as described previously32. The mice
were fed a Western-type diet during the whole experiment (10 weeks). At the
end of the experiment, mice were sacrificed and tissues were harvested after in
situ perfusion with PBS and FormalFixx. Fixated tissues were embedded in OCT
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compound (Sakura Finetek, The Netherlands), snap frozen in liquid nitrogen and
stored at -20◦C until further use.
Treatment with OCH-pulsed DCs
To test the effect of OCH-pulsed DCs, bone marrow cells were harvested from
the femur and tibia of C57BL/6j mice and were cultured for 10 days in complete
IMDM supplemented with GM-CSF. Maturation of the DCs was accomplished
via the addition of 1 µg/ml of LPS (from Salmonella Typhosa, Sigma Aldrich,
The Netherlands) to the medium for 24 hours. Together with LPS, 100 ng/ml of
OCH was added to a fraction of the DCs. Control DCs were incubated with LPS
only. After 24 hours, the DCs were harvested and diluted in PBS. Subsequently,
LDLr-/- mice were injected intravenously 8, 6 and 3 days before the mice were put
on a Western-type diet. The mice received PBS (n=13), 1.5·106 mature DCs (n=9)
or 1.5·106 OCH-pulsed mDCS (n=11). Next, the mice were either sacrificed one
day or three days after the last injection with DCs or the mice were fed a Western-
type diet for 3 weeks and atherosclerosis was induced in both carotid arteries by
bilateral perivascular collar placement as described previously.32 Seven weeks
after collar placement, the mice were sacrificed and tissues were harvested after in
situ perfusion with PBS and FormalFixx. Fixated tissues were embedded in OCT
compound (Sakura Finetek, The Netherlands), snap frozen in liquid nitrogen and
stored at -20◦C until further use.
Homing of injected DCs
To investigate the homing of injected DCs, bone marrow DCs were isolated
from GFP+ mice and were cultured for 10 days in presence of GM-CSF. Sub-
sequently, the cells were maturated with LPS (1 µg/ml) and injected intra-
venously in LDLr-/- mice fed a normal chow diet or a Western-type diet. 48
hours after injection, the mice were sacrificed and the distribution of GFP+-
DCs was determined via FACS-analysis of several organs. These organs were
isolated and mononuclear cells were isolated using Lympholyte according to the
manufacturers protocol (Cedarlane, Hornby, Ontario, Canada).
Histological analysis
After sacrificing the mice, the carotid arteries were sliced (5 µm) proximal of the
collar and the cryosections were stained with hematoxylin (Sigma Aldrich, The
Netherlands) and eosin (Merck Diagnostica, Germany). Cryosections of the aortic
root (10 µm) were stained with Oil-red-O and hematoxylin to determine plaque
size. Corresponding sections of carotid arteries and aortic root were stained
with a macrophage specific marker (MOMA-2, Research Diagnostic Inc., New
Jersey) and a collagen specific marker (Masson’s Trichrome, Sigma Aldrich, The
Netherlands). All images were analyzed using the Leica DM-RE microscope and
LeicaQwin software (Leica Imaging Systems, UK).
Cholesterol and triglyceride levels
During the experiment, plasma samples obtained by tail vein bleeding were used
to determine the total plasma cholesterol and triglyceride levels. Cholesterol
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levels were quantified spectrophotometrically using an enzymatic procedure
(Roche Diagnostics, Germany). Triglyceride levels were quantified by using a
ready-made kit (Roche Diagnostics, Germany). Precipath standardized serum
(Boehringer, Germany) was used as an internal standard. Via SMART-analysis
(3.2 x 30 mm, Smart System, Pharmacia) using the Superose 6 column the
cholesterol distribution over different lipoproteins was analyzed.
Flow Cytometry
To check the maturation status of the DCs, cells were stained with the antibodies
CD80-PE, CD86-FITC, CD40-PE, MHC II-PE, CD1d-FITC and CD11c-FITC (eBio-
science, Belgium). In order to detect effects on cytokine production, 3 days
after the last injection with β-GalCer or OCH, leukocytes were isolated from
spleens using Lympholyte (Cedarlane, Canada). Per well of a 96-wells plate,
5·105 of these mononuclear cells were stimulated for 24 hours with αCD3/αCD28
(5 µg/ml) and 100 ng/ml OCH. Next the splenocytes were incubated with a
leukocyte activation cocktail containing Golgi-stop (Becton Dickinson, CA). After
4 hours we performed intracellular staining as suggested by the manufacturers
protocol. In this experiment CD4-PerCP, IFNγ-APC, IL-10-PE and IL-4-FITC
antibodies were used. To determine NKT cells in blood during DC treatment,
blood was collected at several time points in EDTA-coated tubes. Red blood cells
were lysed using a lysis buffer containing 0.83% NH4Cl in 0.01 M Tris/HCL
(pH 7.2). Subsequently the cells were stained with CD3-PerCP and NK1.1-
FITC antibodies. To detect intracellular cytokines after the DC treatment, the
mice were sacrificed three days after the last injection with DCs. Leukocytes
were isolated using Lympholyte (Cedarlane, Hornby, Ontario, Canada) and
CD3-PerCP, NK1.1-FITC, IL-10-APC and IFNγ-APC antibodies were used to
detect intracellular cytokines. All antibodies were purchased from eBioscience
(Belgium). Staining of the cells was done in PBS with 1% normal mouse serum.
FACS analysis was performed on a FACSCalibur (Becton Dickinson, CA). Data
were analyzed with Cell Quest software.
Antibody detection
Cu-oxLDL was synthesized as described previously.33,34 MDA-LDL was made
by addition of 0.5 M MDA to 10 mg of LDL for 3 hours at 37◦C. Antibodies
against MDA-LDL and oxLDL were determined according to Damoiseaux et
al.35 Briefly, maxiSorp 96 well plates (Nunc, Roskilde, Denmark) were coated
overnight with 100 µg MDA-LDL or oxLDL in 100 µl PBS at 4◦C. Plates were
washed 5 times with 0.01 M Tris, 0.15 M NaCl and 0.05% Tween20 (pH 8.0).
Mouse serum was added in duplicate at a 1:50 dilution in incubation buffer (0.1
M Tris, 0.3 M NaCl and 0.05% Tween20 (pH 8.0) overnight at 4◦C. After washing,
plates were incubated with either alkaline phosphatase-labelled anti-mouse IgM
or IgG (Jackson Immuno-Research, Pennsylvania) both at a 1:4000 dilution in
incubation buffer for 1 hour at 37◦C. After washing, substrate (1 mg/ml disodium
p-nitrophenyl phosphate, Sigma, The Netherlands) was added. After 2 hours at




Values are expressed as mean±SEM. A two tailed Student’s t-test was performed
to compare data. When necessary a Mann-Whitney test was performed. Proba-
bility (P ) values below 0.05 were considered significant.
Results
Effect of multiple intraperitoneal injections with OCH on atherosclerosis
To investigate the effect of OCH on atherosclerosis, LDLr-/- mice in which
atherosclerosis was induced by Western-type diet feeding and perivascular
collar placement around the carotid arteries, were used. Following collar
placement, β-Galactosylceramide (β-GalCer) and OCH (100 µg/kg) were admin-
istered intraperitoneally twice a week for 7 weeks. The control, β-GalCer, has a
β-linkage of galactose to the ceramide group and binds to CD1d but is not able
to activate NKT cells.9 After treatment, the mice were sacrificed and the degree
of atherosclerotic plaque formation in β-GalCer-treated mice and OCH-treated
mice was determined in the carotid arteries (Figure 6.1A and 6.1B, respectively)
and in the aortic root (Figure 6.1D and 6.1E, respectively). Treatment with
OCH had no significant effect on plaque size in both the carotid arteries (Figure
6.1C; 38758±6937 µm2 versus 39211±9363 µm2) or the aortic root (Figure 6.1F;
438163±41923 µm2 versus 499456±52299 µm2) when compared with β-GalCer
treated mice. During the experiment, total plasma cholesterol levels and body
weight were not significantly different between both groups of mice (data not
shown).
Multiple intraperitoneal injections with OCH influence the cytokine profile.
OCH is reported to induce a Th2-like cytokine profile in NKT cells. Therefore we
isolated spleens of β-GalCer-treated and OCH-treated mice 3 days after the last
injection with β-GalCer and OCH and performed an intracellular FACS staining
to determine the cytokine profile. Following restimulation with OCH in vitro, the
number of IFN-γ producing cells within the CD4+ population of the splenocytes,
decreased significantly with 34% from 1.20±0.14% in the β-GalCer-treated mice
to 0.79±0.08% in the OCH-treated mice (Figure 6.2; P<0.05). Furthermore, a
76% increase in IL-10 producing cells within the CD4+ population was observed
(Figure 6.2; 0.76±0.14% versus 1.34±0.15%; P<0.05), while there was no effect on
the number of IL-4 producing CD4+ cells.
OCH priming of DCs
In order to test the effect of OCH-pulsed DCs on atherosclerosis, DCs had to
be pulsed with OCH first. Therefore, bone marrow cells were isolated from
the femur and tibia of C57Bl/6 mice and cultured for 10 days in presence of
GM-CSF. To maturate the DCs, LPS (1 µg/ml) was added to the culture for 24
hours. The maturation status of the DCs was checked by FACS analysis. CD11c
was constitutively expressed on all DCs i.e. imDCs, mDCs and OCH-pulsed
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Figure 6.1: Effect of intraperitoneal injections with OCH on atherosclerotic plaque formation.
Atherosclerosis was induced in LDLr-/- mice by Western-type diet feeding and collar placement around both
carotid arteries. Immediately after collar placement, the mice were treated with β-GalCer (n=11) or OCH
(n=13) twice a week. Seven weeks later, the mice were killed and the carotid arteries of β-GalCer-treated (A)
and OCH-treated (B) mice were sectioned and stained with hematoxylin and eosin. The scale bar represents
100 µm. Sections of the aortic root of β-GalCer-treated (D) and OCH-treated (E) mice were stained with Oil-
red-O and hematoxylin. These scale bars represent 200 µm. Lesions in the carotid arteries and aortic roots
were quantified by computer assisted morphometric analysis and the plaque size was determined (C and F,



































Figure 6.2: In vivo administration of OCH affects the cytokine profile within the spleen. After multiple
treatment with OCH, spleens of LDLr-/- mice fed a Western-type diet and equipped with collars around both
carotid arteries were dissected and splenocytes were isolated. The splenocytes of β-GalCer-treated (n=5) and
OCH-treated mice (n=6) were re-stimulated with αCD3/αCD28 (5 µg/ml) and OCH (100 ng/ml) in vitro. After
24 hours the percentage of CD4+ T cells producing IFN-γ, IL-10 and IL-4 was determined via intracellular
FACS analysis after gating for CD4+ lymphocytes. Values are mean±SEM. ∗P<0.05
mDCs. CD40, CD80 and CD86, well known maturation markers for DCs are
upregulated after the addition of LPS. The peptide-antigen presenting molecule
MHC class II was already present on imDCs and is only slightly upregulated due
to maturation, while the lipid-antigen presenting molecule CD1d is upregulated
due to the addition of LPS. OCH, when added together with LPS, had no












































































Figure 6.3: The effect of OCH on the maturation of DCs. Bone marrow derived DCs were incubated with
GM-CSF for 10 days. Subsequently they were incubated with LPS (1 µg/ml) to induce maturation. Part of the
DCs were simultaneously incubated with OCH to get mature OCH-pulsed DCs. After 24 hours of maturation
a FACS analysis was performed and the percentage of CD11c, CD40, CD86, CD80, MHC class II, and CD1d








































Figure 6.4: Homing of dendritic cells. DCs were isolated from bone marrow of GFP+ mice and 1.5·106
of mature GFP+ DCs were administered intravenously to LDLr-/- mice fed a chow diet (left panel, n=4) or
a Western-type diet (right panel, n=4). After 48 hours the mice were sacrificed and the percentage of GFP+
cells in the liver, spleen, lymph nodes around the heart (HLN) and the lungs was determined via FACS analysis.
Values are mean±SEM.
Intravenously injected mDCs accumulate in several organs
To investigate the homing of intravenously injected DCs, DCs were isolated
from GFP+ mice and maturated by the addition of LPS. Forty-eight hours after
injection of mature GFP+ DCs in chow diet fed and Western-type diet fed LDLr-/-
mice, DCs were recovered in the lung, liver, spleen and lymph nodes around
the heart (HLN). When fed a chow diet 18.6% of the lymphocytes in the lung
were GFP+, while in the liver 3.8% was GFP+. Relatively low percentages of
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the injected mDCs were found in spleen and lymph nodes (Figure 4, left panel).
When mice were fed a Western-type diet, 16.5% of the lymphocytes in the liver
were GFP+. The number of GFP+ cells in other organs was not really different
from that in the chow diet fed mice (Figure 6.4, right panel). Taken into account
the large number of leukocytes within the liver we conclude that large numbers













































Figure 6.5: Effect of immunomodulation with OCH-pulsed mDCs on atherosclerosis in the carotid
arteries. LDLr-/- mice were treated with mDCs or OCH-pulsed mDCs three times prior to Western-type diet
feeding and collar placement around both carotid arteries. Seven weeks after collar placement, the mice were
sacrificed and sections of the carotid arteries of mDC-treated mice (A, n=11) and OCH-pulsed mDC-treated
mice (B, n=9) were stained with hematoxylin and eosin. Plaque size (C) and intima/lumen ratio (D) were
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Figure 6.6: Effect of immunomodulation with OCH-pulsed mDCs on atherosclerosis at the aortic root.
LDLr-/- mice were treated with mDCs (A, n=11) or OCH-pulsed mDCs (B, n=9) three times prior to Western-
type diet feeding. After 10 weeks of Western-type diet feeding, the mice were sacrificed and sections of the
aortic roots were stained with Oil-red-O and hematoxylin. The scale bars represent 200 µm. Plaque size was
determined by computer assisted analysis (C). Plaque sizes are mean±SEM. ∗∗P<0.01
Repetitive vaccination with OCH-pulsed DCs reduces atherosclerosis
To determine the effect of DCs on atherosclerosis, PBS, mDCs and OCH-pulsed
mDCs were administered 3 times in 8 days intravenously to LDLr-/- mice.
After the treatment, atherosclerosis was induced by Western-type diet feeding
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and perivascular collar placement around both carotid arteries. Representative
examples of hematoxylin-eosin stained atherosclerotic lesions in the carotid
arteries of mDC-treated and OCH-pulsed mDC-treated mice are shown in Figure
6.5A and 6.5B, respectively. Injection of OCH-pulsed mDCs (9400±2185 µm2)
resulted in a significant 70.6% reduction in plaque size in the carotid arteries
when compared to mDC-treated mice (Figure 6.5C; 31920±7914 µm2; P<0.05).
Injection of OCH-pulsed mDCs (0.164±0.048) also reduced the intima/lumen
ratio with 64.4% (Figure 6.5D; 0.461±0.089; P<0.01). Additionally, the treatment
with mDCs did not differ from the treatment with PBS in plaque size (48578±9231
µm2; P=0.20) and intima/lumen ratio (0.560±0.097; P=0.48) (not shown). A
significant 58.1% reduction in plaque formation at the aortic root was observed
when comparing OCH-pulsed mDC-treated mice (122846±21470 µm2) with
mDC-treated mice (Figure 6.6C; 293181±36193 µm2; P<0.01). Representative
Oil-red-O and hematoxylin stained examples of plaques at the aortic root of
mDC-treated mice and mice treated with OCH-pulsed mDCs are shown in Figure
6.6A and 6.6B, respectively. Plaque size at the aortic root of PBS-treated mice
(228667±32747 µm2) was again not significantly different from the plaque size
in the mDC-treated mice (P=0.22, not shown). Both in plaques in the carotid
arteries and at the aortic root no significant changes in plaque morphology were
observed. Macrophages, smooth muscle cells and collagen were present to the
same extent (data not shown). Because mDC-treatment and PBS-treatment gave
similar results, only the mDC treatment was used as a control for further analysis.
Increase in NKT cells due to vaccination with OCH-pulsed mDCs
During the experiment blood was withdrawn to determine the effect of
vaccination with DCs on the number of NKT cells in blood. One day after
the third vaccination with OCH-pulsed mDCs, which is 9 days after the start
of the experiment, the percentage of CD3+NK1.1+ cells in the blood of mice
treated with OCH-pulsed mDCs was significantly increased when compared
with blood of mDC-treated mice (Figure 6.7A; 2.09±0.42% versus 0.94±0.24%,
respectively; P<0.05). At the end of the experiment (day 50), the percentage of
NKT cells in blood of mice treated with OCH-pulsed mDCs was still increased
when compared to the mice treated with mDCs, but no significant difference
was observed (1.18±0.14% versus 2.29±0.74%; P=0.20). To detect any changes
in numbers of NKT cells in other organs we performed a new experiment in
which we repeated the treatment with the mDCs and OCH-pulsed mDCs as
above but now sacrificed the mice three days after the last DC-injection. FACS
analysis showed that treatment with OCH-pulsed mDCs significantly increases
the number of NKT cells within the liver (16.98±3.08%) when compared with
the mDC-treated mice (Figure 6.7B; 8.60±0.89%; P<0.01). No differences in
NKT cell numbers were detected in other organs. The NKT cells in the liver of
mice treated with OCH-pulsed mDCs also show a Th2-like cytokine profile. The
percentage of IL-10 producing NKT cells increased two-fold from 0.91±0.08%
in mDC-treated mice to 1.94±0.22% in mice treated with OCH-pulsed mDCs
(Figure 6.7C; P<0.01). In addition, the percentage of IFN-γ producing NKT
cells in mice treated with OCH-pulsed mDCs (0.93±0.15%) was not significantly
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Figure 6.7: Effect of OCH-pulsed mDCs on the number and cytokine profile of NKT cells. During the
experiment, blood samples were obtained via tail vein bleeding and at several critical time points the number
of NKT cells was determined using FACS analysis. On the x-axis the days after the start of the experiment
are depicted. The grey line represents mDC treated mice (n=3), the black one represents mice treated with
OCH-pulsed mDCs (n=3) (A). In an independent experiment the mice were sacrificed three days after the last
injection with DCs and the number of CD3+NK1.1+ cells in the liver of the mDC (n=5) and OCH-pulsed
mDC treated mice (n=5) was determined (B). The cytokine profiles of these NKT cells were determined using
an intracellular FACS protocol. The production of IL-10 (C) and IFN-γ (D) was monitored. All values are
mean±SEM. ∗P<0.05, ∗∗P<0.01
different from the percentage of IFN-γ producing NKT cells in mDC treated mice











































Figure 6.8: Effect of OCH-pulsed mDCs on cholesterol levels. During the experiment with
immunomodulating DCs, serum samples were obtained via tail vein bleeding and the serum cholesterol levels
were measured at different time points (A). 0 weeks is at the beginning of the experiment, 3 weeks is just before
collar placement, 7 weeks is 4 weeks after collar placement and 10 weeks is at the end of the experiment (white
bars = mDC-treated mice (n=11), black bars = mice treated with OCH-pulsed mDCs (n=9)). Serum of all mice
was subsequently loaded onto a Sepharose 6 column and fractions were collected to obtain lipoprotein profiles.
Fractions 3 to 7 represent VLDL, fractions 8 to 14, LDL and fractions 15 to 19, HDL (B). White dots represent
the mDC-treated mice, black dots the mice treated with OCH-pulsed mDCs. Values are mean±SEM. ∗P<0.05
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Vaccination with OCH-pulsed mDCs reduces cholesterol levels
During the in vivo DC vaccination experiment, body weight, serum cholesterol
and serum triglyceride levels were measured at different time points. There
was no significant difference in weight due to the treatment with OCH-pulsed
mDCs (data not shown). Within the first 7 weeks of the DC-vaccination
experiment, also no differences in total serum cholesterol levels were observed.
However, between week 7 and 10 of Western-type diet feeding a significant
23.7% lower cholesterol level was detected in mice vaccinated with OCH-pulsed
mDCs (1132±136 mg/dl) when compared with mDC-treated mice (Figure 6.8A;
1483±67 mg/dl; P<0.05). To investigate whether this reduction in cholesterol
is a reduction in cholesterol levels within a particular class of lipoproteins, a
SMART analysis was performed. In serum of mice treated with OCH-pulsed
mDCs, VLDL-cholesterol (111±21 mg/dl) and LDL-cholesterol (67±9 mg/dl)
were significantly lower when compared with VLDL- and LDL-cholesterol levels
in mDC-treated mice (Figure 6.8B; 188±17 mg/dl and 104±9 mg/dl, respectively;
P<0.05). HDL-cholesterol was also lowered but not significantly (46±12 mg/dl
versus 25±2 mg/dl; P=0.14). No effects were observed on triglyceride levels in
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Figure 6.9: Influence of DC-treatment on MDA-LDL- and oxLDL-specific antibodies. LDLr-/- mice were
treated intravenously with mDCs (n=11) or OCH-pulsed mDCs (n=9) and at the end of the experiment serum
levels of MDA-LDL- and oxLDL-specific IgM antibodies (A) and IgG antibodies (B) were measured using a
capture ELISA. Values are mean OD 405nm±SEM.
Vaccination with OCH-pulsed mDCs has no effect on antibody production
To investigate a possible role of the humoral immune response in reducing plaque
formation, titers of antibodies specific for anti-modified LDL were determined.
Treatment with OCH-pulsed mDCs had no influence on both malondialdehyde
modified (MDA)-LDL and oxLDL-specific IgM and IgG titers in serum of the
mice (Figure 6.9A and 6.9B, respectively).
Discussion
The activation of antigen specific CD4+ T cells is one of the main events in the
inflammatory response of atherosclerosis. Within the atherosclerotic plaque,
CD4+ T cells are re-activated via the recognition of specific peptide-antigens
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presented by MHC class II molecules on APCs. Dendritic cells play a very
important role in this process of antigen processing within the plaque. Normally,
DCs are present in the intima of non-diseased arteries.36 These DCs become
activated in early stages of atherosclerosis10,37,38 while in more advanced stages,
the DCs are recruited from the adventitia39 and blood40 into the lesion. Within
the lesions, DCs are especially located in rupture prone shoulder regions11,39 and
are found to form cell clusters with T cells. Recently, co-localization of DCs with
another T cell subtype, the NKT cell, was observed within the atherosclerotic
plaque.11 The colocalization of DCs and NKT cells in the shoulder regions of
the plaque,37 and the observation of CD1d expression within the atherosclerotic
plaque10,41 suggests that the DCs present a lipidic antigen via CD1d to the NKT
cells resulting in their activation. These NKT cells, present in the atherosclerotic
plaque21,22 were found to have an athero-promoting effect.21–23
The role of NKT cells in atherosclerosis has been studied by using the synthetic
NKT cell ligand α-GalCer. Multiple intraperitoneal and/or intravenous
injections of α-GalCer in atherosclerosis-prone apoE deficient mice resulted
in a surprising aggravation of atherosclerosis due to the production of Th1
cytokines by NKT cells.21–23 Especially increased levels of IFN-γ were found
in these treated apoE-/- mice.21,22 Studies on the effect of α-GalCer on other
Th1-mediated diseases showed however that multiple injections with α-GalCer
induced a more Th2-based cytokine profile of NKT cells.14–20 Therefore it
was surprising that treatment with α-GalCer resulted in an aggravation of
atherosclerosis. Additionally, CD1d deficiency resulted in a reduction in
atherosclerosis. LDLr-/- CD1d-/- and apoE-/- CD1d-/- mice showed a significant
reduction in plaque size when compared with LDLr-/- mice22,42 and apoE-/-
mice,21,23 respectively. From this we suggest that NKT cells in athero-prone
mice are activated by certain endogenous ligands, which are still unknown and
exert an athero-promoting effect. Stimulation with α-GalCer seems to worsen
the situation. One explanation for this may be the increased production of IL-4,
which is probably an athero-promoting Th2 cytokine.43,44
In this study we used OCH, another synthetic NKT cell ligand. OCH has a
lower affinity for CD1d because of a shorter lipid chain and due to this lower
affinity, the TCR stimulation is shorter in time than with α-GalCer. Since IFN-γ
production requires a longer TCR stimulation than IL-4 and IL-10 a more
pronounced Th2 cytokine profile is induced after activation with OCH. Oki et
al. observed that the duration of NKT cell stimulation determines whether the
NF-κB family member transcription factor c-Rel is transcribed effectively. c-Rel
is identified as essential for IFN-γ production by NKT cells. They showed that
c-Rel is transcribed in α-GalCer-stimulated, but not in OCH-stimulated NKT
cells.45
In vivo administration of OCH in several mouse models is shown to abrogate
Th1-mediated immune responses and to be protective against experimental
autoimmune encephalomyelitis,12 arthritis,24 colitis19 and diabetes.25 In this
study, OCH was administered intraperitoneally to LDLr-/- mice and an increased
amount of IL-10 producing CD4+ cells was observed within the spleen. The
increase in IL-10 was accompanied by a decrease in IFN-γ producing CD4+
cells. This cytokine profile is in line with the studies on other Th1-mediated
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autoimmune disease mentioned earlier. There was however no effect on the
formation of atherosclerotic lesions induced by Western-type diet feeding and
collar placement around the carotid arteries of LDLr-/- mice. Nakai et al. showed
before that injections of OCH accelerated the early phase of atherosclerosis. In
that study, 8 weeks old apoE-/- mice, fed a regular chow diet were injected with
OCH once within two weeks, three times in total. In this study they showed
that the IFN-γ levels in serum of OCH-treated mice was lower than in serum
of α-GalCer-treated mice while IL-4 levels were the same. This is however in
contrast with other reports on OCH, because OCH is known for promoting
Th2 cytokine production by NKT cells, especially when administered twice a
week. Nakai et al, administered OCH once within two weeks and it is possible
that this interval between two injections was too long to induce a Th2 profile.
Additionally, data on IL-10 production are not presented.
An explanation for our results may be that the cytokine profile we observed was
very temporal. The mice were sacrificed within 48 hours after the last injection
with OCH and the induced IL-10 production together with the decreased
production of IFN-γ may have been not strong enough to abrogate the Th1
response against several autoantigens in atherosclerosis. A second explanation
could be an ineffective and inefficient presentation of OCH by dendritic cells to
the NKT cells in the liver after intraperitoneal injections.
We therefore looked for another way to administer OCH to LDLr-/- mice. In
several studies, the usefulness of DCs as vaccination units to impair autoimmune
diseases was shown. In our previous study, mDCs pulsed with oxLDL induced
a protective oxLDL specific antibody response and a reduction in atherosclerotic
plaque formation in LDLr-/- mice (Habets et al., unpublished data). In a study
by van Duivenvoorde et al. DCs were pulsed with collagen type II and this
resulted in a reduction in arthritis due to a decrease in the collagen specific ”Th1-
associated” IgG2a response.27 Additionally, Lo et al. showed that immature DCs
pulsed with a peptide of glutamic acid decarboxylase protect NOD mice against
type I diabetes.28
In our current study we show that mDCs injected intravenously, particularly
accumulate within the liver. Dendritic cells loaded with NKT cell ligands would
therefore deliver the ligand directly to the largest pool of NKT cells in the body,
i.e. the liver. In the liver, the DCs can present the ligand via CD1d and induce
the activation of the NKT cells. When LDLr-/- mice were fed a Western-type
diet, even more DCs accumulated within the liver, possibly due to the elevated
inflammatory status in this organ.
It was shown before that NKT cells can be expanded in vivo via the administration
of mature dendritic cells pulsed with α-GalCer.30 This study, performed in
humans, showed a more than 100-fold increase in circulating NKT cells in all
patients treated with the pulsed DCs. In two other studies a prolonged IFN-γ
producing NKT cell response is induced after treatment with α-GalCer loaded
mDCs.29,46
Because OCH induces a Th2-cytokine production by NKT cells and DCs loaded
with NKT cell ligands can induce a prolonged cytokine production by NKT
cells, we used this technique to study the effect of OCH-pulsed mDCs on
atherosclerosis. The maturation of DCs with LPS was not affected by the
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addition of OCH and the OCH-pulsed mDCs were injected in LDLr-/- mice. The
treatment with OCH-pulsed mDCs resulted in a 70.6% decrease in atherosclerotic
plaque size in the carotid arteries when compared with mDC-treated mice. The
same extent of reduction was also observed at the aortic root of these mice (58.1%
reduction). From our results we may suggest that the bad influence of NKT cells
on atherosclerosis can be turned into an athero-protective effect, when the NKT
cells are activated with OCH. The best way to deliver OCH is OCH loaded on
DCs, because the drug itself was ineffective.
To investigate this athero-protective effect of NKT cells due to the DC treatment
the effects on NKT cell numbers and cytokine profile were determined. Three
days after the last injection with DCs, an increased number of NKT cells was
observed in both blood and liver. In addition, more IL-10 producing NKT cells
were found in the livers of mice treated with OCH-pulsed mDCs when compared
with mDC-treated mice. The increased production of IL-10 and the unchanged
production of IFN-γ could explain the reduced plaque size in these mice.47 After
activation within the liver, the NKT cells may possibly migrate out of the liver
and become recruited to the atherosclerotic plaque. This migration to the plaque
may explain the increased levels of NKT cells in blood after treatment with
OCH-pulsed mDCs. Within the atherosclerotic plaque, the NKT cells may start
excreting anti-atherogenic cytokines locally. These cytokines, such as IL-10, may
influence the immune response in the vessel wall directly. It is shown before that
IL-10 protects against atherosclerosis.47–51 Another possibility is that the NKT
cells may induce a bystander effect.52,53 It is known that the bystander effects
induced by activation of NKT cells with α-GalCer and OCH are different. Upon
stimulation with α-GalCer, NKT cells affect the functions of other cells such as
T cells, B cells, NK cells and DCs in a direct or indirect manner. Little is known
about the effect of OCH-activated NKT cells on neighbouring cells but recently
Oki et al. demonstrated that OCH induces less production of IFN-γ and IL-12 by
bystander cells due to a lower expression of CD40L on NKT cells.54 A bystander
effect on neighbouring cells such as macrophages and T cells within the plaque
may contribute further to the abrogation of the Th1 inflammatory response of
atherosclerosis.
Another bystander effect of NKT cell activation in the liver may also explain
the observed reduction in cholesterol levels. During the experiment serum
cholesterol levels were evaluated at several critical time points. Although there
was no effect on the initial cholesterol levels, treatment with OCH-pulsed mDCS
induced a significant 24% reduction in cholesterol levels between week 7 and
10 of the experiment. The reduced cholesterol levels were due to a lowering
of VLDL- and LDL-cholesterol, while HDL-cholesterol was unaffected. This
reduction can be caused by an effect on the activity of parenchymal cells in the
liver. Von der Thüsen et al. showed before that systemic IL-10 administration
resulted in the lowering of VLDL and LDL cholesterol levels in LDLr-/- mice.
In this study, the increased IL-10 production by the NKT cells in the liver may
be responsible for the increased uptake of cholesterol from the blood and the
subsequent secretion of cholesterol in the bile.47
To examine whether there are also some bystander effects of the activation
of NKT cells via OCH-pulsed mDCs on the humoral immune response we
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determined the effect on oxLDL and MDA-LDL specific antibodies. There were
however no effects on both IgM and IgG antibody titers.
In conclusion, the activation of NKT cells via the administration of OCH-pulsed
mDCs reduces the atherosclerotic plaque formation in LDLr-/- mice. The
reduction in atherosclerosis can be explained by an increased number of IL-10
producing NKT cells in the liver. This IL-10 in the liver can induce a bystander
effect that may be responsible for the lowering of cholesterol levels in the treated
mice. Altogether, this strategy of immunomodulation with mDCs loaded with
OCH could be used as a new therapeutical approach to prevent atherosclerosis.
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Abstract
Natural killer T (NKT) cells, unique T cells with characteristics of NK cells, are activated
by lipid antigens presented by CD1d. Thus far a few CD1d-binding plant- and bacteria-
derived glycolipids are found to be natural ligands for NKT cells but their exact role is
unclear. Since atherosclerosis is a disease in which lipids play a predominant role and
since CD1d deficiency reduces atherosclerosis, one could imagine that one of those lipids
might be an endogenous ligand for NKT cells. LDLr-/- mice were fed a Western-type diet
for 0-24 weeks and during this period the frequency of NKT cells firstly increased in the
liver and subsequently in spleen and lymph nodes. LDLr-/- mice were crossbred with
Jα281-/- mice, deficient in NKT cells, and fed a Western-type diet for 12 weeks. Lesion
size at the aortic root was unaffected in Jα281-/-LDLr-/- mice when compared to LDLr-/-
mice. Interestingly, splenocytes from Jα281-/- mice, which do not respond to α-GalCer
stimulation, showed an impaired proliferation upon stimulation with oxLDL as compared
to LDLr-/- mice. To conclude, NKT cells do not play a role in later stages of atherosclerosis.
OxLDL, which is one of the most important (modified) lipids in atherosclerosis, or one
of its components, may be an endogenous ligand for NKT cells but does not utilize the




Natural killer T (NKT) cells represent a small population of T cells, which share
characteristics with NK cells. A majority of the NKT cells express NK1.1 and a
TCR composed of the Vα14-Jα18 α-chain paired with a Vβ8 or Vβ2 β-chain.1,2
This TCR is different from the normal TCRs because it recognizes glycolipid
antigens, which are presented to NKT cells by CD1d, an MHC class I related
molecule present on most antigen presenting cells (APCs). α-Galactosylceramide
(α-GalCer) was the first described glycolipid presented by CD1d to NKT cells and
able to induce their proliferation.3–8 Most studies on NKT cells use this ligand or
one of its analogues to activate NKT cells. α-GalCer stimulation of NKT cells
results in an enormous secretion of both Th1 and Th2 cytokines.5–9 Repetitive
administration of α-GalCer is shown to protect against several autoimmune
diseases,10–12 however several studies in apoE-/- mice showed that α-GalCer
activated NKT cells accelerate atherosclerotic plaque formation.13–15 Deficiency
in CD1d, which leads to a lack of CD1d dependent NKT cells, also resulted in an
amelioration of atherosclerosis in both apoE-/- and LDLr-/- mice.13–16 These data
suggested that NKT cells aggravate atherosclerosis and it also indicates that NKT
cells are activated by endogenous ligands during the onset of atherosclerosis.
In these studies, experiments were performed with CD1d-/- mice. These mice
lack CD1d-restriced NKT cells but are also deficient in other T cells that are
activated via the presentation of glycolipids or hydrophobic peptides presented
by CD1d.17–19 Another problem is that CD1d-independent NKT cells are still
present in these mice. To avoid this problem, Jα281-/- mice are used in this study.
These mice are deficient in both CD1d-restricted and CD1d-non-restricted NKT
cells, while other CD1d-dependent T cells are unaffected.
X-ray data revealed that the lipid portion of ligands for NKT cells fits in a
CD1d-binding groove whereas the carbohydrate part is exposed for recognition
by the TCR of NKT cells.20,21 Synthetic variants of α-GalCer showed that also
sulfatides bind to CD1d and effectively stimulate NKT cells.22 A few natural
ligands for NKT cells are known nowadays. Recently some microbial ligands
were found. Glycosphingolipids present in the outer membrane of Sphingomonas
strongly activate NKT cells and NKT cells are important for the clearance
of this infection.23–25 In addition, more recently a self-ligand for NKT cells
was found. The endogenous lysosomal glycosphingolipid isoglobotrihexosylce-
ramide (iGb3) may activate mouse Vα14 and human Vα24 NKT cells and seems
to be important for the intra-thymic development of NKT cells,26,27 while a role
for iGb3 in activation of peripheral NKT cells has also been described.23 Others
showed that plant-derived glycolipids may be natural CD1d-binding ligands for
NKT cells.28 The active plant- and bacteria-derived glycolipids are especially
phosphatidyl choline (PC) and phosphatidyl ethanloamin (PE) or glycolipids
that have lipid moieties which are almost identical to PC and PE.28,29 Whether
these ligands affect the Th1/Th2 cytokine secretion of NKT cells and whether
these ligands can be used as treatment for diseases needs further investigation.30
Atherosclerosis is a disorder in which enhanced plasma lipid levels play a central
role. Because the TCR of NKT cells recognizes lipid antigens presented on CD1d
it is plausible that one of the lipids in atherosclerosis may be an endogenous
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ligand for NKT cells. Among these lipids, phospholipids and triglycerides are
mainly bound to proteins for transport: the lipoproteins.
In this study we observed an increased frequency of NKT cells in several organs
after Western-type diet feeding of LDLr-/- mice. In addition we showed that
oxLDL may be an endogenous ligand for NKT cells since NKT cell deficient
splenocytes did not proliferate in response to oxLDL when compared to LDLr-/-
splenocytes. Deficiency in NKT cells at advanced stages of atherosclerosis did not
affect lesion size and therefore we conclude that NKT cells play a pro-atherogenic
role only in initial stages of atherosclerosis.
Materials and Methods
Animals
All animal work was approved by the regulatory authority of Leiden University
and carried out in compliance with the Dutch government guidelines. Male
LDLr-/- mice on a total C57BL/6 background were obtained from Jackson
Laboratory, Bar Harbor, Me. Jα281-/- mice on a C57BL/6 background were
obtained from Dr M. Taniguchi. Double deficient LDLr-/-Jα281-/- mice were
generated by crossing Jα281-/- mice with the LDLr-/- mice. The offspring was
intercrossed to produce mice with homozygous deletion in both LDLr and
Jα281 genes (LDLr-/-Jα281-/-). For experiments, 10-12 week old male LDLr-/-,
Jα281-/- and LDLr-/-Jα281-/- mice were used. All mice were kept under standard
laboratory conditions and bred in-house. The mice were fed a normal chow diet
or a Western-type diet containing 0.25% cholesterol and 15% cocoa butter (Special
Diet Services, Witham, Essex, UK). Water and food were administered ad libitum.
Media and reagents
The complete cell culture medium used for splenocytes was RPMI 1640 (with L-
Glutamine) (Cambrex, Belgium) supplemented with 10% fetal calf serum (FCS),
100 U/ml penicillin, and 100 µg/ml streptomycin (all from BioWhittaker Europe)
was used as culture medium. LDL was isolated from serum of a healthy
volunteer after centrifugation of the serum according to Redgrave et al.31 The
isolated LDL was dialyzed against phosphate buffered saline (PBS) with 10 µM
EDTA (pH 7.4) for 24 hours at 4◦C and oxidized by exposure to 10 µM CuSO4 at
37◦C for 20 hours as previously described.32
Effect of Western type diet feeding on NKT cells
To investigate the effect of Western-type diet on the number of NKT cells, LDLr-/-
mice were fed a Western-type diet for 0, 1.5, 4.5, 9 and 24 weeks. After diet
feeding, the mice were sacrificed and the liver, spleen, mediastinal lymph nodes
and iliac lymph nodes were dissected. Also blood was collected from these mice.
Mononuclear cells were isolated from spleen, liver and blood using Lympholyte
(Cedarlane, Ontario, Canada) conform the manufacturers protocol. The lymph
nodes were squeezed through a 70 µm cell strainer and a single cell suspension
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was used. Subsequently, the mononuclear cells were stained with PerCP-
conjugated CD3 and FITC-conjugated NK1.1 antibodies (eBioscience, Belgium)
for 30 min. To block a-specific binding of cytokines, samples were incubated
with normal mouse serum for 30 min. before staining. After staining, the
cells were washed two times and analyzed immediately by flow cytometry on a
FACSCalibur. All data were analyzed with CELLQuest software (BD Biosciences,
The Netherlands).
Splenocyte proliferation
To test the responsiveness of splenocytes to α-GalCer, spleens from LDLr-/-,
Jα281-/- and LDLr-/-Jα281-/- mice were dissected and single cell suspensions
were obtained by squeezing the spleen through a 70µm cell strainer (Falcon,
The Netherlands). The erythrocytes were eliminated by incubating the cells
with erythrocyte lysis buffer (0.15 M NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA,
pH 7.3). Subsequently, the splenocytes were cultured in triplicate at 2·105
cells per well of a 96-wells round-bottom plate in complete medium with or
without 100 ng/ml or 500 ng/ml of α-GalCer. The splenocytes were incubated
for 48 hours in a humidified atmosphere (37◦C; 5% CO2). Cultures were
pulsed for the final 16 hours with [6-3H]-thymidine (1 µCi/well, sp. act. 24
Ci/mmol; Amersham Biosciences, The Netherlands). The amount of [6-3H]-
thymidine incorporation was measured using a liquid scintillation analyzer
(Tri-Carb 2900R). The magnitude of the proliferative response is expressed as
stimulation index (SI) defined as the ratio of the mean counts per minute of
triplicate cultures with α-GalCer to the mean counts per minute in culture
medium without α-GalCer. To investigate the response of different splenocytes to
oxLDL, spleens were dissected from LDLr-/- and Jα281-/- mice. Splenocytes were
isolated as above and cultured with 0, 0.5 or 1 µg/ml of oxLDL for 24 hours.
FACS analysis
To verify the deficiency in NKT cells in the LDLr-/-Jα281-/- mice, livers were
isolated from both LDLr-/-Jα281-/- and LDLr-/- mice. Mononuclear cells were
isolated from the non-parenchymal cell population in the liver using Lympholyte
(Cedarlane, Ontario, Canada) conform the manufacturers protocol. Subse-
quently, the cells were stained with APC-conjugated CD3 and PE-conjugated
α-GalCer/CD1d tetramer (NIH tetramer core facility, GA) for 30 min. Cells
were washed two times and analyzed immediately by flow cytometry on a
FACSCalibur. All data were analyzed with CELLQuest software (BD Biosciences,
The Netherlands).
Induction of atherosclerosis
To determine the effect of a deficiency in NKT cells on atherosclerosis, athero-
sclerosis was induced in LDLr-/- and LDLr-/-Jα281-/- mice. The mice were fed
a Western-type diet for 12 weeks. The diet response is followed by measuring
the cholesterol levels in serum of these mice. Total cholesterol levels were quan-
tified spectrophotometrically using an enzymatic procedure (Roche Diagnostics,
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Germany). After 12 weeks, the mice were anaesthetized by a s.c. injection with
ketamine-hypnorm and exsanguinated by femoral artery transsection. The mice
were perfused and fixated through the left cardiac ventricle with PBS for 15 min.
and subsequently with FormalFixx for about 30 min. The hearts with the aortic
root were removed and were embedded in OCT compound (TissueTek; Sakura
Finetek, The Netherlands). 10µm cryosections of the aortic root were made on
a Leica CM 3050S Cryostat (Leica Instruments, UK). These cryosections were
stained with hematoxylin (Sigma Diagnostics, MO) and Oil-red O. Plaque areas
were measured using a Leica DM-RE microscope and LeicaQwin software (Leica
Imaging Systems, UK).
Statistical analysis
All data are expressed as mean±SEM. The two-tailed student’s t-test was used
to compare all data. P-values less than 0.05 are considered to be statistically
significant.
Results
Increased NKT cell frequency after Western-type feeding
LDLr-/- mice were fed a Western-type diet for 0, 1.5, 4.5, 9 or 24 weeks.
Subsequently, the mice were euthanized and the frequency of NKT cells was
determined in several organs. After 1.5 weeks of high fat diet, an increase in
CD3+NK1.1+ cells was observed in the liver (19.05±1.21% versus 42.37±2.21%;
P<0.05) and the spleen (3.24±0.14% versus 6.95±0.42%; P<0.01), compared to
mice sacrificed before high fat diet feeding was started. This increase persisted
in the spleen after 4.5 weeks of diet feeding (7.50±0.84%; P<0.05), whereas the
frequency of CD3+NK1.1+ cells decreased to basal level again in the liver. This
remained for an additional 20 weeks of high fat diet feeding (Figure 7.1, upper
part). After 9 weeks, an increase in CD3+NK1.1+ cells was also observed in
the mediastinal lymph nodes, located near the ascending aorta and the heart
(5.85±0.98% versus 8.97±0.60%; P<0.05). After 24 weeks of high fat diet feeding,
the frequency of CD3+NK1.1+ cells in all organs returned to basal level like
before the mice were fed a high fat diet. During these 24 weeks there was no
significant effect on the frequency of CD3+NK1.1+ cells in blood and iliac lymph
nodes (Figure 7.1, lower part).
NKT cell response to α-GalCer and oxLDL
To investigate whether oxLDL could be a ligand for NKT cells, splenocytes
were isolated from LDLr-/-, Jα281-/- and LDLr-/-Jα281-/- mice. As a control,
the responsiveness of splenocytes from these mice to α-GalCer was tested first.
Splenocytes from LDLr-/- mice showed a large response to 100 and 500 ng/ml of
α-GalCer; stimulation indexes of 22.2±1.4 and 15.2±2.9 (P<0.001), respectively.
Splenocytes from the NKT cell deficient Jα281-/- and LDLr-/-Jα281-/- mice were
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Figure 7.1: NKT cell frequency in different organs after high fat diet feeding. LDLr-/- mice were fed
a Western-type diet for 1.5, 4.5, 9 or 24 weeks. Subsequently, the mice were sacrificed and the number of
CD3+NK1.1+ cells in the spleen, liver, blood, iliac lymph nodes and mediastinal lymph nodes was measured
using FACS analysis. As a control, mice were sacrificed before high fat diet feeding was started (indicated as
0). Values are mean ± SEM. ∗P<0.05, ∗∗P<0.01
any significant proliferative response to α-GalCer (Figure 7.2). To investigate
whether oxLDL could be a ligand for NKT cells, splenocytes were isolated from
LDLr-/- mice and Jα281-/- mice and were incubated with different concentrations
of oxLDL. Low concentrations of oxLDL induced a 9.8 to 18.7-fold increase
(P<0.01) in proliferation of splenocytes from LDLr-/- mice when compared to
splenocytes incubated without oxLDL. The proliferative response of splenocytes
from Jα281-/- mice was much lower. Only a non-significant 0.8 to 2.8-fold increase
was observed and a large proliferative response was only observed at higher













































Figure 7.2: Spleen cell proliferation in response to α-GalCer. Splenocytes were isolated from LDLr-/-,
Jα281-/-, and LDLr-/-Jα281-/- mice. The splenocytes were incubated in vitro with or without 100 ng/ml or 500
ng/ml of α-GalCer for 48 hours. Proliferation was measured by incorporation of 3H-thymidine. Data are shown
as the stimulation index ± SEM. This stimulation index is the ratio of the mean cpm of cultures with α-GalCer
to the mean cpm of cultures without α-GalCer. ∗∗∗P<0.001.
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Figure 7.3: Spleen cell proliferation in response to oxLDL. Splenocytes were isolated from LDLr-/- and
Jα281-/- mice. These splenocytes were incubated in vitro with or without 0.5 and 1 µg/ml of oxLDL for 24
hours. Proliferation was measured by incorporation of 3H-thymidine. Data are shown again as the stimulation
index ± SEM. The stimulation index in this experiment is the ratio of the mean cpm of cultures with oxLDL to
the mean cpm of cultures without oxLDL. ∗∗P<0.01.
Effect of NKT cell depletion on atherosclerosis
To investigate the role of NKT cells in atherosclerosis, LDLr-/- mice were cross-
bred with Jα281-/- mice. These LDLr-/-Jα281-/- mice were tested for the presence
of NKT cells in the liver using the α-GalCer/CD1d tetramer and anti-CD3
antibodies. In the liver of LDLr-/- mice, 10.9±1.2% of the lymphocytes are
CD3+Tetramer+ (Figure 7.4D). These CD3+Tetramer+ cells were absent in the
LDLr-/-Jα281-/- (Figure 7.4E; 1.5±0.2%). To determine whether the deficiency
in NKT cells has an effect on atherosclerosis, LDLr-/- and LDLr-/-Jα281-/- mice
were fed a Western-type diet for 12 weeks. In figure 7.4A and 7.4B representative
examples of plaques at the aortic root of LDLr-/- and LDLr-/-Jα281-/- mice are
shown, respectively. An equal level of atherosclerosis was observed at the aortic
root of the LDLr-/- mice (623925±38750 µm2) and LDLr-/-Jα281-/- mice (Figure
7.4C; 662186 ± 49988 µm2; P=0.58) and the lesions were rather advanced in size.
In addition there was no effect on total plasma cholesterol levels and body weight
during the experiment (data not shown).
Discussion
The fact that NKT cells are a unique subset of T cells recognizing lipid antigens in-
stead of peptide antigens may provide them a unique position in atherosclerosis
research, since atherosclerosis is a disease in which both natural and modified
lipids play a pivotal role. Most studies on NKT cells are however performed
with synthetic ligands, because only a few natural ligands are known. Recently,
some bacterial, plant-derived and lysosomal glycosphingolipids which strongly
activate NKT cells were found, but their role in NKT cell activation in correlation
with diseases remains unclear.23–27,30 It is of great interest to investigate the
possibility whether one of the lipids important in atherosclerosis may form a
natural ligand for NKT cells. In the present study we observed an increased
frequency in NKT cells in the liver and spleen after 1.5 weeks of Western-type diet
feeding to LDLr-/- mice. This increased frequency is still seen in the spleen after
4.5 weeks, whereas in the liver this frequency returned to basal level again. This






























Figure 7.4: The effect of a deficiency in Jα281 on atherosclerosis. LDLr-/- mice were crossbred with
Jα281-/- mice to get LDLr-/-Jα281-/- mice. These LDLr-/-Jα281-/- mice and LDLr-/- mice were fed a Western-
type diet for 12 weeks. Subsequently, the mice were euthanized and sectioned aortic roots of LDLr-/- (A) and
LDLr-/-Jα281-/- (B) mice were stained with hematoxylin and Oil-red O. Lesions were quantified by computer-
assisted morphometric analysis and plaque size was determined (C). To verify that the LDLr-/-Jα281-/- mice lack
NKT cells, a FACS analysis was performed. Lymphocytes from the liver of LDLr-/- (D) and LDLr-/-Jα281-/- (E)
mice were stained for CD3 and the α-GalCer/CD1d tetramer. Values are mean ± SEM.
however no increase in the frequency of NKT cells in blood. Whether NKT cells
can migrate to the spleen via lymphatic vessels needs further investigation. The
migration theory is however further supported by the observation of an increased
NKT cell frequency in the mediastinal lymph nodes after 9 weeks of diet. After
24 weeks of diet the levels were the same as without diet feeding. It is however
possible that the number of athero-specific NKT cells, specific for one of the lipids
in the Western type diet, increased after this long period of diet feeding, but that
this was not detectable because of the large decline in total number of NKT cells.
The data on prolonged diet feeding (24 weeks) are in contrast with observations
by Nakai et al.15 They observed a significant decrease in both total NKT cells and
α-GalCer/CD1d tetramer+ cells in the hepatic mononuclear cell population after
20 weeks of atherogenic diet feeding to wild type mice. They suggested that this
decrease might be due to activation-induced cell death caused by for example
oxLDL, due to a continuous down-modulation of NK1.1 and the TCR or due to a
migration of NKT cells to other locations. Our data support this last suggestion.
In addition we can confirm that NKT cells may play a role in the initiation of
atherosclerosis since NKT cells seem to respond to diet feeding within the first
weeks.
Since high fat diet seems to induce NKT cell proliferation and probably stimulate
NKT cell migration, the next interesting question was whether oxLDL may be
able to activate NKT cells. It is known that oxLDL-reactive T cells exist in the
vessel wall and plaques of atherosclerosis patients.33,34 In a previous study we
observed that splenocytes from LDLr-/- mice respond to oxLDL in terms of an
increased proliferation.29 This indicates that a certain cell type responds to one
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of the components of oxLDL. We showed that these cells were CD3+ cells and
not macrophages or B cells. Since oxLDL contains both proteins and lipids,
epitopes of oxLDL could be both peptidic and lipidic. The macrophages and
dendritic cells that ingest and process oxLDL, express different types of antigen
presenting molecules such as MHC molecules and CD1d. These molecules can
respectively become loaded with peptidic and lipidic antigens. It was therefore
of interest to investigate if a part of the CD3+ T cells proliferating in response
to oxLDL could be NKT cells. Splenocytes isolated from Jα281-/- mice showed a
much lower proliferative response to oxLDL when compared to splenocytes from
LDLr-/- mice. This may indicate that NKT cells represent at least a fraction of the
proliferating splenocytes when cultured with oxLDL. The observed proliferation
of Jα281-/- splenocytes may be due to the proliferation of T cells responding to
peptidic epitopes of oxLDL. In a recent study, VanderLaan et al. showed that
LDL, isolated from the serum of LDLr-/- mice fed a Western-type diet, was able
to induce IL-2 production by a NKT cell hybridoma when loaded on C57BL/6
DCs. This effect was absent when CD1d-/- DCs were used.35 This confirms our
hypothesis that NKT cells may be activated by an endogenous ligand present
in the mice after Western-type diet feeding. However, they did not observe an
effect of cupper-oxidized LDL on NKT cell activation. They postulated that the
putative antigen in LDL was destroyed by extensive oxidation, but our results
show that this may vary with isolation and the grade of oxidation of LDL.
It is however clear that further investigation is needed to detect the specific
structure in oxLDL that is recognized by the specific TCR on NKT cells. A
few studies showed that phosphatidyl-choline (PC) may be a CD1d-binding
ligand for NKT cells.28,36 PCs are also present in oxLDL such as 1-(Palmitoyl)-
2-(5-oxovaleroyl)-phosphatidyl-choline (POV-PC) and oxidized 1-palmitoyl-2-
arachidonoyl-phosphatidyl-choline (oxPAPC). Both PCs trigger inflammation
and promote atherosclerosis.37–39 In future studies we will test these ligands for
their possible NKT activating capacities and the effect thereof on atherosclerosis.
Because NKT cells seem to play a role in atherosclerosis the effect of a deficiency
in NKT cells on lesion formation was investigated. LDLr-/- mice were crossbred
with Jα281-/- mice. These mice are deficient in both CD1d-dependent and
CD1d-independent NKT cells and are different from CD1d-/- mice. CD1d-/-
mice lack only CD1d-dependent NKT cells and in addition also T cells that are
activated via the presentation of glycolipids or hydrophobic peptides presented
by CD1d. Therefore, Jα281-/- mice are really different from CD1d-/- mice and
Jα281-/- mice are an interesting model to investigate the exact role of NKT cells
in atherosclerosis. We however observed that LDLr-/-Jα281-/- mice fed a Western
type diet for 12 weeks had similar lesion sizes as LDLr-/- mice. In an earlier
publication,16 it was shown that CD1d-/-LDLr-/- mice fed an atherogenic diet for
8 and 12 weeks also have similar lesion size as LDLr-/- mice. In that study it was
concluded that CD1d-dependent NKT cells only play a role in the initial stage
of lesion development because a deficiency in CD1d reduced lesion formation
in mice fed the diet for 4 weeks. In conclusion we describe in this study that
the initial effect of NKT cells on atherosclerosis may be due to an activation of
NKT cells by a ligand present in LDLr-/- mice after Western-type diet feeding.
One of the candidate ligands may be oxLDL, or at least one of its components.
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The exact role of activation of NKT cells by these lipids in atherosclerosis needs
further investigation but we assume that these ligands activate the NKT cells
which consequently accelerate atherosclerosis.
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During the last decades, more and more effort is put into the quest for a treatment
of atherosclerosis, which is the major underlying pathology of cardiovascular
diseases. Lipid lowering statins, anti-thrombotic drugs, and life style advice
contributed to the decline in the incidence of atherosclerosis, but despite all the
efforts, atherosclerosis remains the leading cause of death in the Western society.
Atherosclerosis is a chronic inflammatory disease of the vasculature and is
driven by a disturbed lipid metabolism and an autoimmune immune response
against several autoantigens. The main aim of this thesis was to modulate the
various autoimmune responses as a way to develop experimental treatments for
atherosclerosis. In chapter 2 and 3, the protective role of regulatory T cells was
studied. In chapter 4 and 6, dendritic cells were used in a vaccination protocol
and in chapter 5, 6 and 7, the role of NKT cells in atherosclerosis was evaluated.
The most important modulators of immune responses and thus of atherosclerosis
are cytokines. These cytokines can be roughly divided in two groups, the Th1
and the Th2 cytokines. The most important Th1 cytokines produced by Th1 cells
are IL-12, IFN-γ, and TNF-α and these cytokines are mainly pro-atherogenic.
On the other hand, most of the Th2-cytokines produced by Th2 cells (IL-5,
IL10 and IL-13) are anti-atherogenic. It was long accepted that a disturbed
balance between these Th1 and Th2 cells underlies the immune response in
atherosclerosis. T cell responses in atherosclerosis are directed against several
autoantigens. In figure 8.1 (processes I and II), the immune response to several
possible antigens is shown. HSPs, oxidatively modified apoB100 and modified
lipids such as oxLDL and MDA-LDL may elicit an immune response in which
several cell types are important, especially the T cells. The antigens are ingested
and processed by antigen presenting cells (DCs and macrophages) both within
the atherosclerotic lesion and in secondary lymphoid organs such as the spleen
and draining lymph nodes, which are lymph nodes near the atherosclerotic
lesion (Figure 8.1, process I). The uptake of oxLDL by APCs can result in foam
cell formation, both in macrophages and DCs. Normally, a DC, which has
ingested an antigen maturates and migrates from the inflamed tissue towards
the secondary lymphoid organs where they may induce a specific T cell or B
cell response (Figure 8.1, process II). Subsequently, these activated T cells may
migrate back to the inflamed tissue and to draining lymph nodes and elicit an
immune response against the specific antigen, presented by the APCs in the
lesion or lymph nodes (Figure 8.1, process II). In atherosclerosis, the DCs that
ingest (modified) lipids and become foam cells show impaired migration to the
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secondary lymph nodes.1–3 There is however still activation of T cells specific for
atherosclerotic antigens and this is due to the presence of the specific antigens
through the whole body and not only within the lesion. The T cell response in
atherosclerosis is mainly driven by Th1 cells, which produce IFN-γ, TNF-α and
IL-12 within the lesion (Figure 8.1, process III). These cytokines are responsible




























Figure 8.1: Potential sites for antigen-specific activation of T and B cells in atherosclerosis. Several
critical steps are indicated by numbers: I=antigen uptake by APCs II=T and B cell activation and proliferation
III=production of pro-atherogenic cytokines by Th1 cells within the atherosclerotic plaque.
Oral tolerance induction as treatment in atherosclerosis
Reducing the expression of Th1 cytokines or stimulating the production of Th2
cytokines are excessively used techniques to reduce atherosclerosis in mouse
models. IL-4, considered to be a Th2 cytokine, has however pro-atherogenic
properties.4–6 Recently, the view on the disturbed balance between Th1 and Th2
cells has changed. Mallat et al. postulated that in atherosclerosis a disturbed
balance exists between pathogenic Th1 and Th2 antigen-specific T cells and
regulatory T cells (Tregs).7 The Tregs mainly produce IL-10 and TGF-β, both
strong anti-atherogenic cytokines. Reducing the number of Tregs accelerates
atherosclerosis, whereas a stimulation and a transfer of Tregs ameliorates
atherosclerosis.7–9 Recently, Yang et al. showed that in vitro induced HSP60-
specific Tregs prevent atherosclerotic lesion development.10 The different types
of Tregs develop in the thymus from a common ancestor. In the thymus both
Foxp3+ and Foxp3- Tregs T cells exist. The Foxp3+ or natural Tregs migrate to
the periphery and can exert their immune-suppressing properties via cell-cell
contact and cytokine secretion (TGF-β and IL-10). The exact fate of natural Tregs,
whether they can be antigen-specific and whether they can be activated and
expand in the periphery is still not clear. In contrast with the natural Tregs, the
adaptive Tregs are known for their ability to become activated in the periphery
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such as in the Peyer’s patches. These adaptive Tregs, which are Foxp3− when
they leave the thymus, can be subdivided in Tr1 cells producing IL-10 and
Th3 cells producing TGF-β. Tr1 cells do not express Foxp3, but Th3 cells may
express Foxp3 upon activation11 (Figure 8.2, process I). Adoptive Tregs may be
induced via mucosal tolerance induction and may be antigen specific. In the
Peyer’s patches, located around the small intestines, tolerogenic DCs are present.
These DCs develop especially in an environment rich in IL-10. Induction of
Tregs specific for antigens in atherosclerosis was the aim of chapters 2 and 3.
Oral tolerance is a technique that can be used to induce a Treg-response against
harmful autoantigens. The fed antigens are transported into the Peyer’s patches
by M cells where they can be ingested by the tolerogenic DCs. This may result
in the activation and proliferation of adaptive Tregs (Figure 8.2, process II).
Whether natural Tregs are important in this process is not clear. In chapter 2, oral
administration of low doses of oxLDL resulted in an increase in oxLDL-specific
CD4+CD25+Foxp3+ Tregs in both the spleen and the mesenteric lymph nodes.
Tregs isolated from these lymph nodes produced more TGF-β upon in vitro
re-stimulation with oxLDL, when compared with Tregs from control-treated
mice. This indicates that the activated Tregs are most likely adaptive Th3 cells
expressing Foxp3. In addition they may be natural Tregs that expand in the
Peyer’s patches, but this needs further investigation. The induced Tregs showed
to be effective in reducing atherosclerotic plaque formation in an early and an
advanced stage (Figure 8.2, processes IV and V). However, tolerance induction
to MDA-LDL was not effective in inducing Tregs and consequently no effect
on lesion formation was observed. The exact reason for this observation is
not clear but oral tolerance induction to MDA-LDL did not induce an increase
in Tregs specific for this antigen. We suggest that after uptake, MDA-LDL is
not presented by the tolerogenic DCs in such a way that this leads to a proper
activation of Tregs.
In the study described in chapter 3, HSP60 and a small peptide of HSP60
(aa 253-268) were administered orally and this resulted in an increase in
CD4+CD25+Foxp3+ Tregs in blood, Peyer’s patches, mesenteric lymph nodes
and spleen. The presence in blood and the decrease in Peyer’s patches after two
weeks indicate a migration of Tregs from the gut to the secondary lymphoid
organs (Figure 8.2, process III). After re-stimulation with HSP60 in vitro, the
splenocytes from HSP60-treated mice produced increased levels of TGF-β and
IL-10 and they showed a lower HSP60-specific proliferative response when
compared with splenocytes from control-treated mice. The Tregs induced after
oral treatment with HSP60 ameliorated atherosclerosis in an early stage. The
observation of an increased level of IL-10 upon re-stimulation may indicate that
in addition to Th3 cells also Tr1 cells are induced, but these cells do not contribute
to the increase in Foxp3+ cells. In both studies on oral tolerance induction, an
increased expression of Foxp3, CD25 and CTLA-4 in the atherosclerotic lesion
indicated that the Tregs induced in the Peyer’s patches may migrate to the site
of inflammation i.e. the atherosclerotic lesion (Figure 8.2, process III). These
data are in line with a recently published study in which oral tolerance was
induced with an antigen conjugated to cholera toxin B subunit. They found
several different types of Tregs that are important in oral tolerance induction i.e.
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the natural Tregs but also Foxp3+ and Foxp3−CD25−CD4+ Tregs.12 The data
obtained in chapter 2 and 3 show for the first time that the protective effect of
oral tolerance induction in atherosclerosis may be caused by an activation of
specific Tregs. These data support the hypothesis of Mallat et al.7 that Tregs can
counteract the pathogenic Th1 and Th2 cells specific for the same and different
antigens. Within the lesion the Tregs may suppress the Th1 and Th2 response
directed against the same or different antigens. This suppression may be indirect
via the production of TGF-β and IL-10 (adaptive Tregs), which may result in an
inhibition of the immune response against several antigens (Figure 8.2, process
IV) or the suppression may be direct via cell-cell contact (natural Tregs) (Figure
8.2, process V). Normal CD4+ T cells (Th1 or Th2) may upregulate the expression
of the TGF-β receptor II (TβRII) after recognition of the antigen presented by
APCs. Tregs specific for the same antigen also recognize the presented antigen on
the APCs and start expressing surface-bound TGF-β. The subsequent interaction
between TGF-β on natural Tregs and the TβRII on pathogenic T cells may result
in a reduced proliferation of the pathogenic T cells (Figure 8.2, enlarged box,
process V). In the future, selective elimination or inducible knockouts of Foxp3
will clarify the exact role of Tregs in atherosclerosis and tolerance induction.
Furthermore, oral tolerance is a rather easy way of treatment for atherosclerosis



























































Figure 8.2: The effect of oral tolerance induction on atherosclerosis; an important role for regulatory
T cells. Several critical steps are indicated by numbers: I=development of Tregs in the thymus II=activation
and proliferation of adaptive Tregs III=migration of Tregs to secondary lymphoid organs and the atherosclerotic
plaque IV=production of atherosclerosis-protective cytokines and the inhibition of the Th1 response within the
plaque V=inhibitory effect of natural Tregs via cell-cell contact.
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Dendritic cells as vaccination units in atherosclerosis
Antigen presenting cells (APCs) play a central role in immune responses and
are necessary for the activation of adaptive Tregs in the gut whereas in the
atherosclerotic plaque and lymphoid organs they present antigens to activate
effector T cells. Dendritic cells (DCs) are the most powerful APCs. In healthy
vessels only small numbers of DCs are present in the intima, immediately beneath
the endothelial layer and in the adventitia.13,14 At atherosclerosis-prone sites
these DCs can start clustering in a very early stage and can elicit the immune
response against autoantigens such as oxLDL and HSPs. In advanced stages,
more DCs enter the lesion and clusters of DCs with T cells and NKT cells are
formed in the rupture-prone shoulder regions.1,15,16 Because of their capacity
to activate T cells and NKT cells, DCs are widely used as immuno-modulating
units in vaccination studies. In chapter 4 and 6, DCs were used to modulate
two different immune responses in atherosclerosis. The DCs were isolated from
the bone-marrow of C57BL/6 mice and maturated by the addition of LPS. In
chapter 4 the DCs were loaded ex vivo with oxLDL. This oxLDL is taken up by
the DCs, shown by an Oil-red-O positive staining. OxLDL will be processed
and small peptidic epitopes of oxLDL may be presented on the surface of the
DCs loaded on MHC class I and II molecules. To modulate the in vivo immune
response to oxLDL these pulsed DCs were injected in LDLr-/- mice (Figure
8.3, process I). After 72 hours, the injected DCs can be found especially in
the lungs and the liver but also in the spleen and lymph nodes. Injections
with the oxLDL-pulsed DCs resulted in an attenuation of atherosclerotic plaque
formation. In addition, a decreased number of macrophages and an increase
in collagen fibers was observed, contributing to a more stable lesion. OxLDL
pulsed DCs also induced a significant decrease in cholesterol after 10 weeks
of Western-type diet feeding. This lowering in cholesterol was accompanied
by an increase in oxLDL-specific IgG antibodies which indicates that there
was an activation of oxLDL specific T cells (Figure 8.3, process II). We now
hypothesize that the injected DCs that homed to the spleen induced an oxLDL-
specific T cell response which subsequently resulted in an activation of B
cells producing oxLDL-specific IgG antibodies (Figure 8.3, process III). These
antibodies may form immune-complexes with oxLDL in the circulation and
this may be responsible for the reduced foam cell formation observed when
macrophages were incubated with oxLDL together with serum of the DC-
treated mice. A possible explanation is that the IgG antibodies form immune-
complexes with oxLDL which may reduce the uptake of oxLDL via scavenger
receptors on macrophages within the atherosclerotic lesion (Figure 8.3, process
IV). Secondly, immune-complex formation may result in a better opsonization of
oxLDL, resulting in a fast Fc-dependent removal of oxLDL from the circulation,
or in neutralization of the effects of oxLDL systemically and locally which may
prevent oxLDL from exerting pro-inflammatory and toxic effects in the vascular
wall (Figure 8.3, process IV). The immuno-protective role of IgG antibodies was
already shown in several studies in which mice were immunized with several
forms of modified lipids and peptides.17–20 The protective function is especially
important because the DCs were injected before the mice were fed a Western-
135
Chapter 8
type diet, and thus before oxLDL was generated. The injected oxLDL-pulsed
DCs may restore the impaired migration of oxLDL-loaded DCs from the plaque
to the secondary lymphoid organs, even before oxLDL was taken up by DCs
within the lesion. Therefore T cells and IgG antibodies are generated that quickly
respond when oxLDL is generated after high fat diet feeding. This process is
like normal vaccination. Several studies already described that immunization
with oxLDL, MDA-LDL or modified apoB100 peptides results in a reduction in
atherosclerosis.20–22 Major difference between this ”vaccination” technique and
ours is that in DC-vaccinations no adjuvant is needed. The clinical application is
therefore wider than with other immunization studies. The only drawback could
be that DCs from the patient itself are needed for vaccination, although these DCs


























Figure 8.3: Dendritic cells pulsed with oxLDL are used to modulate the immune response in
atherosclerosis.Several critical steps are indicated by numbers: I=Intravenous injection of oxLDL-pulsed
DCs II=activation of oxLDL-specific T cells III=production of oxLDL-specific IgG antibodies by B cells
IV=protective effect of oxLDL-specific IgG on the immune response in the atherosclerotic plaque.
NKT cell activation in atherosclerosis
In addition to MHC molecules, DCs also express CD1, another class of antigen
presenting molecules. In mice only CD1d is expressed and this molecule
binds glycolipid antigens instead of peptide antigens like MHC molecules do.
Antigens presented by CD1d are recognized by a specialized subset of T cells,
the NKT cells, which express a T cell receptor (TCR) composed of Vα14 and
Jα18 (previously known as Jα281) subunits paired with a restricted set of Vβ
chains. CD1d expressing DCs were found in the atherosclerotic lesions together
with NKT cells.24–27 NKT cells are known for their unique capacity to produce a
diverse spectrum of cytokines, both Th1 and Th2.28 Since many studies on other
Th1 mediated diseases showed that repetitive injections with α-GalCer, which is
a strong synthetic activator of NKT cells, was protective, it was expected that
α-GalCer activation of NKT cells would also be protective in atherosclerosis.
Accumulating data however proves that NKT cells accelerate atherosclerosis.
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Depletion of CD1d by crossbreeding CD1d-/- mice with LDLr-/- and apoE-/-
mice decreased lesion formation while activation of NKT cells by injecting α-
GalCer in apoE-/- mice resulted in an acceleration of lesion formation.24–26,29
NKT cells were found in atherosclerotic lesions, especially co-localized with DCs,
and the general idea is that the NKT cells within the lesion are activated by an
endogenous ligand. The endogenous ligand for NKT cells in atherosclerosis is
however not known but since NKT cells are activated by lipidic antigens it is
assumed that one of the lipids excessively present in atherosclerotic lesions and
the liver may be able to activate NKT cells. It is suggested that this activation
may result in Th1-biased NKT cells which may promote lesion formation (Figure
8.4, process I). In chapters 5 and 6 we describe for the first time that NKT cells
may however protect against atherosclerosis. In chapter 5, atherosclerosis was
induced in LDLr-/- and apoE-/- mice by a combination of collar placement around
the carotid arteries and feeding a Western-type diet. Subsequently, the mice
were treated with α-GalCer twice a week for 7 weeks by i.v. and i.p. injections
(Figure 8.4, process II). This resulted in a reduced lesion formation in LDLr-/- mice
whereas there was no effect in apoE-/- mice. The difference between both mouse
models is further elucidated by the observation of a lower proliferative response
and a lower cytokine production in response to α-GalCer by apoE-/- splenocytes
than LDLr-/- splenocytes. Additionally, the in vivo cytokine response in apoE-/-
mice treated with α-GalCer was dampened when compared with LDLr-/- mice
which showed an increased production of IL-10 and IL-4 in secondary lymphoid
organs when compared with β-GalCer-treated mice. The difference in responses
to α-GalCer in the two mouse models may be explained by two statements.
First of all, apoE is an important mediator of lipid antigen presentation on CD1
molecules. ApoE-/- mice lack this important protein and consequently have
an impaired ability to present lipid antigens to NKT cells (Figure 8.4, process
III). This however does not explain why an increased plaque size was observed
in other studies on α-GalCer treatment in apoE-/- mice. Another difference
between our study and the other studies could however form an explanation
for this. The most important difference between the studies is that our mice were
fed a Western-type diet in stead of a normal chow diet. We now hypothesize
that this high fat diet may influence the NKT cells before they were treated
with α-GalCer. This is confirmed by the observation that a Western-type diet
results in an increased NKT cell number in liver after 1.5 weeks followed by
an increase in the spleen after 4.5 weeks (Figure 8.4, process IV). Due to this
pre-activation of NKT cells, which may result in NKT cells that accelerate the
disease (Figure 8.4, process I), α-GalCer may switch these pre-activated Th1
cytokine producing NKT cells into Th2 cytokine producing NKT cells (Figure 8.4,
process V). These ”double”-activated NKT cells may migrate to the lesion and
secondary lymphoid organs and dampen the Th1-response via re-stimulation by
endogenous ligands or α-GalCer (Figure 8.4, process VI). This may be explained
by the fact that repetitive activation of NKT cells results in a more Th2-phenotype.
We suggest that the repetitive injection of α-GalCer after continuous Western-
type diet feeding induced a switch in cytokine-profile. In apoE-/- mice, a delayed
response to the Western-type diet was observed. After two weeks of diet feeding
and at the beginning of α-GalCer administration the hepatic and splenic NKT
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cells are not endogenously triggered by the diet. NKT cells in this mouse model
are activated by the injected α-GalCer but this was not protective. However, we
did not observe an increase in lesion size in apoE-/- mice like it was observed in
previous studies and therefore, it is concluded that the endogenous activation of
NKT cells, which is delayed in apoE-/- mice, still affects the previously described
negative effect of α-GalCer activation of NKT cells in a beneficial way, but not
sufficiently enough to reduce atherosclerosis. From this study we can conclude
that the vision on NKT cells accelerating atherosclerosis should be reconsidered.


















































Figure 8.4: NKT cell activation via α-GalCer and its effect on atherosclerosis; an important role for
high fat diet and apoE. Several critical steps are indicated by numbers: I=suggested atherosclerosis-promoting
effect of NKT cell activation by lipids II=intraperitoneal and intravenous injection of α-GalCer III=lack of apoE
results in an impaired ability to present lipids via CD1d to NKT cells IV=activation and proliferation of NKT
cells due to a high fat diet V=proposed effect of α-GalCer; a switch from NKT cells producing Th1-cytokines
to NKT cells producing Th2-cytokines VI=proposed effect of ”double activated” NKT cells on the immune
response in the atherosclerotic plaque.
Dendritic cells used to activate NKT cells
Ex vivo pulsed DCs can also be used as activators for NKT cells. Loading of
α-GalCer on DCs and a subsequent injection of these DCs in mice and patients
resulted in a prolonged activation of NKT cells producing a large amount
of IFN-γ.30,31 In chapter 6 we used an analogue of α-GalCer, OCH, which
triggers the NKT cells to a more Th2-phenotype.32,33 OCH was administered
intraperitoneally to LDLr-/- mice but this had no effect on atherosclerotic lesion
formation. However, intravenous injection of DCs pulsed ex vivo with OCH
(Figure 8.5, process I) reduced the lesion size dramatically. This reduction may be
due to the migration of a high number of OCH-loaded DCs to the liver. There the
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DCs may present OCH to the largest NKT cell pool of the body. This induced a
proliferation and activation of hepatic NKT cells (Figure 8.5, process II) and these
NKT cells produced more IL-10 while the same amount of IFN-γ was produced
when compared with NKT cells from control-treated mice (Figure 8.5, process
III). This whole process may also occur within the spleen, but this needs further
investigation. After activation, the NKT cells may migrate out of the liver (and
spleen) to other locations. This may explain the increased NKT cell number
in the blood of mice treated with OCH-pulsed DCs. Since NKT cells are also
found in atherosclerotic lesions we hypothesize that NKT cells induced in the
liver migrate towards the site of inflammation. There they may be re-stimulated
by OCH on injected DCs or by DCs already present in the lesion which present
endogenous ligands (Figure 8.5, process IV). Upon re-stimulation the NKT cells
secrete Th2 cytokines, especially IL-10, and inhibit the Th1 immune response
within the lesion directly or via a bystander activation (Figure 8.4, process V). In
addition, lower cholesterol levels were observed in the mice treated with OCH-
pulsed DCs. This difference was only present in later stages of atherosclerosis
and therefore can not explain the difference in plaque size, but it may contribute
to the reduction. It is known that IL-10 influences the cholesterol levels in LDLr-/-
mice.34 We now suggest that the increased production of IL-10 by NKT cells in
the liver stimulates the uptake of cholesterol from the blood by parenchymal cells
and the subsequent secretion of cholesterol in the bile.
Endogenous ligands for NKT cells
In chapter 5 we observed that high fat diet feeding may influence the NKT cell
population in LDLr-/- mice. A natural endogenous ligand for NKT cells is how-
ever still not known. Recent publications suggest that some plant- and bacteria-
derived glycolipids may be able to activate the NKT cells.35,36 These glycolipids
contain phosphatidyl choline (PC) and phosphatidyl ethanolamin (PE) of which
the first one is also present in some lipids important in atherosclerosis; POV-
PC and oxPAPC. In chapter 7, LDLr-/- mice were fed a Western-type diet and
again an increase in NKT cell frequency was observed in the liver followed by
the spleen and the iliac lymph nodes (Figure 8.3, process IV). These data confirm
the fact that NKT cells play an important role in the initiation of atherosclerosis29
since the increase in NKT cells is within 4.5 weeks of diet feeding. During
progressive stages no differences in the number of NKT cells was observed. This
is also shown by a deficiency in NKT cells, which has no effect on atherosclerosis
after 12 weeks of Western-type diet feeding. OxLDL is one of the major lipids in
atherosclerosis and a deficiency in NKT cells reduced the proliferative response
of splenocytes to oxLDL. This indicates that oxLDL or at least one of its lipid
components may be an endogenous ligand for NKT cells. We now suggest that
PC units in oxLDL may be responsible for this; especially oxPAPC and POVPC
are interesting candidates. These data are encouraging to continue the search for
endogenous ligands in atherosclerosis. A plethora of lipids will be tested in the
future which may possibly lead to a specific endogenous ligand for NKT cells.
This may consequently lead to a better insight in the role of NKT cells and to new
targets for therapeutic intervention in atherosclerosis. Overall, from the data in
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chapters 5-7 it is suggested that NKT cells are activated by an endogenous ligand
which may be one of the (PC-containing) lipids important in atherosclerosis. This
activation may result in Th1-biased NKT cells accelerating atherosclerotic lesion
development. The activation of the NKT cells may start in the liver, where also
dendritic cells which ingest and process lipid antigens are present. The activation
of NKT cells may subsequently spread through the whole body including the
atherosclerotic lesion. Within the lesion they may be re-stimulated, resulting in
the production of Th1 cytokines, especially IFN-γ, and this may contribute to
the ongoing inflammation. However, re-stimulating the pre-activated NKT cells
with α-GalCer switched the cytokine profile of NKT cells to a Th2-like profile,
and they produce especially IL-10. These Th2 cytokines may dampen the Th1-
mediated immune-response in atherosclerosis. This effect is only observed in
LDLr-/- mice and is absent in apoE-/- mice because apoE is an important mediator
of lipid antigen presentation on CD1 molecules. Activation of NKT cells by OCH,
loaded on DCs, also reduced atherosclerotic lesion formation. This study was also
performed in LDLr-/- mice that were fed a Western-type diet, further suggesting
that a combination of a Western-type diet and a synthetic ligand are important to

































Figure 8.5: The effect of OCH-pulsed DCs on atherosclerosis; altered cytokine profile of NKT cells.
Several critical steps are indicated by numbers: I=intravenous injection of OCH-pulsed DCs II=activation and
proliferation of NKT cells via presentation of OCH by the injected DCs III=increased IL-10 production by NKT
cells IV=restimulation of activated NKT cells within the atherosclerotic plaque by OCH or lipids presented by
APCs V=proposed inhibition of the Th1-mediated immune response by IL-10 produced by the restimulated
NKT cells within the atherosclerotic plaque.
Perspectives
In this thesis, several strategies to modulate the immune system during
atherosclerosis have been studied in experimental therapies. These strategies
provide different forms of immunotherapy and the goal of these strategies is
to achieve a very efficient treatment for atherosclerosis that may be applied in
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addition to the use of statins, aspirin and blood pressure lowering medication.
The necessity for such as therapy is high because the current therapies in
atherosclerosis are still insufficient. Statins are prescribed to patients to lower
the cholesterol levels and aspirin is prescribed because of the anti-coagulative
effects. Both medications resulted in a decline in the incidence of cardiovascular
disease (CVD) during the last decade, but the fact that CVD is still the leading
cause of death in the Western world implies that new therapies that regulate
the immune response in atherosclerosis may be able to substantially reduce the
incidence of CVD. This forms the reason why a substantial effort is put into the
development of immunotherapies for atherosclerosis.
One of the strategies described in this thesis is vaccination using oxLDL-
loaded DCs. This technique has some benefits when compared with existing
vaccination/immunization protocols against oxLDL. DC-vaccination as used in
chapter 4 was very efficient, reducing atherosclerosis with more than 85%, and
no adjuvant is needed to activate the immune system, which will reduce the
time needed to optimize the vaccination protocol. When immunizing mice with
modified LDL, an adjuvant is needed and the reduction in atherosclerosis was
less prominent than in the DC vaccination study. An adjuvant gives an extra
boost of the immune system and more specific strategies without an adjuvant are
supposed to lead to less side effects. Therefore, the use of DCs as a vaccination
unit is considered to be promising. At the moment, DC vaccination therapies are
tested in clinical trials to treat several types of tumors. A complication of this
technique is however that the DC production is labor-intensive and expensive,
requiring specialized and costly manufacturing facilities.
A second strategy used in this thesis is the induction of oral tolerance and
activation of Tregs. Tregs are increasingly used as therapeutic intervention
method. In several diseases the number or function of Tregs is decreased and
restoring the normal numbers may be protective. Adoptive transfer of Tregs
could be successful but no clinical trials in humans have been reported yet. A
major problem in this strategy is to obtain large numbers of these cells as per
patient a high number of cells will be needed. Another method to induce Tregs
is oral tolerance induction. Oral tolerance has been used in mouse models to
treat several autoimmune diseases and it is currently tested in several clinical
trials to treat type 1 diabetes mellitus, allergy, arthritis, multiple sclerosis etc.
In chapter 2 and 3 oral tolerance was induced to two important auto-antigens
in atherosclerosis; HSP60 and oxLDL. The results of the clinical trials on other
autoimmune disorders are very diverse. Some are successful, while others have
no effect. Most of the clinical trials to treat several autoimmune disorders that are
performed nowadays have however one common problem, which is the fact that
the administered antigens are non-self molecules. Examples are clinical trials
with myelin in patients with multiple sclerosis and collagen in patients with
arthritis. In this thesis, oxLDL is used, which can be generated via oxidation of
the patient’s own LDL. This will be an advantage in clinical trials, because less




The third strategy used as an immunotherapy in this thesis was the activation
of NKT cells. α-GalCer and OCH are both strong activators of NKT cells with
protective effects in mouse models for several autoimmune diseases. Because
α-GalCer had anti-tumor effects in mice, α-GalCer as used in chapter 6 is tested
in clinical trials to treat several types of cancer. In chapter 5 DC-vaccination was
combined with NKT cell activation via loading of OCH on the DCs. NKT cell
activation via α-GalCer loaded DCs is also tested in clinical trials to treat lung
cancer and it is shown that this activates NKT cells very efficiently. The only
problem however is that the natural activator of NKT cells in atherosclerosis is
not known. The discovery of this ligand will be a breakthrough in atherosclerosis
research and will result in more opportunities for therapies in atherosclerosis.
In chapter 7 it is observed that oxLDL may be one of these ligands but it needs
further investigation to what extent this oxLDL is responsible for activation of
NKT cells in atherosclerosis.
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Hart- en vaatziekten zijn ondanks het vele onderzoek en de verschillende choles-
terol en bloeddruk verlagende middelen nog steeds doodsoorzaak nummer 1 in
Nederland. 33% van alle sterfgevallen in 2006 waren direct of indirect gerelateerd
aan een hart- of een vaat-aandoening met als belangrijkste gevolg een beroerte of
een acuut hartinfarct. Hart- en vaatziekten worden voornamelijk veroorzaakt
door aderverkalking (atherosclerose). Zoals bij de meeste mensen wel bekend
is, dragen veel factoren bij aan het ontstaan van hart- en vaatziekten, zoals hoge
cholesterol waarden in het bloed, een verhoogde bloeddruk, roken, te weinig
lichaamsbeweging en suikerziekte (diabetes). De aderverkalking uit zich als een
verdikking van de bloedvatwand en wordt verkalking genoemd omdat in een
later stadium veel calcium in de verdikking zit die leidt tot de vernauwing van
een slagader. Dit proces begint al op vroege leeftijd en vlak na de puberteit zijn
de eerste verdikkingen waar te nemen in verschillende slagaderen. Verwarrend
is daarom de naam aderverkalking, want atherosclerose vind alleen plaats in
de slagaderen. Wat veel mensen echter niet weten is dat atherosclerose in feite
een autoimmuun component bevat waarbij slechte voeding, roken en weinig
lichaamsbeweging ook via het immuun system de progressie van atherosclerose
kunnen beinvloeden.
Ontstaan van atherosclerose; een grote rol voor het immuun systeem
Het begin van atherosclerose is een ophoping van vet en met name cholesterol in
daarvoor gevoelige plaatsen in de vaatwand van de slagaderen. Deze plaatsen
hebben vaak een turbulente bloedstroom waardoor het endotheel dat zorgt voor
de bescherming van de vaatwand doorlaatbaar wordt voor vetten en bloedcellen.
Het endotheel kan gevoeliger zijn voor de turbulente bloedstroom door bijvoor-
beeld roken, maar ook door de hoeveelheid vet in het bloed. Het beschadigde
endotheel zorgt vervolgens voor het aantrekken van allerlei ontstekingscellen,
de witte bloedcellen. Monocyten en T cellen, twee soorten witte bloedcellen,
migreren in eerste instantie via het endotheel de vaatwand in. Monocyten
differentieren in de vaatwand tot macrofagen en kunnen het opgehoopte vet
in de vaatwand opnemen. Dit leidt tot de vorming van een zogenaamde
’foamcell’ of schuim cel. De T cellen die worden aangetrokken in de vaatwand
kunnen daar opnieuw geactiveerd worden doordat ze specifieke moleculen,
antigenen, herkennen in de verdikking die nu een plaque genoemd wordt. Deze
antigenen worden gepresenteerd door antigeen presenterende cellen zoals de
macrofagen en dendritische cellen (DCs). Omdat er bij atherosclerose sprake is
van een autoimmuun reactie betekent dit dat een immunologische reactie wordt
opgewekt tegen lichaamseigen antigenen. De antigenen kunnen bijvoorbeeld
immunogeen worden doordat ze een structurele verandering ondergaan. Dit is
het geval bij lage-dichtheid lipoproteinen (LDL). In de vaatwand kan dit niet-
145
immunogene LDL geoxideerd worden tot oxLDL. Deze gemodificeerde variant
kan opgenomen worden door macrofagen en DCs en via MHC moleculen
gepresenteerd worden aan T cellen. Naast de modificatie van lichaamseigen
stoffen die zo immunogeen worden, zijn er ook moleculen die immunogeen
worden doordat ze grote structurele overeenkomsten hebben met moleculen
die op bacteriën tot expressie komen. De ”heat shock proteı̈nen” zijn hier het
bekendste voorbeeld van en ook zij vormen een belangrijke groep van auto-
antigenen in atherosclerose.
De T cellen die dit antigeen herkennen raken geactiveerd en produceren cy-
tokines. Deze cytokines zijn kleine moleculen die een grote invloed kunnen
hebben op het verdere verloop van een ontsteking. Over het algemeen zijn de T
cellen in atherosclerose Th1 cellen en produceren ze atherosclerose-bevorderende
cytokines (Th1 cytokines). Tegenover Th1 cytokines staan de Th2 cytokines die
geproduceerd worden door onder andere Th2 cellen. Deze cytokines hebben
over het algemeen een positieve uitwerking op atherosclerose. Lang is er
verondersteld dat een verstoring in de balans van deze Th1 en Th2 cellen aan
de basis lag van de immunologische reactie in atherosclerose.
Regulatoire T cellen
Uit recent onderzoek is gebleken dat niet alleen de verstoorde balans tussen deze
Th1 en Th2 cellen een belangrijke veroorzaker is van de schadelijke immuno-
logische reactie in atherosclerose. Een verstoorde balans tussen pathogene T
cellen (Th1 en Th2) aan de ene kant en regulatoire T cellen (Tregs) aan de andere
kant vormt een nieuwe hypothese. Tregs zijn T cellen die gekenmerkt worden
door de productie van atherosclerose-remmende cytokines als IL-10 en TGF-β.
Natuurlijke Tregs zijn te herkennen aan de specifieke expressie van Foxp3 dat
een rol speelt in de ontwikkeling van de Tregs. Naast de natuurlijke Tregs,
zijn er ook adaptieve Tregs die na activatie Foxp3 tot expressie brengen (Th3
cellen). Deze Th3 cellen produceren voornamelijk TGF-β. In de hoofdstukken
2 en 3 is gebruik gemaakt van een methode waarbij specifieke regulatoire T
cellen kunnen worden geı̈nduceerd. Deze methode, orale tolerantie inductie,
is een eenvoudige methode waarbij een antigeen, waartegen een regulatoire
T cel response opgewekt dient te worden, toegediend wordt via de mond.
Deze route zorgt ervoor dat het antigeen in de darmen komt. Daar wordt het
door gespecialiseerde cellen opgenomen en uiteindelijk wordt het antigeen door
tolerogene dendritische cellen gepresenteerd. Afhankelijk van de toegediende
dosis kan het lokale cytokine milieu in de darmen zorgen voor een activatie van
Tregs. In hoofdstuk 2 werd aangetoond dat de orale toediening van oxLDL
leidde tot een 71% reductie in initiële atherosclerotische plaque vorming. In
een tweede experiment is aangetoond dat orale tolerantie inductie tegen oxLDL
ook een remmend effect heeft op al aanwezige atherosclerose. De tolerantie
inductie tegen oxLDL leidde ook tot een toename in CD4+CD25+Foxp3+ Tregs
in lymfeknopen en de milt. Miltcellen, geı̈soleerd uit met oxLDL behandelde
muizen, produceerden meer TGF-β dan miltcellen uit controle behandelde
muizen. Dit wijst op een activatie van oxLDL-specifieke Tregs. Ook leidde de
tolerantie inductie tot een verhoogde expressie van genen specifiek voor Tregs,
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namelijk Foxp3, CD25 en CTLA-4 in de atherosclerotische plaque.
Dezelfde techniek is gebruikt in hoofdstuk 3. Hier is echter gebruik gemaakt van
HSP60 en een van HSP60 afgeleid peptide (HSP60(253-268)). Orale toediening
van beide antigenen leidde tot een reductie in initiële plaque vorming (81%). In
de met HSP60 behandelde muizen werd 4 dagen na de behandeling een toename
in het aantal CD4+CD25+Foxp3+ Tregs waargenomen in het bloed en de Peyer’s
patches in de darmen. Na 2 weken was het aantal Tregs ook toegenomen in de
mesenterische lymfeknopen en de milt terwijl het aantal in de Peyer’s patches
weer was afgenomen. Dit kan verklaard worden door de migratie van Tregs
van de Peyer’s patches via het bloed naar de lymfeknopen en de milt. In deze
studie bleken de specifieke cellen uit de mesenterische lymfeknopen van HSP60
behandelde muizen in response op HSP60 niet alleen meer TGF-β te produceren
maar ook meer IL-10 dan cellen uit een controle behandelde muis.
Samengevat blijken de specifieke CD4+CD25+Foxp3+ Tregs een zeer positieve
uitwerking te hebben op atherosclerose en beide studies ondersteunen dan
ook de nieuwe kijk op de verstoorde balans tussen verschillende T cellen in
atherosclerose. Het gebruik van orale tolerantie vormt dus een succesvolle
methode om de immunologische reactie in atherosclerose ten gunste te keren.
Dendritische cellen
Dendritische cellen zijn belangrijke antigeen presenterende cellen en spelen een
rol in de activatie van T cellen en ook natuurlijke killer T (NKT) cellen die
later in het proefschrift behandeld zullen worden. Het feit dat ze zo potent
zijn in het activeren van deze cellen maakt ze uitermate geschikt om ze bij
vaccinatie te gebruiken. In verschillende studies was al beschreven hoe DCs
kunnen worden beladen met antigenen en na teruggave aan de muizen een
beschermend effect kunnen uitoefenen. De techniek van het toedienen van
antigenen door ze toe te dienen via DCs die opgeladen zijn met het antigeen
werd gebruikt in hoofdstuk 4. In deze studie werden DCs geladen met oxLDL
en intraveneus toegediend aan LDLr deficiënte muizen alvorens atherosclerose
werd geı̈nduceerd door een vetrijk dieet. Deze geladen DCs leidden tot een 87%
tot 92% reductie in atherosclerose. Daarbij waren de laesies in met oxLDL geladen
DCs behandelde muizen stabieler dan in de controle muizen. De stabielere
plaques hebben minder kans om tot een ruptuur te leiden, mogelijk gevolgd
door een stolling en afsluiting van het bloedvat. Een verklaring voor de reductie
in plaquegrootte werd gevonden in het feit dat er een verhoogde concentratie
van IgG antilichamen tegen oxLDL werd waargenomen in het serum van de
muizen die met oxLDL geladen DCs zijn behandeld. Dit was toe te schrijven
aan een activatie van oxLDL specifieke T cellen. Het serum van de behandelde
muizen bleek ook een remmende werking te hebben op de vorming van met vet
beladen macrofagen, de zogenaamde schuimcellen. Dit kan veroorzaakt worden
door verschillende mechanismen. IgG antilichamen kunnen complexen vormen
met oxLDL waardoor dit oxLDL sneller uit de circulatie wordt verwijderd,
nog voordat het enig negatief effect kan hebben. Een ander verklaring zou
kunnen zijn dat door de complex vorming, het oxLDL minder goed via scavenger
receptoren opgenomen kan worden en daardoor minder vetstapeling geeft. De
147
exacte verklaring is echter nog onduidelijk en meer experimenten zullen hier
uitsluitsel over geven.
NKT cellen
Naast de Th1/Th2 cellen en Tregs is uit recent onderzoek gebleken dat ook NKT
cellen een belangrijke rol spelen in atherosclerose. NKT cellen zijn Natural Killer
cellen met T cel eigenschappen. De normale NK cellen zijn verantwoordelijk
voor het aspecifiek verwijderen van lichaamsvreemde substanties terwijl NKT
cellen een specifieke T cel receptor hebben waardoor ze alleen op bepaalde
antigenen reageren. In tegenstelling tot de normale T cellen worden NKT cellen
echter niet geactiveerd door eiwit-antigenen maar door vet (lipide)-antigenen.
De activatie van NKT cellen leidt tot de productie van verschillende cytokines,
zowel pro-atherogeen (Th1) als anti-atherogeen (Th2). Dit geheel, en met name
de response op lipide-antigenen, maakt deze cellen extra interessant in het
proces van atherosclerose. Uit een aantal recente publicaties is gebleken dat
het uitschakelen van NKT cellen in muizen leidt tot een vermindering van
atherosclerose. Daarnaast is het mogelijk om specifiek NKT cellen te activeren
met een synthetisch ligand, het zogeheten α-galactosylceramide (α-GalCer).
Naast α-GalCer is er op dit moment ook nog een tweede synthetisch ligand,
OCH. OCH leidt net als α-GalCer tot activatie van de NKT cellen, maar in
tegenstelling tot α-GalCer leidt dit tot de productie van meer anti-atherogene
cytokines; voornamelijk IL-10.
In hoofdstuk 5 en 6 is voor het eerst aagetoond dat NKT cellen ook een
beschermende rol kunnen spelen in atherosclerose. In hoofdstuk 5 werden
LDL receptor (LDLr) en apolipoproteine E (apoE) deficiënte muizen na de
inductie van atherosclerose door een vetrijk dieet, gedurende 7 weken twee
maal per week behandeld met α-GalCer. Dit leidde tot een 84% afname in
plaque vorming in de LDLr deficiënte muizen. Er was echter geen significante
afname van atherosclerose in apoE deficiënte muizen. De verschillen tussen
beide muismodellen werden verder benadrukt door de verschillen in proliferatie
en cytokine profiel na in vitro stimulatie van miltcellen met α-GalCer. LDLr
deficiënte miltcellen prolifereerden veel sterker in response op α-GalCer dan
apoE deficiënte miltcellen, terwijl de toename in IL-4 en IL-10 productie na
α-GalCer stimulatie in LDLr deficiënte muizen ook veel groter was. Ook
resulteerde het vetrijke dieet in LDLr deficiënte muizen tot een toename in het
percentage NKT cellen in de milt en de lever. Dit effect was afwezig in de eerste
weken in de apoE deficiënte muizen, maar later na 4.5 week dieet werd ook in
deze muizen een toename in NKT cellen in de lever waargenomen. Uit andere
studies was al gebleken dat de behandeling van apoE deficiënte muizen met
α-GalCer niet bevorderend was voor atherosclerose. Een verklaring voor de
verschillen in response op α-GalCer tussen beide muismodellen kan worden
gevonden in het feit dat apoE een belangrijke rol speelt in de presentatie van
lipide antigenen. ApoE deficiënte muizen missen apoE en hebben daardoor
een minder effectieve lipide antigen presentatie. Daarnaast lijkt het toedienen
van een vetrijk dieet de NKT cellen in LDL deficiënte muizen al te activeren
waarna α-GalCer een positieve uitwerking heeft en een toename in Th2 cytokines
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veroorzaakt. Mede daardoor veroorzaakt dit een vermindering in plaque grootte.
In apoE deficiënte muizen is deze activatie via het dieet afwezig op het moment
dat α-GalCer wordt toegediend. We veronderstellen nu dat de latere effecten van
het dieet in combinatie met α-GalCer resulteren in het feit dat er geen verschil in
plaque grootte wordt waargenomen, terwijl in andere studies zonder een vetrijk
dieet een enorme toename in plaque grootte in deze muizen werd beschreven.
In hoofdstuk 6 is aangetoond dat NKT cellen dusdanig gestimuleerd kunnen
worden zodat ze een positieve uitwerking hebben op de immunologische reactie
tijdens atherosclerose. In dit hoofdstuk werd gebruik gemaakt van de α-GalCer
analoog OCH. Het is bekend dat NKT cellen, geactiveerd door dit ligand, meer
Th2 cytokines produceren. In een eerdere publicatie was gevonden dat dit
ligand echter ook een negatieve werking had op atherosclerose geı̈nduceerd
in apoE deficiënte muizen. In onze studie is dit bestudeerd maar dan in LDLr
deficiënte muizen. In een eerste experiment werden LDLr deficiënte muizen
waarin atherosclerose was geı̈nduceerd gedurende 7 weken twee maal per
week behandeld met OCH door middel van intra-peritoneale injecties. Dit
bleek echter niet succesvol. Daarop werd overgestapt op een ander vorm van
toediening van OCH, namelijk geladen op DCs. Uit de literatuur bleek namelijk
dat dit een effectieve manier kan zijn om een langdurige NKT cel activatie te
induceren. DCs migreerden na intraveneus te zijn geinjecteerd voornamelijk
naar de longen en de lever, maar ook naar de milt. Migratie naar de lever is
belangrijk aangezien daar de meeste NKT cellen aanwezig zijn. De behandeling
van LDLr deficiënte muizen met OCH geladen DCs, nog voordat atherosclerose
werd geı̈nduceerd, leidde tot een significante 58 tot 71% reductie in plaque
vorming. De behandeling ging gepaard met een toename in NKT cellen in
zowel het bloed als de lever. De NKT cellen bleken in response op OCH geladen
DCs ook meer IL-10 te produceren dan NKT cellen uit muizen behandeld met
controle DCs. De toegenomen productie van IL-10, met name in de lever, kan
de oorzaak zijn van de reductie in cholesterol die werd waargenomen in muizen
behandeld met OCH-geladen DCs aan het eind van het experiment.
NKT cel liganden
In hoofdstuk 7 is getracht om de natuurlijke ligand voor de hierboven genoemde
NKT cellen te achterhalen. Aangezien NKT cellen geactiveerd worden door
lipide antigenen en er in atherosclerose veel lipide antigenen aanwezig zijn,
werd het mogelijk geacht dat een van deze lipiden NKT cel activatie tot gevolg
heeft. Deze gedachte werd ondersteund door het feit dat afwezigheid van CD1d
een remmend effect had op atherosclerose. CD1d is een receptor voor lipide
antigenen. In deze studie is net als in hoofdstuk 5 aangetoond dat een vetrijk
dieet een stimulerende werking heeft op NKT cellen. LDLr deficiënte muizen
welke het vetrijke dieet hebben gegeten bezitten veel meer NKT cellen in de
lever, de milt en lymfeknopen dan wanneer er geen vetrijk dieet wordt gegeten.
Er is ook aangetoond dat oxLDL tot minder proliferatie van miltcellen leidt
wanneer NKT cellen afwezig zijn. Het kruisen van LDLr deficiënte muizen met
Jα281 deficiente muizen (missen NKT cellen) had echter verassend genoeg geen
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effect op de plaque grootte. Dit komt overigens overeen met een aantal eerdere
studies, waarin CD1d deficiëntie alleen een vermindering in atherosclerose
veroorzaakte in de initiële fase en niet beschermend voor meer gevorderde
vaatvernauwing.
Samenvattend laat dit proefschrift zien dat de activiteit van verschillende
soorten T en NKT cellen tijdens atherosclerose op verschillende manieren
therapeutisch te beı̈nvloeden is. Regulatoire T cellen blijken een uitermate
positieve uitwerking te hebben op atherosclerose. Daarnaast blijkt dat met
behulp van DCs het activeren van oxLDL-specifieke T cellen en de daarop
volgende toename in oxLDL specifieke antilichamen ook een positief effect heeft
op atherosclerose. Verder is aangetoond dat NKT cellen een complexe rol spelen
in de immunologie van atherosclerose. Ze kunnen een beschermende rol hebben
in atherosclerose, wanneer ze 1) direct geactiveerd worden met behulp van
α-GalCer, of wanneer ze 2) geactiveerd worden met een ligand (OCH) geladen
op DCs. De studies in dit proefschrift leiden niet alleen tot meer inzicht in de rol
van het immuunsysteem bij de vet-geı̈nduceerde aderverkalking, maar creëren
een therapeutisch protocol dat in de toekomst mogelijk kan worden toegepast





APC antigen presenting cell
apoE/apoB apolipoprotein E/apolipoprotein B
CC/CXC chemokine
CCL/CXCL chemokine ligand
CD cluster of differentiation
CIA collagen induced arthritis
CMV Cytomegalovirus
conA concanavalin A
CTLA cytotoxic T-lymphocyte antigen
CVD cardiovascular disease
DC dendritic cell
EAE experimental acquired encephalomyelitis
FACS fluorescent-activated cell sorting




HSP heat shock protein
i.p. intraperitoneal
i.v. intravenous





imDC immature dendritic cell
LDL low-density lipoprotein
LDLr low-density lipoprotein receptor
LPS lipopolysaccharide
MCP-1 monocyte chemotactic protein
M-CSF macrophage colony stimulating factor
MDA-LDL malondialdehyde modified LDL
mDC mature dendritic cell
MHC major histocompatibility complex
MMP matrix metalloproteinase
NF-κB nuclear factor κB
NK natural killer
NKT cell natural killer T cell
oxLDL oxidized low-density lipoprotein
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SMC smooth muscle cell
SR scavenger receptor
STI soybean trypsin inhibitor
TβRII transforming growth factor β receptor II
TCR T cell receptor
TGF transforming growth factor
Th1/Th2 T helper 1/T helper 2
TLR Toll-like receptor
TNF tumor necrosis factor
Tr1 regulatory T cell type 1
Treg regulatory T cell
VCAM-1 vascular cell adhesion molecule-1




van Puijvelde GHM, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJC,
van der Zee R, van Eden W, van Berkel TJC, Kuiper J: Induction of oral tolerance
to oxidized LDL ameliorates atherosclerosis. Circulation. 2006; 114:1968-1976.
van Puijvelde GHM, Habets KLL, van Duivenvoorde LM, van Wanrooij EJA, de
Vos P, Cohen Tervaert JW, van Berkel TJC, Toes R, Kuiper J: Immunotherapy of
atherosclerosis using dendritic cells. Submitted for publication.
van Puijvelde GHM, van Es T, de Vos P, van der Zee R, van Eden W, van
Berkel TJC, Kuiper J: Induction of oral tolerance to HSP60 or an HSP60-peptide
activates T cell regulation and reduces atherosclerosis. Submitted for publication.
van Puijvelde GHM, Habets KLL, van Duivenvoorde LM, Litjens REJN,
van Wanrooij EJA, de Vos P, van der Marel GA, Overkleeft HS, Cohen Tervaert
JW, van Berkel TJC, Toes R, Kuiper J: Immunomodulation with OCH-pulsed
dendritic cells attenuates atherosclerosis. Submitted for publication.
van Puijvelde GHM, Habets KLL, Theune CA, van Wanrooij EJA, de Vos
P, Hauer AD, van Berkel TJC, Kuiper J: Effect of NKT cell activation on
atherosclerosis depends on the presence of apoE. Submitted for publication.
van Puijvelde GHM, van Es T, Theune CA, Habets KLL, van Wanrooij EJA,
van Es T, van Berkel TJC, Kuiper J: Endogenous ligands for NKT cells in
atherosclerosis. Manuscript in preparation.
Kuiper J, van Puijvelde GHM, van Wanrooij EJA, Hauer AD, van Berkel
TJC: Immunomodulation of the inflammatory response in atherosclerosis.
Current opinion in lipidology, 2007 in press.
van Wanrooij EJA, van Puijvelde GHM, de Vos P, Yagita H, van Berkel TJC,
Kuiper J. (2007): Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway
attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
Arterioscler Thromb Vasc Biol. 27: 204-210.
van Wanrooij EJA, van Puijvelde GHM, Happe H, de Vos P, Habets K, van Berkel
TJC, Kuiper J: Vaccination against CD127 severely aggravates atherosclerosis in
LDLr deficient mice. Manuscript in preparation.
van Es T, Hauer AD, van Puijvelde GHM, van Wanrooij EJA, de Vos P,
153
Peterse N, van Berkel TJC, Kuiper J: DNA vaccination against IL-17 attenuates
atherosclerosis in LDL receptor deficient mice. Manuscript in preparation.
Hauer AD, van Puijvelde GHM, Peterse N, de Vos P, van Weel V, van Wanrooij
EJA, Biessen EAL, Quax PHA, van Berkel TJC, Niethammer AG, Reisfeld RA,
Kuiper J: Induction of cellular immunity against VEGFR2 by DNA vaccination
attenuates atherosclerosis. Submitted for publication.
Peer reviewed abstracts
van Puijvelde GHM, van der Zee R, de Vos P, van Berkel TJC, van Eden W,
Kuiper J: Oral tolerance with heat shock protein 60 and a heat shock protein 60
peptide (253-268) reduces plaque size in atherosclerotic mice. Atherosclerosis.
2003; 4:315:4P-1095
Oral Presentation at the AHA Scientific Sessions 2003. Circulation 2003; 108:
IV-130
van Puijvelde GHM, de Vos P, van der Zee R, van Eden W, van Berkel TJC, Kuiper
J: Oral tolerance to oxidized LDL ameliorates atherogenesis. Atherosclerosis. 2004;
5:43:W07.185
Circulation. 2004; 110:III-996
van Puijvelde GHM, Habets KLL, van Duivenvoorde LM, Litjens REJN,
van Wanrooij EJA, de Vos P, van der Marel GA, Overkleeft HS, Cohen Tervaert
JW, van Berkel TJC, Toes R, Kuiper J.: Immunomodulation with OCH-pulsed
dendritic cells attenuates atherosclerosis. Oral presentation at the AHA Scientific
Sessions 2006. Circulation. 2006; 114:II-257
van Puijvelde GHM, Theune CA, de Vos P, van Wanrooij EJA, van Berkel
TJC, Kuiper J: Activation of NKT cells and the effect on atherosclerosis.
Atherosclerosis Supplements. 2005; 6:82:W12-P-081
Hauer AD, de Vos P, Peterse N, van Weel V, Quax P, van Puijvelde GHM,
van Berkel TJC, Reisfeld R, Kuiper J: Vaccination against VEGF receptor 2 blocks
initiation and progression of atherosclerosis. Atherosclerosis Supplements. 2005;
6:68:W12-P-028
Circulation. 2004;110:III-370
van Wanrooij EJA, van Puijvelde GHM, de Vos P, Yagita H, van Berkel TJC,
Kuiper J: Interruption of the TNFRSF4/TNFSF4 ligand pathway attenuates
atherogenesis in LDL receptor deficient mice. Circulation. 2006; 114:II-23
Van Wanrooij EJA, van Puijvelde GHM, Happ H, de Vos P, van Berkel TJC,
Kuiper J: CD127 is required for macrophage and regulatory T cell function and
has a protective role in athersclerosis. Circulation. 2006; 114:II-286
Habets KLL, van Puijvelde GHM, van Duivenvoorde LM, van Wanrooij
154
Abbreviations
EJA, de Vos P, Cohen Tervaert JW, van Berkel TJC, Toes R, Kuiper J: OxLDL-
pulsed dendritic cells: An immunotherapy in atherosclerosis. Circulation. 2006;
114:II-256
Van Es T, Hauer AD, van Puijvelde GHM, van Wanrooij EJA, de Vos P,
Peterse N, van Berkel TJC, Kuiper J: DNA vaccination against IL-17 attenuates




Gijs van Puijvelde werd geboren op 6 oktober 1978 in Terneuzen. In mei 1997
werd het VWO diploma behaald aan de Stedelijke Scholengemeenschap ”De
Rede” te Terneuzen. In datzelfde jaar werd begonnen met de studie Medische
Biologie aan de Vrije Universiteit van Amsterdam. Het propaedeutisch examen
werd in augustus 1998 gehaald. Van januari tot en met september 2000 werd
in het kader van de hoofdvakstage onderzoek verricht binnen de vakgroep
CelBiologie onder leiding van drs. S. Floris en dr. E. de Vries met als onderwerp
’Expression of CS-1 sequence by astrocytes and its role in the adhesion of
monocytes’. Van november 2000 tot en met augustus 2001 werd een tweede stage
gevolgd bij de vakgroep Neurobiologie aan het Swammerdam institute for Life
Sciences, onderdeel van de Universiteit van Amsterdam, onder leiding van drs.
D. Marsen en Prof.dr. W. Wadman. Dit onderzoek was getiteld ”The effects of
5-MOP on two types of voltage-gated K+ currents: the A- and D-current.” Het
doctoraal examen werd in januari 2002 gehaald.
Van februari 2002 tot augustus 2006 werd als assistent in opleiding het in dit
proefschrift beschreven onderzoek uitgevoerd bij de vakgroep Biorfarmacie van
het Leiden/Amsterdam Center for Drug Research onder leiding van dr. J Kuiper
en Prof. dr. Th.J.C. van Berkel. Dit onderzoek maakte deel uit van een door
de Nederlandse Hartstichting gefinancieerd project. Tijdens zijn periode als
assistent in opleiding heeft hij in januari 2003 een prijs gekregen voor de beste
posterpresentatie tijdens ”The 5th St. Gerlach Vascular Biology Workshop.”
In april 2004 ontving hij een minifellowship tijdens het 7e symposium van
de ”Dutch Atherosclerosis Society”. Daarnaast onving hij in april 2004 een
prijs voor de beste poster presentatie tijdens het ”LACDR Spring Symposium”.
Van oktober 2006 tot april 2007 werd er vervolgonderzoek verricht aan het
Karolinska instituut in Stockholm, Zweden. Dit met als doel het opzetten van
een langdurig samenwerkingsverband tussen de afdeling Biofarmacie in Leiden
en de afdeling ”Experimental Cardiovascular Reasearch” in Stockholm. Sinds 15
mei 2007 is hij aangesteld als Post-doc binnen de vakgroep Biofarmacie van het





Op moment van schrijven van het nawoord zit ik op het vliegveld van Stockholm.
Zes maanden heb ik daar onderzoek gedaan en ook een groot deel van mijn
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